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ABSTRACT  
Calmodulin (CaM) is a ubiquitous intracellular protein that regulates biological 
activities of numerous enzymes and ion channels. Upon responding Ca2+ concentration 
change, Ca2+- dependent CaM activates the hydrolyzation of cGMP by PDE and Ca2+ 
releasing channel activity of ryanodine receptor. In this dissertation, a series of CaM 
variants were engineered to enhance Ca2+ binding affinities by increasing the number of 
negative charged residues in individual EF-hand. The capability of shifting the biphasic 
Ca2+-activation profile of RyR1 is significantly altered by changing Ca2+ binding affinity of 
CaM at the C-terminal. This indicates that examining Ca2+-CaM affinity is a valid strategy 
to tune the activation profile of CaM-regulated ion channels. To further understand 
interactions between CaM and RyR1, NMR was used to determine their binding mode. 
To dissect roles of structural components of CaM in metal binding and regulation of 
biological functions of target proteins, we created half-CaMs and Del-CaM. Binding 
affinities of these variants to Ca2+, Tb3+ and Gd3+ were determined by fluorescence 
spectroscopy; functional studies were conducted using single channel analysis and PDE 
function assay.  
Another objective of my dissertation is to design a protein based contrast agent for 
molecular imaging. CaM was selected as the scaffold protein for designing Gd3+ based 
MRI contrast agent by modifying metal binding sites as well as grafting a biomarker 
peptide into the linker region to specifically target cancers with efficient and optimized 
modifications. The physical kinetic properties and animal imaging effects of these 
designed contrast agents were investigated by various methods.  
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1. Introduction 
 
 
1.1. Biological functions and structure of calmodulin  
 
                Calmodulin (CaM) is an acidic (PI ~4.0) intracellular Ca2+ signaling protein 
comprised of 148 amino acids with a molecular weight of 16.7 kDa. It was first 
discovered as a cyclic nucleotide phosphodiesterase activator protein (PAF) in the brain 
and heart1.  It was subsequently rediscovered several times, since many Ca2+-
dependent cellular processes were eventually shown to involve the same Ca2+-binding 
protein. The name CaM, was first suggested by W. Y. Cheung. Calcium-free CaM is 
referred to as apo-calmodulin (ApoCaM). It was then rediscovered as a calmodulin by 
Saimi Y, et al 2.  
 
Calmodulin is widely distributed in nature. It is a ubiquitous intracellular calcium 
binding protein located in all mammalian cells including vertebrates and plants 3,4.  The 
sequences of CaM are highly conserved in all eukaryotic proteins (Figure.1.1). All 
known vertebrate CaMs are identical, and all metazoan CaMs are essentially the same. 
CaM of paramecium is 94% similar to the mammalian counterpart and that of human, 
bovine and rat are the same 5. In mammals, there are three genes in each species which 
are 80% identical in nucleotide sequence but encode 100% identical protein sequence 6. 
This high degree of conservation may be essential for the maintenance of interaction 
with a diverse family of CaM-binding proteins 7. 
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Ca2+-free CaM
(1cfc)(NMR)
Ca
Ca2+-bound CaM 
(3cln)(2.2Å)  
         
Human_CaM           
MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADD 60 
Bovine_CaM          
MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDAD- 59 
Rabbit_CaM          
MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDAD- 59 
Rat_CaM             
MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDAD- 59 
Paramecium_CaM      
MAEQLTEEQIAEFKEAFALFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDAD- 59 
                    
**:**************:*****************************************  
 
Human_CaM           
LPGNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKL 120 
Bovine_CaM          --
GNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKL 117 
Rabbit_CaM          --
GNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKL 117 
Rat_CaM             --
GNGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKL 117 
Paramecium_CaM      --
GNGTIDFPEFLSLMARKMKEQDSEEELIEAFKVFDRDGNGLISAAELRHVMTNLGEKL 117 
                      ***********::******: *****: ***:***:**** 
***************** 
 
Human_CaM           TDEEVDEMIREADIDGDGQVNYEEFVQMMTAK 152 
Bovine_CaM          TDEEVDEMIREADIDGDGQVNYEEFVQMMTAK 149 
Rabbit_CaM          TDEEVDEMIREADIDGDGQVNYEEFVQMMTAK 149 
Rat_CaM             TDEEVDEMIREADIDGDGQVNYEEFVQMMTAK 149 
Paramecium_CaM      TDDEVDEMIREADIDGDGHINYEEFVRMMVSK 149 
                    **:***************::******:**.:* 
 
 
 Figure 1.1.PDB structures of apo, holo form calmodulin and sequence alignment. 
A). Structures of ApoCaM (PDB code 1cfc) and Ca2+-CaM (PDB code 3cln). 
B). Sequences alignment of CaM from different sources. Amino acids that are not 
different from the human sequence are shown in red. 
 
A 
B 
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As shown in Figure 1.1, CaM is composed of three structural components: the N- 
and C- terminal domains with two EF – hand motifs in each domain, and a flexible linker 
which connects these two domains. EF hand is a helix-loop-helix structural domain 
found in the large family of Ca2+-binding proteins. It was first discovered from 
parvalbumin 8, a Ca2+ buffering protein containing three EF hand motifs and involved in 
muscle relaxation via its Ca2+-binding property. An EF hand motif contains a helix-loop-
helix structure, in which the Ca2+ ions are coordinated by ligands within the loop. It 
consists of two α helices positioned perpendicular to one another and linked by a short 
loop region (typically 12 amino acids). This loop will form a binding pocket to bind Ca2+ 
(Figure 1.2). 
 
In the EF hand binding pocket is coordinated in a pentagonal bipyramidal 
configuration. The six residues contribute to the binding are located in positions 1, 3, 5, 7, 
9 and 12; these residues are denoted by X, Y, Z, -Y, -X and –Z as a space axis. Glu or 
Asp at position 12, named as an anchor, provides two oxygens for binding Ca2+ (see 
detailed discussion in Chapter 3). Ca2+ is bound with oxygens from both the protein 
backbone and side chains. Chare-charge interaction is the major driven force for Ca2+ 
binding to this EF hand pocket. In most proteins, the sixth residue in the loop is found to 
be glycine due to the conformational requirements of the backbone. The remaining 
residues are usually hydrophobic and form a hydrophobic core that stabilizes the two α-
helices. 
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Figure 1.2. EF hand structures of Ca2+ binding sites in CaM. 
A).EF-hand motif contains a helix-loop-helix topology, and looks like the spread 
thumb and forefinger of the human hand tropology. B). Ca2+ binding pocket of the 
EF hand motif with a pentagonal bipyramidal configuration. 
 
Ca2+ is one of the most important second messengers in eukaryotic cells9. 
Temporal and spatial changes of the Ca2+ concentration in different compartments of 
cells affect the regulation of cellular signaling.   Through signal stimulation or alteration in 
the membrane potential, the cytosolic Ca2+ concentration rises from 10-7 to 10-5 M. As 
shown in Figure 1.3, CaM is capable of transducing the intracellular Ca2+ signal changes 
into a number of diverse cellular events, including apoptosis, cell differentiation and cell 
proliferation through its reversible or irreversible binding to Ca2+. The flexible 
conformational changes allows  interactions with more than 100 functional target 
enzymes, cellular receptors and ion channels 10,11,12. Currently, the Yang laboratory is 
studying several calcium binding proteins that are regulated by CaM, such as ryanodine 
receptor, gap junction, phosphodiesterase (PDE), and G-protein coupled receptor 
(GPCR). Section 1.2 introduces the ryanodine receptor and PDE as model systems for 
our studies in this dissertation. 
A B 
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Among  myriads of Ca2+-binding proteins which modulate cell signalling, CaM plays 
an essential role and is extensively studied due to its ubiquitous expression in 
eukaryotes in addition to its versatile ability to activate or inhibit more than 300 functional 
enzymes, cellular receptors and ion channels 10,11,12. Although quite a few studies have 
been done on CaM, there are still large numbers of unknown scopes for this protein. For 
example, the binding sites of CaM to distinct enzymes are different, which suggests the 
function of CaM is changed by changing the Ca2+ binding affinity in each binding site. 
This study aims to investigate the structural and functional characteristics of CaM.  
 
Structural data from the protein data bank (PDB) indicates that CaM adopts different 
structures in the apo- and holo- forms. More hydrophobic residues are exposed and a 
flexible linker as a result of binding to Ca2+. Most enzymes that are activated by Ca2+-
CaM require that three or four Ca2+ molecules be bound. Ca2+ induced conformational 
rearrangements within CaM, resulting from the complex formed by binding of  Ca2+ may 
provide a mechanism for transferring intracellular signals to diverse target enzymes. 
Figure 1.3 summarizes the interacting modes of CaM with target enzymes. Upon 
binding to Ca2+, CaM adopts a more helical structure, whichmakes it easier to bind the 
target proteins. By binding to the peptide on the targeting enzymes, the two domains of 
CaM will either wrap closer, such as skeletal muscle myosin light chain kinase (skMLCK) 
13, or remain extended, as seen in the Ca2+ pump and IQ motif of myosin V 14,,15. 
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CaMKII
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          Figure 1.3. Interaction modes of CaM to various peptides in binding sites of its 
target enzymes. 
CaM interacts with the target enzymes in two major modes: the collapsed mode 
(1-7,1-10,1-14,1-16) 16,7,17, 15 and the extended mode 18, 14, 13, 19.  
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Figure 1.4 shows that the cytosolic Ca2+ concentration rises from 10-7 to 10-5 M 
through signal stimulation or alteration in the membrane potential.  CaM undergoes a 
conformational change and interacts with numerous target proteins, such as ryanodine 
receptor and IP3 receptor at the ER, gap junction proteins at the plasma membrane, and 
phosphadieasterase in the cytosol to modulate Ca2+ signaling 20,21. Insights into the role 
of Ca2+ binding to CaM with respect to the regulation of targeting enzymes have been 
reported using site-direct mutations, for example, replacing the anchor glutamate within 
the EF- hand loop with other hydrophobic residues 22,23.  Therefore, it may be possible to 
selectively enhance a specific CaM function on targeting enzymes by manipulating the 
affinity of each EF-hand loop in CaM. 
 
The Ca2+ concentration range to which CaM responds increases as a result of the 
10-fold higher Ca2+ affinity of the C-terminal domain (Ca2+-binding sites III and IV) 
compared to the N-terminal domain (Ca2+-binding sites I and II) 24,25, 26. These different 
Ca2+ affinities contribute to CaM‟s functional bifurcation which allows the two domains of 
CaM to serve different functions 27,28. For example, Ca2+-dependent facilitation of Cav2.1 
voltage-gated Ca2+ channels requires Ca2+ binding to CaM‟s C-terminal while Ca2+-
dependent inhibition of these channels requires Ca2+ binding to CaM‟s N-terminal29. 
Further, the two lobes of CaM may separately decode global and local Ca2+ signals 30,31. 
Therefore, one strategy to manipulate cellular responses to Ca2+ signals may be to 
modify the Ca2+ affinity of the protein which decodes the signal. Because of its functional 
bifurcation, CaM is an attractive target. By manipulating the affinity of one domain of 
CaM it may be possible to selectively enhance a specific CaM function. 
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phosphodiesterase
 
          
   Figure 1.4.Cellular distribution and targeting enzymes of calmodulin (CaM). 
Calmodulin is distributed across different cellular compartments including nuclei, 
ER and mitochondria. In addition, CaM has been reported to interact with 
membrane proteins such as ion channels, gap junctions and pumps as well as 
cytoskeletal proteins, and quite a few enzymes in the cytoplasm. 
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1.2. Ryanodine receptor and PDE are regulated by CaM  
 
        Ryanodine receptor Ca2+ release channels from the efflux pathway for the 
mobilization of Ca2+ stores from the sarco/endoplasmic reticulum (Figure 1.4)32. Three 
types of ryanodine receptors have been described so far (Figure 1.5). The skeletal 
muscle isoform of the ryanodine receptor (RyR1) is essential for Ca2+ release from the 
sarcoplasmic reticulum (SR) to activate contraction33. RyR1 is a homotetramer 
composed of four 565 kDa subunits, each with a single high-affinity CaM binding site34 
35,36. Cardiac muscle cell Ca2+ release channel ryanodine receptor 2 (RyR2) is a 
homotetramer consisting of a COOH-terminal transmembrane assembly and a massive 
cytoplasmic NH2-terminal domain with a molecular weight ~ 2000 kDa. The physiological 
importance of regulation of RyR2 by CaM is currently understood. More recently, the 
third gene RyR3 has been identified in rabbit brain37, mink lung epithelial cells 38, and 
human Jurkat T-cell39. Based on the fact that RyR3 has been detected in specific region 
of the brain, e.g. hippocampus, thalamus, and corpus striatum, it may have an important 
role in specific brain functions. Presently, however, the properties of RyR3 are still 
unclear. 
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             Figure 1.5.Comparison of 3D reconstructions of RyR1, RyR2, RyR3. 
(A).The solid body representations of RyR3 (blue), RyR1 (green), and RyR2 
(red) viewed onto the cytoplasmic surface. Note conservation of domain 
architecture. (B) RyR3 superimposed with the major differences (yellow) 
obtained when the 3D reconstruction of RyR3 is subtracted from that of RyR1. 
Arrows indicate the main difference which is tentatively attributed to the D2 
region which is absent from RyR3 (Wagenknecht T, Samsó M) 40. 
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In vitro, the RyR1 channel opening exhibits a biphasic Ca2+  dependence 
attributed to high- and low-affinity Ca2+ binding sites which when occupied will, 
respectively, activate or inhibit channel opening 41. At micromolar Ca2+ concentrations, 
CaM inhibits both RyR1 and RyR2. However, at sub-micromolar Ca2+ concentrations, 
CaM activates RyR1(Figure 1.6A) but inhibits RyR2 42 (Figure 1.6B). CaM shifts the 
Ca2+ dependence of the RyR1 opening to lower Ca2+ concentrations, effectively 
increasing channel opening at sub-micromolar Ca2+ level and inhibiting the channel in 
micromolar Ca2+ concentration43. The switch from a channel activator to a channel 
inhibitor is due to Ca2+ binding to CaM as Ca2+ insensitive mutants of CaM activate but 
do not inhibit RyR136. The Ca2+-induced conversion of CaM from a RyR1 activator to a 
channel inhibitor suggests that the RyR1 activation profile might be manipulated by 
tuning the CaM Ca2+ affinity. This strategy requires that the CaM Ca2+ binding site(s) 
acting as the RyR1 regulatory switch be identified and the Ca2+ affinity of the specific site 
be modified without significantly altering the RyR1-CaM functional interaction. We chose 
RyRs as a model system to study the binding properties of CaM to its target enzyme 
because of extensive studies of the structure, function, importance of RyR in regulation 
of Ca2+ signaling and homeostasis and mutations in RyR related to many human 
diseases such as malignant hyperthermia (MH) and Duchene muscular dystrophy 
(DMD). 
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Figure 1.6. Regulation of CaM on the RyR1 and RyR2 channels in a Ca2+ dependent way. 
CaM lowered both RyR1 (green line in A) and RyR2 (red line in B) channels open 
probability from low micromolar to submicromolar Ca2+ concentrations by decreasing the 
number of channel events and increasing the duration of close times .                                                                                                                                                                                                                                                              
A). CaM activate the RyR1 channel opening at low Ca2+ concentration and inhibit the 
channel at higher Ca2+ concentration. 
B). RyR2 channel is mainly inhibited by CaM with low activity in the presence of Ca2+.  
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Cyclic nucleotide hydrolysis activity was first characterized by Sutherland and Rall 
following their discovery of cyclic adenosine 3‟:5‟ – monophosphate (cAMP)44 . In 
general, the cAMP and cyclic guanosine 3‟:5‟ – monophosphate (cGMP) are intracellular 
secondary messengers that exhibit rapid concentration changes in response to a wide 
variety of cell – specific stimuli.  The concentrations of both cAMP and cGMP are 
determined by the relative synthetic activity of adenylate cyclase and the degradative 
activity of cyclic nucleotide phosphodiesterase (PDE).  Hydrolysis of the cyclic 
nucleotides by PDE is a unique mechanism for their degradation. The substrate 
specificities and affinities, and the sensitivities of PDEs isolated from different tissues are 
distinguished. Three major forms of PDE were classified into three groups based on their 
functions: cAMP PDE, cGMP PDE and those with dual substrates for both cAMP and 
cGMP45. The activity of PDE is Ca2+/CaM dependent. Since the role of Ca2+/CaM in PDE 
activity has been studied in several research groups. We chose PDE1 as a model 
system to test the roles of structural components of CaM in activation of PDE     
(Chapter 6). 
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/cGMP
 
                          Figure 1.7. Functional regulation of phosphadieasterase in the cytosol. 
Phosphodiesterase (PDE) catalyzes the hydrolysis of cGMP/cAMP to the 
corresponding 5’-nucleoside monophosphates, thereby terminating cyclic 
nucleotide signaling.  The buildup of cGMP stimulates the uptake of Ca2+ into the 
SR/ER, reducing cytoplasmic Ca2+, promoting relaxation of vascular smooth 
muscle and Vasodilation46.  
 
 
 
 
15 
 
1.3. Designing protein based MRI contrast agent  
 
       Magnetic resonance imaging (MRI) is a relatively new technology first developed by 
Lauterbur, P.C et.al in the University of Aberdeen, UK. The first MR image was 
published in 1973 using MnSO4 as the magnetic agent 
47,48 and the first cross-sectional 
image of a living mouse was acquired by Lai et.al through a 2D image 49. The first 
studies performed on humans were published in 1977 with video images generated of a 
cross-section through the chest at the level of the eighth thoracic vertebra 50,51. Magnetic 
resonance imaging (MRI) has been applied as an advanced imaging technique in both 
clinical and research studies.  MRI has emerged as one of the most important tools for 
diagnosing various disease including cancers due to several advantages, such as the 
high resolution, the ability to map three-dimensional structures and the function of soft 
tissues in vivo without any limitation of depth. Clinical MRI takes advantages of the 
magnetic properties of protons (mostly from water) and their interaction with both the 
strong external magnetic field and the electro-radio wave to produce highly detailed 
images of the human body. In addition, the application of contrast agents particularly 
enhances the MRI signals among different tissues and organs. Contrast agents can be 
defined either based on their physical properties or according to their applications. For 
example, T1 / T2 weighted contrast agents, or non specific / specifically molecular- 
targeted contrast agents. MR imaging can be helpful for characterizing normal tissue 
and diseased ones by giving different contrast in the images. In particular, gadolinium-
enhanced MR imaging can help distinguish between benign and malignant tumors. 
However, most of the clinically contrast agents use Gd3+ with small organic chelators 
which often include drawbacks such as low relaxivities, high toxicity and short retention 
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time in the human body.  As a result, there is a strong need to develop novel classes of 
contrast agents with high sensitivity, high relaxivity and low toxicity.  
 
Rapid development in biomarkers and molecular imaging allows monitoring disease 
progression at a molecular level. Several targeted therapies against tumor biomarkers 
such as HER2 and gastric releasing peptide (GRP) receptor largely expressed at tumor 
cell surface have been developed. To facilitate the application of MRI to molecular 
imaging of cancer progression and evaluate drug effect, it is important to develop target 
contrast contrasts. To satisfy the essential requirement for targeting biomarkers 
expressed on tumor cell surface, we need to significantly improve molecular relaxivity of 
the contrast agents in addition to enhancing the MRI signal for targeted disease 
biomarkers.  
 
Based on the criteria of designing contrast agent (for details please see Chapters 7-9) 
and our detailed investigation of the properties of metal binding and selectivity of CaM 
and key determinants for molecular recognition of  calmodulin and its target proteins, we 
select CaM as a strong candidate for the development protein based contrast agents by 
protein engineering. Our project initially entailed enhancing the metal bind affinity of CaM 
to Gd3+ and selectivity over physiological metal ions by protein engineering. Next, we 
reduced calmodulin‟s endogenous recognitions to its target proteins by site directed 
mutagenesis and PEGylation.  Further, we carefully investigated their relaxation 
properties as protein based contrast agents. Finally, we further developed targeted 
contrast agents for the prostate and breast cancers  using gastrin releasing peptide and 
HER-2 affibody as a targeting moiety against their corresponding biomarkers 
respectively. 
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1.4. The objective of this dissertation 
 
The first objective of this research is to study the Ca2+ binding affinity to one of the 
most significant intracellular proteins, CaM, and the effects on the function of RyR . A 
series of CaM variants designed to enhance the affinity of specific Ca2+- binding sites 
was engineered by increasing the number of negative charge from acidic residues within 
individual EF-hands, which we propose will thereby affect the Ca2+-activation profile of 
RyR1. The functional effects of these mutants were assessed via their effects on the 
Ca2+-activation profile of RyR1. The experimental results indicate that tuning CaM‟s 
Ca2+-binding affinities offers a potential strategy for tailoring the activation profile of CaM 
targets.  
  The second objective of this dissertation is to understand the roles of the 
structural components of the two domains and the linker region of CaM. We think they 
may play diverse roles in both metal binding and biological functions of CaM considering 
that CaM displays a tremendous conformational change through binding to Ca2+ and the 
fact that N- and C- terminal domains of CaM have distinct binding affinities to Ca2+. More 
interestingly, previous studies have reported that lanthanides may occupy Ca2+ binding 
sites in a reverse order to Ca2+ for the N- and C- domains of CaM52. To probe binding 
affinities, CaM mutants were created including half-CaM constructs (either the Isolated 
N- or C- terminal of CaM), and a deletion variant where five residues in the central linker 
were removed (Del-CaM) by molecular cloning. The binding affinity between the CaM 
mutants and several metals, including Ca2+ and Tb3+ / Gd3+ were determined mainly by 
fluorescence spectroscopy; Functional studies were conducted using single channel 
analysis and PDE function assay.  
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The third objective of my dissertation was to design a protein based contrast agent 
for molecular imaging. CaM was selected as the scaffold protein for designing 
Gadolinium based MRI contrast agent by modifying metal binding sites as well as 
grafting a biomarker peptide into the linker region to specifically target cancers with 
efficient and optimized modifications. The physical kinetic properties and animal imaging 
effects of these designed contrast agents were investigated by a variety of techniques. 
 
 
 
1.5. The overview of this dissertation 
 
First, we designed a series of mutations from CaM based on the hypothesis that the 
Ca2+ binding affinity to CaM can be tuned by optimizing the number of charged residues.  
Furthermore, the significant changes in biological functions when CaM and its mutants 
interact with RyR1 suggest that tuning Ca2+ binding affinity will affect the related 
functions.  Second, isolated CaMs were created to further understand the functional role 
each domain in CaM plays as well as the hinge linker. Both structural and functional 
properties were determined comparably. Third, the structures of CaM and peptide 
complex in both apo- and Ca2+ conditions were analyzed through NMR experiments. 
Finally, protein based contrast agents (ProCAs) with multiple metal binding sites were 
designed. These ProCAs indicated high relaxivities and high Gd3+ binding affinities. The 
enhancement in MR imaging also proves that they are potential contrast agents with 
high specificity targeting properties to various cancers. 
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Chapter 3 discussesthe single mutations in each EF- hand loop of CaM designed to 
tune the activity of Ryanodine receptor. Ca2+ binding affinities of these mutants were 
determined by domain specific fluorescence titration. 
Chapter 4 focuses on analyzing the binding mode of CaM with ryanodine receptor 
using a peptide model. NMR is the essential method in this discussion. 
In Chapter 5 and Chapter 6, we use ryanodine and phosphadiesterase as examples 
to dissect the structural components of CaM to the regulation of biological functions. 
In Chapter 7 and Chapter 8, we try to apply CaM and its structural components as a 
protein based MRI contrast agent.   
In Chapter 9, we optimized the protein based MRI contrast agent using PEGylation 
to increase the stability and relaxivity as well as enhance the MR images.  
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Table 1.1Summarized table of CaM variants studies in this dissertation. 
CaM variants  Change in CaM Purpose  chapt
er 
wt CaM   3 
T26D Increase one negative 
charge in loop I 
Effect on the Ca2+  binding affinity  
in the N- terminal 
3 
N60D Increase one negative 
charge in loop II 
Effect on the Ca2+  binding affinity  
in the N- terminal 
3 
N97D Increase one negative 
charge in loop III 
Effect on the Ca2+  binding affinity 
 in the C- terminal 
3 
Q135D Increase one negative 
charge in loop IV 
Effect on the Ca2+  binding affinity 
 in the C- terminal 
3 
N60D+N97D Increase one negative 
charge in loop II and III 
Design protein based contrast agent 7 
T27W Introduce Trp in N-
terminal  
Monitor Trp fluorescence signal N/A 
Y99W Introduce Trp in C-
terminal 
Monitor Trp fluorescence signal N/A 
D20A Decrease one negative 
charge in loop I 
Effect on the Ca2+  binding affinity 
 in the N- terminal 
N/A 
D56A Decrease one negative 
charge in loop II 
Effect on the Ca2+  binding affinity 
 in the N- terminal 
N/A 
D93A Decrease one negative 
charge in loop III 
Effect on the Ca2+  binding affinity 
 in the C- terminal 
N/A 
D129A Decrease one negative 
charge in loop IV 
Effect on the Ca2+  binding affinity 
 in the C- terminal 
N/A 
N-CaM Isolated N-terminal 
domain of CaM 
Dissect the functional contributions of CaM 
structural components ; 
Design protein based contrast agent 
5,6,8 
C-CaM Isolated C-terminal 
domain of CaM 
Dissect the functional contributions of CaM 
structural components ; 
Design protein based contrast agent 
5,6,8 
Del-CaM Delete five residues in 
the helical linker region 
Dissect the functional contributions of CaM 
structural components ; 
Design protein based contrast agent 
5,6,8 
N60D-N97D-
affibody-
CaM(ProCA22) 
Insert affibody between 
AA 80 and 81of CaM 
Design protein based contrast agent with 
HER-2 target peptide 
7 
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2. Materials and methods 
 
2.1. Molecular cloning and protein engineering 
2.1.1. Site mutation of CaM in single EF- hand loop 
 
Mutations targeting specific CaM Ca2+-binding single site in each EF- hand loop were 
introduced using a polymerase chain reaction (PCR) and further purified through the 
QuikChange mutagenesis kits (Stratagene, La Jolla CA). These mutations were 
verified by DNA sequencing respectively.  
2.1.2. RyR1 mini domain peptide containing CaM binding site 
 
The mini domain peptide of RyR1with the two reported binding sites for CaM 
( RyR11975-1999 and RyR13614-3643 ) was inserted into pGEX- 2T vector after the BamHI 
restriction site with GGSGG linker between these two peptides. New constructed DNA 
was purified by using a standard PCR method and sequencing by GENEWiz. INC. 
 
2.2.  Protein over-expression and purification  
2.2.1.  Expression and purification of CaM and its variants 
 
Recombinant rat CaM and its mutants were over expressed in E.coli strain BL21 
(DE3) pLysS using the pET-7 vector 53,54 expressed in the Luria Bertani (LB) medium 
with 100 mg/L ampicillin for 4 hrs at 37 °C after induced with IPTG. Proteins were 
purified by phenyl-sepharose chromatography55. Protein concentrations were 
determined based on tyrosine absorbance at 277 nm and using the molar extinction 
coefficient 3030 M-1 cm-1 with Beer – Lambert equation 56.  
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2.2.2. Expression and purification of RyR1 mini domain 
 
The mini domain peptide of RyR1 in the CaM binding sites was constructed in the 
plasmid pGEX-2T and expressed in E.coli cell strain BL21 (DE3) in LB medium with 100 
mg/L ampicillin and was induced by IPTG when the OD reached to ~ 0.6. The 
purification procedures followed the protocols for GST-fusion protein purification using 
glutathione sepharose 4B beads (GE Healthcare). The GST-tag fused to proteins was 
cleaved on beads by thrombin. The purified peptide was confirmed by MALDI-TOF-MS 
in the Advanced Biotechnology Core Facilities of Georgia State University. The 
concentrations of engineered mini domain variants were determined using ε280 of      
8250 M-1cm-1. 
 
2.2.3. Expression and purification of 15N isotopic labeled proteins  
 
15N isotopically labeled proteins were expressed in a medium consisting of K2HPO4, 
KH2PO4, MgSO4 and (NH4)2FeSO4.   
15NH4Cl was added into the mini (200 ml) overnight 
and full (1 L) expressed medium as a source for the isotopic nitrogen labeling protein.   
Temperature was reduced from 37 to 25 degree (or even lower, such as 16 degree) after 
induction by IPTG when the optical density (OD600) reached 0.6 and then expressed 
overnight. The collected cell pellets  were purified using the same method as normal 
proteins.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
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2.3. Circular Dichroism Spectroscopy 
 
     Circular dichroism (CD) spectra were obtained in the far UV (190 - 260 nm) 
wavelength region on a Jasco-810 spectropolarimeter at room temperature using a Tris-
KCl buffer (10 mM Tris pH 7.4, 100 mM KCl) in a 1 cm light-path length quartz cuvette. 
All spectra are evaluated with the background subtracted and were comprised of an 
average of at least 10 scans. Protein concentrations are used for 10 µM. The spectra 
with Ca2+ and without Ca2+ were collected respectively to compare the conformational 
changes due to the binding with Ca2+.To determine the structural changes of RyR3614-3643 
upon binding to CaM. Far UV CD spectra of RyR1 peptide alone were subtracted from 
the spectra of CaM plus the peptide.  
 
2.4. Equilibrium Calcium Titrations 
 
     The CaM lobe-specific Ca2+-affinities were determined by monitoring the intrinsic 
fluorescence of phenylalanine (λex = 235 nm, λem = 280 nm) and tyrosine (λex = 277 nm, 
λem = 320 nm) which are sensitive indicators of Ca
2+ binding to CaM‟s N- and C-terminal 
lobes, respectively 57 58. The lobe specific Ca2+ -affinities of CaM bound to the putative 
RyR1 CaM binding domain, RyR13614-3643 
35, were similarly determined but with tyrosine 
excited at 265 nm and emission monitored at 292 nm to avoid interference from the 
peptide intrinsic tryptophan fluorescence. All spectra were collected at ambient 
temperature using a PTI spectra fluoremeter with a 1 cm path length quartz cuvette. 
Ca2+ stock solution (15 or 50 mM) was titrated into 5 or 10 µM CaM in a buffer containing 
50 mM HEPES, 100 mM KCl, 5 mM NTA, 0.05 mM EGTA, pH 7.4. Free Ca2+ 
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concentration was determined by using Oregon Green 488 BAPTA – 5N (0.2 µM) 
according to Equation 1. 
Fluorescence signal decrease of CaM by monitoring the phenylalanines located in the N-
terminal domain. 
 
                                                                                      Equation 1 
 
Where F is the fluorescence at each titration point, Fmin and Fmax are the fluorescence 
intensities at zero Ca2+ and saturating Ca2+ respectively. The Oregon Green dissociation 
constant for Ca2+ is 21.7 µM (λex = 495 nm, λem = 520 nm) [30]. Titration data were fit 
with a nonlinear Hill equation (Equation 2). 
  
                                                                                    Equation 2
                 
 
Where f is the relative fluorescence change, Kd is the dissociation constant of Ca
2+ to 
CaM, n is the Hill coefficient, and [Ca2+] is the free Ca2+ concentration. 
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2.5. Nuclear Magnetic Resonance Spectroscopy  
 
2.5.1. 1H NMR spectra 
 
One-dimensional 1H NMR spectra were recorded on a Varian 500 MHz NMR 
spectrometer with a spectral width of 6600 Hz. Samples with concentration of 100 μM 
were prepared in 10 mM Tris-100 mM KCl, 10% D2O at pH 6.8. Ca
2+ from a stock 
solution was gradually added into the NMR sample tube and the temperature was 
maintained at 37 °C. The program FELIX98 (MSI) was used to process NMR data with 
an exponential line broadening of 2 Hz window function and the suppression of water 
signal with a Gaussian deconvolution function with a width of 20.  
 
2.5.2. CaM – RyR1 binding mode determination by HSQC NMR 
 
 Heteronuclear Single Quantum Coherence (HSQC) experiment was applied on 
Varian Inova 600 MHz spectrometer.  Apo-CaM was prepared in 100 mM KCl, 5 mM 
MES, 100 µM NaN3, pH = 6.3, with 10 mM EGTA at 23°C with a final concentration of 
0.25 mM. Ca2+-CaM was prepared in 10 mM Bis-Tris, 5 mM MES, 100 µM NaN3 buffer, 
pH = 6.5, with 10 mM CaCl2 at 37 °C, and final concentration was 0.45 mM. All these 
NMR samples were prepared containing 10% D2O. NMR spectra were acquired with a 
spectral width of approximately 13 ppm in the 1H dimension and 36 ppm in the 15N 
dimension. Two different RyR1 peptides (3614-3643 and 1975-1999) were prepared in 
mM concentration stock used to titrate into the proteins. The collected NMR data from 
each titration point were processed by NMRpipe and analyzed using Sparky.  
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2.5.3. Size determination of CaM and its variants by NMR  
 
 The pulse-field-gradient diffusion NMR spectra were collected with a modified 
PG-SLED pulse sequence59 on a 600 MHz Varian Inova spectrometer. Each FID was 
processed with 8k complex data points over a spectral width of ~13 ppm. The pulse field 
gradient level (G) was arrayed from ~0.2 to ~31.0 Gauss/cm with a pulse gradient time 
(δ) of 5 ms and a diffusion time (Δ) of 112.5 ms.  The data were processed using FELIX 
(Accelrys).  
 The relationship between the NMR signal intensity (A) and the diffusion constant 
(D) follows Equation 3. 
        
            A = A0exp [-(γδG)
2(Δ-δ/3)D]        Equation 3 
Where A0 is the signal intensity when pulse gradient is not used and  is the gyro 
magnetic ratio of the proton. In the data processing, the signal intensity as a function of 
pulse field gradient level was fitted with Equation 4 using KaleidaGraph 3.5 (Synergy).  
The values discussed in this article are all from the fitting with linear correlation 
coefficient ≥ 0.999.  
                    A = A0exp (-CG
2)       Equation 4                         
The associate diffusion constants and the hydrodynamic radii were obtained by 
comparing the C values of different molecules measured under identical conditions using 
Equation 5 and 6. 
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                     D/D0 = C/C0                Equations 5 
                          R/R0=C0/C               Equations 6 
Where D0, R0 and C0 are the diffusion constant, hydrodynamic radius, and the measured 
C value of lysozyme respectively.  The hydrodynamic radius and diffusion constant of 
lysozyme has been reported previously 60. 
 The gradients were calibrated at 25 C on the residual 1H signal in a sample of 
99.9% D2O, using the published value of 1.902 ± 0.002  10
-9 m2 s-1 for the self-diffusion 
coefficient of HDO at 25 C 61,62.   
 
    NMR samples contained 0.23 mM proteins in 10% D2O, 100 mM KCl, and 10 mM 
imidazole at pH 6.5, with 10 mM Ca2+ for Ca2+-bound or 1 mM EGTA for Ca2+-free 
sample. The intensities of the protein signals were integrated from the methylene and 
methyl region of ~2 ppm spectral width (-0.2 – 1.8 ppm). The integrate regions for each 
species were carefully selected to avoid or reduce interferences from buffer signals. The 
integrated intensities were further normalized to minimize the experimental errors from 
phase adjustment and baseline correction during processing.  
 
2.6. Single channel recording 
 
SR Ca2+ release channel protein was purified from SR membrane vesicles as 
described by Lai et al [34]. Briefly, SR membranes (1 mg/ml were solubilized in 1 M 
NaCl, 25 mM piparazine-N,N’-bis(2-ethanesulfonic acid) (PIPES, pH 7.1), 1.0%             
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3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 0.5% 
phosphatidylcholine (PC), 2 mM dithiothreitol, 0.8 mM benzamidine, 0.1 mM 
phenylmethylsulfonly fluoride (PMSF), 0.6 μg/ml pepstatin, 1 μg/ml  leupeptin, and 1 
μg/ml aprotinin for 2 h at 4⁰C with gentle agitation. Insoluble material was removed by 
centrifugation at 100,000 g for 30 min. The supernatant was applied to a 5-20% linear 
sucrose gradients containing 1 M NaCl, 25 mM PIPES (pH 7.1), 0.75% CHAPS, 0.25% 
PC plus protease inhibitors and centrifuged at 24,500 revolutions per minute (rpm) in a 
Beckman SW28 rotor at 4o C for 16 h. Gradients were fractionated and tubes containing 
the RyR were identified by [3H]ryanodine binding. Fractions containing the RyR were 
pooled, concentrated with an Amicon centirprep 30, aliquotted, frozen in liquid N2 and 
stored at -80o C until use.  
RyR1 mediated currents were recorded as previously described 63. Muller-Rudin planar 
lipid bilayers were formed by painting a lipid mixture (phosphatidylethanolamine, 
phosphatidylserine, and PC in a 5:3:2 ratio by wild type, 50 mg/ml dissolved in n-decane) 
across a 150-250 µm aperture in a Delrin cup. Recording solution consisted of 
symmetrical 200 mM KCl, 20 mM MOPS, pH 7.0, 1.0 mM EGTA and 0.8087 mM CaCl2. 
The cis chamber, to which solubilized channels were added, was connected to the head 
stage input of an Axoclamp 200B patch-clamp amplifier (Axon Instruments, Foster City, 
CA). The trans chamber was held at virtual ground. Channels incorporate into the bilayer 
in a fixed orientation, with the cytoplasmic face toward the chamber into the channels 
were added, thus the cis chamber corresponds to the cytoplasmic side of the channel. 
To investigate the effects of CaM and the variants on RyR1 channel activity, aliquots of 
concentrated wild type or mutant CaM were added to the cis chamber. Single channel 
currents were recorded at +70 mV (Clampex program, pCLAMP 9.2 software, Axon 
Instruments). Currents were filtered at 1 kHz and recorded at 5 kHz. Only those channels 
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that had a conductance of at least 600 pS were used for analysis. Single channel Po was 
calculated (Clampfit program, pCLAMP 9.2 software, Axon Instruments) from at least 2 
minutes of recording using a half-amplitude threshold. When two channels were present 
in the bilayer, indicated by current amplitudes of twice the expected magnitude, Po was 
estimated as the average Po of
 the two channels, calculated as  
                       [Polevel 1 + (Polevel 2
 × 2)]/2.     Equations 7 
Bilayers in which three channels were incorporated were dealt with similarly; 
recordings were not made from bilayers containing more than three channels.  
 
2.7. Phosphodiesterase (PDE) assay 
 
 The Phosphodiesterase 3‟, 5‟ – cyclic nucleotide activator – deficient from bovine 
heart and the substrate 2‟-methylanthraniloyl-cGMP (Mant-c-GMP) were purchased from 
Sigma-Aldrich. All samples were prepared in 10 mM Mops, 100 mM KCl, 200 µM EGTA, 
10 mM CaCl2, pH 7.2. The time based fluorescence signal was monitored at excitation 
wavelength at 282 nm and emission wavelength at 442 nm on the PTI at room 
temperature. Total scan time was defined as 200 ~ 300 s. The substrate itself was firstly 
scanned for 50 s; then protein samples of diverse concentrations mixed with the 
substrate were scanned for another 50 s, followed by addition of PDE with scanning over 
the last 100 or 200 s. The EC50 values were obtained by fitting the catalytic rate of each 
reaction calculated from the fluorescence intensity. 
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2.8. Dye competition method to determine the Gd3+ binding affinity with CaM and 
its variants 
 
Gd3+-binding affinity of wild type and the mutant CaMs were determined by a 
competition fluorescence titration method with a metal ion indicator Fura-6F (Invitrogen 
Molecular Probes) applied as a Gd3+ indicator. The fluorescence spectra of Furo-6F 
were acquired using a fluorescence spectrophotometer (Photon Technology 
International, Inc.) with a 10 mm path length quartz cell at 25 °C. Fura-6F excitation 
spectra were acquired at two wavelengths 340 and 380 nm with an emission wavelength 
at 510 nm. Gd3+-binding affinity of Fura-6F, Kd1, was first determined by a Gd
3+ titration 
with Gd3+ buffer system containing 1 mM nitrilotriacetic acid (NTA). Free Gd3+ 
concentration was calculated with a NTA Gd3+-binding affinity of 2.6 × 10-12 M. Fura-6F 
was mixed with Gd3+ in 1 to 1 ratio for a competition titration accompanied with gradual 
addition of proper amount of protein aliquots. An apparent dissociation constant, Kapp, 
was estimated by fitting the fluorescence excitation intensity ratio of Fura-6F at 340 and 
380 nm with a various concentrations of wt CaM and designed protein based contrast 
agents by a 1:1 binding model.  Gd3+-binding affinity of CA1.CD2, Kd2, was calculated 
with the following equation: 
                    
Td
d
appd
FFuraK
K
KK
]6[1
1
2

             Equation 8 
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2.9.  Modification of designed protein based contrast agents (ProCA22) by 
PEGylation 
 
To optimize the protein solubility, blood circulation time, and reduction of 
immunogenicity, (Methyl-PEO12)3-PEO4-NHS Ester (P40), with tri-branches of 12 units 
PEG was used to react with CaM in the PBS buffer with pH 7.2 at room temperature for 
one hour. The protein concentration was 100 µM and P40 was five times higher than 
proteins. Samples were run through a 5 ml Mono-Q column on the Amersham 
Bioscience AKTA-Fast Protein Liquid Chromatography (AKTA-FPLC) instrument to 
separate the PEGylated protein and free PEG.  Solution samples were taken out from 
the corresponded fractions to run SDS gel and iodine gel respectively.  
 
2.10. Relaxivity determination of protein base contrast agents 
 
Relaxation times (T1 and T2) of vary protein based contrast agents (ProCA), were 
determined at 1.41 T using a 60 mq Bruker Mini Spec relaxometer. The lattice relaxation 
time T1 of ProCAs  was determined on 1.41 T by inversion recovery pulse sequence and 
the data were fitted by the equation 
 S = A× (1 - 2×e (-Ti/T1)).         Equation 9 
The transverse relaxation time T2 of ProCAs was determined through t2_cp_mb 
pulse sequence which is the Carr-Purcell-Meiboom-Gill (CPMG) spin echo method and 
the data were fitted by the equation 
             S = A×e(-Ti/T2).            Equation 10 
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The protein based contrast agent samples (200 μL) with different concentrations 
were placed in matched glass tubes. The tubes were kept in a water bath at 37°C for 10 
min before measurement were taken. Relaxivity r1 and r2 were achieved by liner fitting 
the relaxation times with corresponding concentrations. The second way to measure 
relaxivities is to prepare samples of one specific concentration mixed with Gd3+ as a 
proper binding ratio, and then measuring relaxation times T1 or T2 at 37°C. For this 
method, r1 and r2 were calculated based on 
                     r1 = (1/T1- 1/T1c)/C       Equation 11 
                    r2 = (1/T2 - 1/T2c)/C      Equation 12 
Where T1 and T2 are relaxation times with contrast agent and T1c and T2c are relaxation 
times without contrast agent. C is the concentration of contrast agent in the unit of mM.  
To further evaluate the effect of environment on the relaxivities of protein based 
contrast agent using CaM as a candidate (ProCA22), relaxivities measured and 
compared for ProCA22 in diverse buffers (10 mM HEPES / 10 mM Tris, pH 7.4) and 
under the condition of high salt (100 mM KCl or NaCl) or low salt without adding any KCl 
or NaCl were compared. Moreover, the relaxivities of ProCA22 mimic the in vivo 
environment mixed with human serum for a number of time points were tested using the 
same method on 1.41 T relaxometer. In addition, relaxivities of different series of 
ProCAs were obtained on distinct magnetic field, such as 4.7 T and 7 T. Other mutants 
of CaM, for example the isolated N- and C- terminal, and linker deleted CaM were also 
prepared in the same way to measure their relaxivities on 1.41 T. 
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2.11. Water number measurement by Tb3+ luminescence decay 
 
The designed protein based contrast agent samples prepared in H2O buffer system 
solution were replaced with D2O by first lyophilizing the samples and then redissolving 
them in D2O. This process was repeated for at least three times. Tb
3+-luminescent decay 
in both H2O and D2O were measured to determine the number of water ligands 
coordinated to Gd3+-ProCA22 and ProCA22-P40 complex. The Tb
3+ excitated-state 
lifetime was measured using a fluorescence spectrophotometer (Photon Technology 
International, Inc.) with a 10 mm path length quartz cuvvet at room temperature (22 °C). 
Following excitation at 265 nm with a XenoFlash lamp (Photon Technology International, 
Inc.), in a time based decay fluorescence experiment, Tb3+ emission was monitored at 
545 nm in both H2O and D2O systems. Luminescence decay lifetime was obtained by 
fitting the acquired data with a mono exponential decay function. The water number 
coordinated to the Tb3+-ProCA22 and ProCA22-P40 complexes were then obtained by 
fitting the acquired Δkobs value to the standard curve.     
 
2.12. Cell targeting of protein based contrast agents 
 
Tow human cancer cell lines, SKOV-3 and MDA-MB-231 were selected to examine 
whether the designed ProCA22 can target to cancer cells. SKOV-3 is an ovarian cancer 
cell line with estimated 3 x 106 HER-2 / cell. MDA-MB-231 is a breast cancer cell line 
with modest HER2 levels (~ 3 x 104 HER-2 / cells). Binding of the Gd-ProCA22 and 
ProCA22 – P40 to the selected cells was first analyzed by immuno-fluorescence staining 
using the polyclonal antibody against PEGylated parental protein ProCA22. The cell 
binding analyses showed that the SKOV-3 cancer cells bind more ProCA22 compared to 
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MBD-MDA-231. These results indicated that the designed ProCA22 was able to target 
the cancer cells with high HER-2 expression level. 
 
2.13. MR imaging of protein based contrast agents 
 
We examined the in vivo performance of MRI of CD-1 mice (20-25g, N = 4) using a 
4.7 T Varian MRI system with a dedicated rodent coil with modified parameters and 
variable pulse sequences. During MR scanning, the mice were anesthetized with 1.5% 
iso-flurane and kept warm with a heated pad. MR images were acquired by T1- and T2-
weighted fast spin echo sequences (TR = 2 s, TE =0.022 s, and ESP = 0.01 s) with field 
of view of  3×3 cm, matrix of  256×256, and slice thickness of 1 mm. The tumors were 
dissected after MRI experiments.  Image J was used to quantitatively analyze the MRI 
images obtained. The regions of interest (ROI) were selected by circling the tumor sites. 
Then the signal intensities of the ROIs were calculated and compared. Six adjacent 
slides were selected to measure signal changes which were averaged to obtain 
statistically significant results. 
Here we also introduced an optical imaging capability by conjugating a near-IR dye, 
Cy5.5 Mono Maleimide, a dye that produces an intense signal in the Near IR (NIR) 
region of the spectrum, to a Cystine residue at the C-terminal of the protein to facilitate 
imaging analyses.  The Cy5.5 Mono Maleimide has a maximum absorbance at 674 nm 
and a maximum emission wavelength at 689 nm. The labeling yield is as high as 70%; 
the unlabeled free dye was separated from labeled proteins by dialysis in 10 mM HEPES 
buffer. Cy5.5 Mono Maleimide NIR imaging has high sensitivity and accompanied with 
the MR imaging to confirm the accurate targeting of selected biomarkers to cancer cells. 
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2.14. Immuno-histo-Chemistry (IHC) stainning  
 
To further verify the designed protein based contrast agent targeted to the HER-2 
positive tumor, we carried out immunohistochemistry (IHC) staining using the antibody 
PAb with tissue slides made from the tumor samples and selected organs collected from 
the mice after MR and NIR imaging. Three different kinds of antibodies were applied 
during this process and then samples were taken images under the microscope based 
the vary fluorescence dye labeled on correlated antibodies. 
 
2.15. Statistical Analysis 
 
Data are presented as mean ± SEM.  Parameters derived from the Hill equation and 
equations 3 were compared using a one-way analysis of variance with a Holm-Sidak 
multiple comparison as a post-hoc test. Statistical analysis was performed using 
SigmaStat 3.1 (Systat Software, Point Richmond, CA). Statistical significance was set at 
p<0.05.   
36 
 
 
3. Ca2+ Binding Affinity and the Activation Profile are tuned by Site Specific 
Modification of Calmodulin 
 
 
          CaM regulates the functions of many target proteins, including a number of ion 
channels in multimodal. For example CaM can facilitate or inhibit Cav2.1 depending on 
which lobe of CaM is Ca2+-bound 29. Similarly, RyR1 activation can be enhanced or 
inhibited depending of the Ca2+ saturation of the C-terminal lobe. Thus, by altering the 
Ca2+ affinity and thereby the Ca2+ saturation state of a specific lobe of CaM, it should be 
possible to selectively enhance (or reduce) a particular mode of CaM regulation of ion 
channels.  
In this work, we tuned the activation profile of the RyR1 channel by introducing a 
point mutation into CaM (Asn97Asp) that generated a CaM variant which when bound to 
a putative RyR1 CaM-binding peptide specifically increased the Ca2+ affinity of CaM‟s C-
domain without altering the Ca2+ affinity of the N-domain or substantially altering the 
mode of interaction with the peptide. To identify this site as critical for the conversion of 
CaM from a channel activator to an inhibitor, CaM mutations were designed to increase 
the affinity of each individual CaM EF-hand Ca2+-binding motif by increasing the number 
of acidic residues in Ca2+-coordinating positions within each EF-hand. The Ca2+ affinity 
of each of CaM‟s lobes was then determined by monitoring the Ca2+ dependence of the 
intrinsic phenylalanine and tryptophan fluorescence, which has previously been shown 
to reflect Ca2+ binding to sites I and II of CaM‟s N-domain and sites III and IV of CaM‟s 
C-domain, respectively 57. The functional effects of these substitutions were then 
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determined by examining CaM modulation of Ca2+ activation of the RyR1 Ca2+ release 
channel.  
 
 
3.1. Analysis of the coordinated binding of Ca2+ with CaM and the induced    
conformational changes 
 
 
CaM is an important intracellular protein. There are two globular domains connected 
by a flexible linker in CaM. Each of the two domains contains a pair of well conserved 
canonical EF-hand calcium binding motifs which bind Ca2+ in a cooperative manner 64.   
The canonical EF-hand consists of a helix-loop-helix motif 20,65,66. Ca2+ is coordinated 
within the EF-hand by seven oxygen atoms from six amino acids, five of these residues 
are within the loop, and the sixth is located in the exiting helix. The coordinating residues 
can be designated as in a classical EF- hand loop by their positions in the linear 
sequence within the loop (1, 3, 5, 7, 9, and 12) and by their locations in the tertiary 
geometry of the coordinating site (±X, ±Y, and ±Z)67. The residues of the coordinating 
site form a pentagonal bipyramid where the Y- and Z-axis pairs align along the vertexes 
of a planar pentagon with the X axis pair lying perpendicular to the Y- and Z-axis plane. 
The residue at position 1 (+X) is a conserved aspartate and position 3 (+Y) is most 
frequently an aspartate or asparagines.  The residue at position 9 (-X) does not directly 
coordinate Ca2+, rather the interaction is mediated by a bridging water molecule. The 
residue at position 12 (-Z) is a conserved bidentate glutamate. Unlike the other 
coordinating residues which chelate Ca2+ via side-chain oxygens, the residue at position 
7 (-Y) coordinates Ca2+ via its backbone carbonyl oxygen. Residues 7 to 9 form a small 
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anti-parallel beta-sheet between the two coupled EF-hands within each domain    
(Figure 3.1). 
 
The key factors contributing to the Ca2+-binding affinity of EF-hand proteins, 
especially CaM, has been the subject of extensive work 67, 68, 69, 70.  Thus, CaM variants 
were designed based on considerations of site-specific calcium binding affinities, 
cooperativity between EF-hands within a domain; inter domain cooperativity and impact 
on CaM regulatory function. First, increasing the number of negatively charged residues 
from three to four within the EF-hand coordination sphere stabilizes the protein-Ca2+ 
complex. Increasing the number of charged residues beyond four may decrease the 
stability of the complex due to electrostatic repulsion between nearby similarly charged 
residues 70. Four CaM variants, Thr26Asp, Asn60Asp, Asn97Asp, and Gln135Asp, were 
designed with one additional charged ligand residue (Asp) introduced into EF-hand 
loops I, II, III and IV (Figure.3.1), respectively. Site I of wild type CaM contains four 
acidic residues at coordination positions +X, +Y, and ±Z. The –Y and –X positions are 
occupied by threonines. Because the residue at the –X position contributes to Ca2+ 
coordination via water bridge, the   –Y residue (Thr26) was replaced with aspartate. Site 
II contains four acidic residues located at coordinating positions ±X, +Y and –Z, an 
asparagine at +Z and a threonine at –Y. Given the fact that the most common residue at 
the +Z location is aspartate 66; the asparagine at residue 60 was replaced with aspartate. 
Site III contains three acidic residues at +X, +Y, and –Z along with an asparagine at +Z, 
a tyrosine at –Y, and a serine at –X. Following the same reason as for site II, an 
aspartate was substituted for the asparagine at residue 97 (+Z). Site IV is similar to site 
me, containing four acidic residues at + X, + Y and ± Z, a glutamine at –Y and an 
asparagine at –X. Again, following the same logic as for site I, the glutamine at residue  
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135 (-Y) was replaced by an aspartate.  Second, domain specific calcium binding 
affinity can be altered by changing the electrostatic interactions between coupled EF-
hands within a domain 70.  Changing residues within each Ca2+-binding site can have 
significant effects on inter domain cooperativity 69.  Finally, by tailoring the affinity of 
individual CaM Ca2+-binding sites, Ca2+ loading of the target-specific, functionally 
important lobe of CaM can be manipulated. This strategy will allow CaM regulation of the 
biological activity of specific targets, in this case the activation profile of RyR1, to be 
tuned. 
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A
B
EF-1 E F K E A F S L F D K D G D G T I T T K E L G T V M R S L
D
EF-2 E L Q D M I N E V D A D G N G T I D F P E F L T M M A R K 
D
EF-3  E I R E A F R V F D K D G N G Y I S A A E L R H V M T N L  
D
EF-4  E V D E M I R E A D I D G D G Q V N Y E E F V Q M M T A K
D
Residue #              20  22 24 26  28    31
Geometric position    +X  +Y  +Z  -Y  -X    -Z
Loop position 1  3  5   7  9    12
56  58  60   62  64   67
93  95  97   99 101   104
129 131 133 135 137   140
F12
F19
F16 F68
F65
T26
N60
Q135
N97Y138
Y99
 
                    Figure 3.1.Sequence alliangment of Rat Calmodulin in the presence of Ca
2+
.                          
A) Ca
2+ 
-CaM reconstructed using PyMol with the PDB   file 3cln as a template. The location 
of each EF-hand point mutations (T26, N60, N97, and Q135; red sticks) used in my work 
(chapter 3) and with the aromatic residues phenylalanines -- F (residues 12, 16, 19, 65, and 
68; orange sticks) and tyrosines --Y (residues 99 and 138; blue sticks) contributing to the 
CaM intrinsic fluorescence is indicated. B) Residues coordinating Ca
2+
 within the 
pentagonal bipyramid are in bold and their location in the EF-loop, geometric position and 
location in the primary sequence is indicated at the top of the figure. The substitutions to 
increase the number of acidic residues in each EF-hand are indicated in red italics.  
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3.2. Conformational analysis of CaM variants and peptide binding effects on the 
secondary structures 
 
To determine the effect of the EF-hand charge mutations on the conformation of 
CaM in solution and when bound to the RyR13614-3643 peptide, the secondary structure of 
the CaM variants was examined using far UV circular dichroism (CD). Consistent with 
the substantial α-helical content of both apo- and Ca2+-loaded CaM, wild type CaM had 
large negative troughs at 208 and 222 nm in buffer containing 1 mM EGTA and in buffer 
containing 1 mM Ca2+ (Figure 3.2.A). In EGTA containing media, CaM variants 
Thr26Asp, Asn60Asp, and Asn97Asp (Figure 3.2.B-D) exhibited a 30-34% decrease in 
ellipticity at 222 nm. In contrast, the Gln135Asp substitution resulted in only a 9% 
decrease in ellipticity (Figure 3.2.E). In Ca2+-containing buffer, substitution in Ca2+-
binding sites I and III caused a 30-40% decrease in ellipticity, while substitution in sites II 
and IV had only small effects (2-8% decrease). 
Upon addition of the RyR13614-3643 peptide to wild type CaM in EGTA containing 
buffer, there was 22% decrease in ellipticity at 222 nm attributable to CaM            
(Figure 3.2.A). In Ca2+ containing buffer, addition of the peptide caused a 9% increase 
in the ellipticity of CaM. Thus, both the Ca2+-free and Ca2+-bound forms of wild type CaM 
interact with the RyR13614-3643 peptide. CaM variants Thr26Asp, Asn60Asp and 
Asn97Asp showed similar ellipiticity changes (27-39% decrease) upon the addition of 
RyR1 peptide in EGTA containing media (Figure 3.2.B-D). Again, the Gln135Asp    
(loop IV) CaM variant differed and exhibited a 64% decrease in ellipticity under these 
conditions (Figure 3.2.E). 
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In Ca2+-containing buffer, the addition of RyR13614-3643 peptide caused a 9% increase 
in the wild type CaM ellipticity at 222 nm (Figure 3.2.A). CaM variants Thr26Asp, 
Asn60Asp, and Asn7Asp all exhibited similar increases (7-10%) in ellipticity upon the 
addition of peptide in Ca2+ containing media (Fig 3.2.B-D). The Gln135Asp CaM variant 
was again the exception. Upon addition of the RyR13614-3643 peptide to Gln135Asp CaM 
in Ca2+ containing media, there was a 22% decrease in ellipticity (Fig 3.2.E). 
 
These results, summarized in Figure 3.2.F and 3.2.G, suggest that the addition of a 
charged residue to EF-loops I, II or III causes only minor conformational changes to the 
apo- and Ca2+-loaded forms of these CaM variants. Further, these CaMs undergo similar 
conformational changes upon binding to the RyR13614-3643 peptide. In contrast, the 
conformations of the apo- and Ca2+-loaded forms of the Gln135Asp CaM variant upon 
RyR13614-3643 peptide binding are likely to be significantly different from those of the 
bound wild type CaM. 
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Figure 3.2. CD spectra of CaM and the variants in apo-and holo - form with and   
without RyR1 peptide. 
(A: wt CaM; B: Thr26Asp CaM; C: Asn60Asp CaM; D: Asn97Asp CaM; 
E:Gln135Asp CaM). Ca2+ (broken lines) or EGTA (solid lines) and with RyR13614-3643 
(grey) or without RyR13614-3643 (black). F and G) Molar ellipicities of CaM variants as 
a fraction of wt CaM without peptide in (F) EGTA form without RyR13614-3643 (black 
bars) or with RyR13614-3643 (white bars) and (G) Ca
2+ without RyR13614-3643 (black bars) 
or with RyR13614-3643 (white bars).  
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3.3.  Effects of charge variants on domain specific Ca2+ affinity 
 
Lobe-specific Ca2+ binding affinities of the CaM variants were determined by 
monitoring intrinsic phenylalanine and tyrosine fluorescence changes during equilibrium 
Ca2+ titrations 57,58. Figure 3.1.A shows the positions of the intrinsically fluorescent 
residues. Although three phenylalanines are located in the C-terminal lobe (C-domain) 
VanScyoc et al 57 showed that these residues are non-reporting. Thus, the decrease in 
phenylalanine fluorescence intensity reflects the conformational changes in the N-
terminal lobe (N-domain) of CaM as a result of Ca2+ binding to sites I and II. The 
increase in tyrosine fluorescence signal shown in Figure 3.3.C and D reflects the 
conformational changes in CaM‟s C-domain as a result of Ca2+-binding to CaM sites III 
and IV. The Ca2+-dependence of phenylalanine and tyrosine fluorescence of wild type 
and mutant CaMs were fit with the Hill equation and are illustrated in Figure 3.3.A-D. 
CaM Ca2+ dissociation constants (Kd) and Hill coefficients (nH) as well as the free energy 
of Ca2+ binding (ΔG) derived from these fits and are summarized in Figure 3.3.E-H and 
in Table 3. 1. As previously established 24,71, the C-domain of CaM has a significantly 
higher Ca2+ affinity than the N-domain (C-domain Kd = 2.04 ± 0.02 μM; N-domain Kd = 
11.5 ± 0.68 μM, p<0.05). Overall, the free energy of Ca2+ binding to the C-domain was 
~1 kcal/mol lower than the free energy of binding to the N-domain (Table 3.1). The 
Thr26Asp mutation at -Y in EF-hand I significantly increased the Ca2+ affinity of both the 
N- and C- domains. In contrast, the Asn60Asp mutation at +Z in loop II had no significant 
effect on Ca2+ affinity of either the N- or C- domain of CaM.  
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CaM Variant 
N-domain  C-domain  
Kd (µM) nHill  ΔG1 Kd (µM) nHill ΔG2 
Wild Type 11.5 ± 0.68 1.72 ± 0.08 -6.73 ± 0.18 2.04 ± 0.02 2.31 ± 0.15 -7.76 ± 0.16 
Thr26Asp 8.8 ± 0.46* 1.48 ± 0.13 -6.89 ± 0.11 1.38 ± 0.01* 2.07 ± 0.12 -7.99 ± 0.15 
Asn60Asp 13.1 ± 0.25 1.70 ± 0.06 -6.66 ± 0.12 2.30 ± 0.01 2.39 ± 0.11 -7.69 ± 0.16 
Asn97Asp 14.6 ± 0.25* 1.61 ± 0.05 -6.59 ± 0.15 1.24 ± 0.01* 2.58 ± 0.20 -8.05 ± 0.14 
Gln135Asp 8.2 ± 0.36* 1.05 ± 0.02* -6.93 ± 0.13 3.94 ± 0.01* 2.01 ± 0.11 -7.37 ± 0.15 
wtCaM-
RyR13614-3643 
2.5 ± 0.02 1.2 ± 0.02 -7.64 ± 0.15 0.764 ± 0.03 1.0 ± 0.03 -8.34 ± 0.15 
Asn97Asp-
RyR13614-3643 
2.4 ± 0.02 1.2 ± 0.02 -7.66 ± 0.13 0.069 ± 0.01
# 
2.6 ± 0.01
# 
-9.76 ± 0.11
# 
   
Equilibrium Ca2+ titrations were performed as described under Experimental. Data are 
presented mean ± SEM, n=3. *Significantly different from Wild Type, p<0.05.  # indicates the 
significantly different from wtCaM-RyR13614-3643, p<0.05. ΔG(kcal/mol) = -RTlnKa.  
 
3.1. Lobe-specific Ca2+ affinity of EF-hand CaM mutants. 
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Figure3.3. Equilibrium Ca2+ titrations of wild type and CaM mutants monitored by 
phenylalanine and tryrosine fluorescence. 
A and B) Ca
2+
-induced decrease in N-terminal Phe fluorescence. C and D) Ca
2+
-induced 
increase in C-terminal Tyr fluorescence. A and C) wild type and N-terminal CaM variants. B 
and D) wild type and C-terminal CaM variants. Titration curves were fit by the Hill equation, 
wild type CaM (○), Thr26Asp CaM (●), Asn60Asp CaM (■), Asn97Asp CaM (▲), Gln135Asp 
CaM (▼). E) Comparison of N-domain Ca
2+
 Kd for CaM variants; F) Comparison of C-
terminal Ca
2+
 Kd of CaM variants. G)N-terminal Hill coefficient, H) C-terminal Hill coefficient. 
Data are the mean ± SEM, n = 3. *Significantly different from wild type CaM, p < 0.05. 
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Mutations in the C–domain had more significant effects on the Ca2+ affinity than 
mutations in the N-domain. The Asn97Asp mutation significantly increased the C-domain 
Ca2+ affinity, significantly decreased the N-domain affinity and thus further increased the 
difference in affinity between the two lobes of CaM.  In addition, the free energy of Ca2+ 
binding to the C-domain of this CaM was the lowest of any lobe of any variant. In 
contrast to all other substitutions studied, the Gln135Asp mutation significantly 
decreased the Ca2+ affinity of the domain in which it was located and increased the Ca2+ 
affinity of the opposing domain. This substitution narrowed the difference in Ca2+ affinity 
between the two lobes and reduced the free energy difference between N- and C- 
domains to ~0.4 kcal/mol (compare to ~1.0 kcal/mol for wild type). Further, the 
Gln135Asp mutation was the only substitution to significantly affect the cooperativity of 
Ca2+ binding, reducing the Hill coefficient for the N-domain (nH: wild type = 1.72 ± 0.08; 
Gln135Asp = 1.05 ± 0.02) and thus uncoupling the cooperativity between sites I and II 
within the N-domain. Interestingly, this mutation did not significantly alter the 
cooperativity between sites III and IV in the C-domain. 
Of the six Ca2+ coordinating residues within each of the four EF-hands of 
mammalian CaM, the Asp at positions 1 and 3 and the Glu at position 12 are conserved 
(Figure 3.1). The conservation of these residues suggests they are critical for CaM 
function and indeed, replacing the charged Glu with an uncharged Gln or Ala at loop 
position 12 (-Z axis) in any of the EF-hands substantially decreased the Ca2+ affinity of 
the binding site 72, 73. The identity of the residue at each of the remaining positions is 
variable. Reid and Hodges 67 proposed the acid pair hypothesis to relate the Ca2+ affinity 
of EF-hands to the location of negatively charged residues in chelating positions. This 
hypothesis predicted that the highest Ca2+ affinity would occur in an individual EF-hand 
when acid pairs are located in the X- and Z-planes and that additional carboxylate 
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residues would decrease the affinity of the binding site due to electrostatic repulsion. 
However, additional factors contribute to EF-hand Ca2+ binding affinity, including the 
hydrophobicity of the loop and flanking residues 74,75,76, the nature of the chelating 
residues within the loop 77, and electrostatic interactions, especially those between 
charged liganding residues 78, 79, 80. 
Work with synthetic peptides and uncoupled EF-hands in intact CaM supported 
the hypothesis 73,81.  Black et al 68 directly tested the acid-pair hypothesis in coupled EF-
hands by monitoring the N-domain Ca2+ affinity of intact CaM via the Ca2+-dependent 
change in fluorescence of a Trp which replaced a Phe at residue 19 and systematically 
adding or removing acidic residues in Ca2+ coordinating positions within EF-hands I or II. 
Their findings generally supported the acid pair hypothesis in that increasing the number 
of acid pairs within each hand from zero, to one and then to two, increased the affinity of 
N-domain Ca2+ binding sites. Adding an additional acidic residue to either EF-hand 
further increased Ca2+ affinity which then fell upon the completion of the third acid pair. 
Rather than introducing an additional mutation to monitor the concentration dependence 
of CaM Ca2+ binding we took advantage of the method of VanScyoc et al and 
determined the domain specific Ca2+ affinities by monitoring Tyr and Phe fluorescence 
within each domain (Figure 3.3) 57. The acid pair hypothesis was insufficient to predict 
our results. In accordance with the hypothesis, increasing the number of acidic residues 
from 3 to 4 (site III, Asn97Asp) increased the Ca2+ affinity of the C-domain. However, 
rather than decreasing the domain Ca2+ affinity, further increases in the number of acidic 
residues had variable effects including increasing the N-domain Ca2+ affinity (Thr26Asp), 
having no effect on the N-domain Ca2+ affinity (Asn60Asp), and decreasing the C-
domain Ca2+ affinity (Gln135Asp). Differences in the location of the acidic residues did 
not seem to account for their varying effects on the Ca2+ affinity. The Thr26Asp variant 
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increased the Ca2+ affinity while the Gln135Asp variant had a decreased affinity despite 
the fact that both mutations added a negative charge at the –Y position and resulted in 
acidic residues at +X, ±Y and ±Z.   
These results can be explained in terms of a charge ligand-balanced model in 
which both the number of negatively charged ligand residues and the balanced 
electrostatic dentate-dentate repulsion by adjacent charged residues are major 
determinants of the Ca2+-binding affinities of EF-loops in CaM 70.  In addition to acidic 
residues at positions 1, 3, 5 and 12, EF-hand I also has positively charged Lys residues 
at positions 2 and 11 which may reduce the electrostatic repulsion arising from closely 
situated carboxylates. Thus, the Thr26Asp substitution increased the net charge from -2 
to -3 and increased the N-domain Ca2+ affinity. In contrast, site IV has an additional 
negative residue at position 11. Thus, the Gln135Asp substitution increases the net 
charge within this site from -5 to -6, increases the charge repulsion within the EF-hand 
and decreases C-domain Ca2+ affinity. 
Two CaM variants we created (Th26Asp and Asn60Asp) were similar to those 
generated by Black et al 68 (Phe19Trp/Thr26Asp and Phe19Trp/Asn60Asp). Both studies 
reported an increase in the N-domain Ca2+ affinity upon replacing Thr 26 with Asp. 
However, the results differ in regards to the Asn60Asp variant. We observed no change 
in the N-domain Ca2+ affinity of the Asn60Asp CaM while Black et al 68 reported a 
significant increase. Although substitution of Trp for Phe19 provided for a highly 
sensitive measure of the Ca2+-induced conformational changes in the N-lobe of CaM, the 
substitution may subtly perturb the structure of CaM, and thus have also altered the Ca2+ 
affinities of sites I and II.  
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3.4. Functional effects of CaM EF-hand mutations on RyR1 activity 
 
RyR1 channel opening exhibits biphasic Ca2+ dependence. CaM shifts this activation 
profile to lower Ca2+ concentrations, enhancing channel opening at low Ca2+ 
concentration and inhibiting opening at higher concentrations. Based on the lack of 
channel inhibition by a Ca2+-insensitive CaM mutant, the RyR1 activation at low Ca2+ is 
ascribed to the Ca2+-free form of CaM and the inhibition is attributed to Ca2+ binding to 
CaM. Using domain-specific EF-hand knockdown mutations, Rodney et al 82 and Fruen 
et al 83  showed that Ca2+ binding to the C-domain of CaM is the switch to convert CaM 
from a RyR1 activator to a channel inhibitor. However, recently published work84 
conflicts with this view. Boschek et al 84 compared the Ca2+ dependence of skeletal 
muscle SR [3H]ryanodine binding with Ca2+-induced change in signals from CaM that 
had been fluorescently labeled on either the N- or C-domain and bound to a putative 
RyR1 CaM-binding peptide. The Ca2+-dependent conformational changes in the C- 
domain of CaM occurred in the same concentration range as the Ca2+ activation of SR 
vesicle ryanodine binding. Further, the Ca2+-dependent conformational changes in the N- 
domain of CaM occurred in the same concentration range as the Ca2+ inhibition of SR 
vesicle [3H]ryanodine binding. Therefore, the authors concluded that Ca2+ binding to 
CaM‟s C-domain caused activation of RyR1 and Ca2+ binding to CaM‟s N-domain 
resulted in channel closure. We used our CaM variants to determine whether Ca2+ 
binding to CaM‟s N-domain or C-domain are the switch to convert CaM from a RyR1 
activator to a channel inhibitor. We reasoned that increasing the Ca2+ affinity of the 
functionally important CaM domain, with no change in the affinity of the opposing domain, 
would lower the Ca2+ concentration at which CaM was converted from a channel 
activator to a channel inhibitor (switch-point). 
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In the media containing sub-micromolar Ca2+, CaM increases RyR1 channel opening; 
whereas in the media containing micromolar Ca2+, CaM plays an inhibitory role. 
Therefore, to determine whether our EF-hand site mutations altered the ability of CaM to 
regulate RyR1 we determined the CaM concentration dependence of SR vesicle 
[3H]ryanodine binding in media containing either 100 nM or 700 μM Ca2+. In media 
containing 100 nM Ca2+ (Figure 3.4), wild type CaM increased ryanodine binding 12.9 ± 
0.9% with an EC50 of 109.0 ± 18.4 nM and a Hill coefficient of 1.07 ± 0.17. All four CaM 
variants increased SR vesicle ryanodine binding to a similar extent as wild type CaM 
(Table 3.2). However, the site II mutation, Asn60Asp, decreased the EC50 for CaM 
activation (Table 3.2). None of the remaining mutations altered the CaM EC50 for SR 
vesicle [3H]ryanodine binding and none of the mutations significantly altered the Hill 
coefficient. 
 
  In media containing 700 μM Ca2+, wild type CaM decreased SR vesicle 
ryanodine 16.7 ± 0.8% with an IC50 of 30.9 ± 3.0 nM and a Hill coefficient of 1.80 ± 0.28 
(Figure3.4, Table 3.2). Gln135Asp was the only mutation to significantly alter the 
efficiency of CaM inhibition. At saturating concentrations, inhibition by this mutant was 
only 59% of the inhibition induced by wild type CaM. The reduced efficacy of inhibition 
suggests that this variant interacts with RyR1 in a mode that differs from that of wild type 
CaM. Two variants, Thr26Asp and Gln135Asp increased the CaM IC50 (73.7 ± 10.0 and 
57.8 ± 6.7 nM respectively). None of the mutations altered the Hill coefficient. 
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Table 3.2.Fit parameters for the Calmodulin concentration dependence of activation 
Calmodulin 
Variant 
Extent of 
Activation 
(% Bmax) 
na EC50 (nM) 
Extent of 
Inhibition 
(% Bmax) 
ni IC50 (nM) 
Wild Type 12.9±0.9 1.07±0.17 109.0±18.4 16.7±0.8 1.80±0.28 30.9±3.0 
Thr26Asp 15.5±1.0 0.97±0.16 141.6±29.2 18.0±1.2 1.80±0.42 73.7±10.0* 
Asn60Asp 15.3±1.5 1.32±0.36 27.4±6.0* 17.3±1.5 1.48±0.37 15.9±2.9 
Asn97Asp 11.3±1.4 1.27±0.41 75.1±20.4 15.2±1.4 1.88±0.53 39.6±7.0 
Gln135Asp 16.4±1.1 1.14±0.18 95.6±14.8 9.8±0.7* 2.60±0.70 57.8±6.7* 
SR vesicle [3H]ryanodine binding was performed as described under Experimental in 
media containing either 100 nM Ca2+ for activation or 700 μM Ca2+ for inhibition. 
*Significantly different from Wild Type, p < 0.05; n = 6-13.  
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              Figure 3.4.CaM concentration dependence of activation (A, B) and inhibition  
(C, D)of SR vesicle [
3
H]ryanodine binding. 
Ryanodine binding was performed as described under Experimental in media containing 
100 nM Ca
2+
 (A, B) or 700 μM (C and D) and the indicated concentration of CaM; n = 6-13. 
Lines are fits to the Hill equation. A) Comparison of activation by wild type CaM (○) with 
activation by N-terminal mutants Thr26Asp CaM (●) and Asn60Asp CaM (■). B) 
Comparison of activation by wild type CaM (○) with activation by C-terminal EF-hand 
mutants Asn97Asp (▲) and Glc135Asp (▼). C) Comparison of inhibition by wild type CaM 
(○) with inhibition by the N-terminal mutants Thr26Asp CaM (●) and Asn60Asp CaM (■). D) 
Comparison of inhibition by wild type CaM (○) with inhibition by C-terminal EF-hand 
mutants Asn97Asp (▲) and Gln135Asp (▼). Note that for comparison and clarity the wild 
type data in panels A and C are duplicated in panels B and D respectively. 
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  To determine whether manipulating the site-specific Ca2+ affinity of CaM modifies 
the RyR1 activation profile, we next examined the effects of CaM variants on the Ca2+ 
dependence of SR vesicle [3H]ryanodine binding (Figure3.5, Table 3.3). In the absence 
of CaM, ryanodine binding exhibited the expected biphasic Ca2+ dependence (EC50 = 
1.69 ± 0.25 μM; IC50 = 367.1 ± 53.5 μM). With Ca
2+ as the sole channel regulator, SR 
vesicle [3H]ryanodine binding reached 63.1 ± 2.1% of the estimated maximal binding. 
Including 2 μM wild type CaM in the incubation media significantly reduced the extent of 
Ca2+ activation of RyR1 to 39.4 ± 3.0% of maximal, significantly reduced the Ca2+ EC50 to 
0.23 ± 0.08 μM and reduced the Ca2+ IC50 to 70.6 ± 25.6 μM. This resulted in a leftward 
shift in the Ca2+ dependence of RyR1 activation such that both channel activation and 
inhibition occurred at lower Ca2+ concentrations. The switch from RyR1 activator to 
inhibitor is attributed to Ca2+ binding to CaM, thus we define a Ca2+ switch-point as the 
Ca2+ concentration at which CaM  is converted from a channel activator to an inhibitor. In 
practice, this point was the Ca2+ concentration at which the line from equation 3 fitted to 
the ryanodine binding data obtained in the presence of CaM intersected the curve fitted 
to the binding data obtained in the absence of CaM, i.e. the Ca2+ concentration at which 
the ratio of [3H]ryanodine bound in media containing CaM to the [3H]ryanodine bound in 
media lacking CaM was equal to one (Figure 3.5 C and D). Thus, the switch point for 
wild type CaM occurred at 3.8 ± 0.7 μM Ca2+ (arrows labeled 1 in Figure 3.5). Including 
2 μM CaM variants in the binding media caused a similar leftward shift in the Ca2+ 
dependence of ryanodine binding significantly decreasing both the Ca2+ EC50 and Ca
2+ 
IC50. Further, mutations in CaM‟s N-terminal Ca
2+-binding sites had no significant effect 
on CaM-induced decrease in Ca2+-activated SR vesicle ryanodine binding. Thus, the 
Ca2+ dependence of ryanodine binding in media containing N - terminal CaM mutants 
virtually overlapped the Ca2+-dependence of binding in media containing wild type CaM. 
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In contrast, mutations in CaM‟s C-domain Ca2+-binding sites had substantial 
effects on CaM modulation of RyR1 activation. When Asn97Asp, the site III CaM mutant, 
was included in the binding media the extent of Ca2+ activation was significantly reduced 
compared to wild type CaM (27.1 ± 1.7% vs 39.4 ± 3.0%). When compared to wild type 
CaM, this site III CaM variant switched from activating RyR1 to inhibiting the channel at 
a significantly lower Ca2+ concentration (1.2 ± 0.2 μM vs 3.8 ± 0.7 μM). However, the site 
IV mutation Gln135Asp increased the extent of Ca2+ activation to 77.0 ± 7.3% of 
maximal. The switch-point for this CaM variant was significantly increased to             
38.2 ± 7.2 μM, approximately 10 fold higher that the switch-point for wild type CaM.  
 
 
Table 3.3.Fit parameters for the Ca2+-Dependence of SR vesicle [3H]ryanodine 
binding in the presence of CaM and its variants. 
Calmodulin 
Variant 
Bmax 
(pmol/mg) 
Bo 
 (% of Bmax) 
EC50 (μM) IC50 (μM) 
Switch 
Point 
(μM) 
No CaM 8.04±1.01 63.1±2.1 1.69±0.25 367.1±53.5  
Wild Type 8.04±1.01 39.4±3.0* 0.23±0.08* 70.6±25.6* 3.8±0.7 
Thr26Asp 6.57±1.14 31.1±2.6* 0.12±0.05* 115.3±49.1* 2.5±0.4 
Asn60Asp 7.10±1.53 34.6±3.4* 0.13±0.06* 93.9±47.9* 3.4±0.4 
Asn97Asp 7.20±1.08 27.1±1.7*# 0.37±0.15* 119.7±36.6* 1.2±0.2# 
Gln135Asp 6.79±1.69 77.0±7.3*# 0.53±0.19* 59.8±22.3* 38.2±7.2# 
SR vesicle [3H]ryanodine binding was performed as described under Experimental 
± 2 μM calmodulin. *Significantly different from No CaM, p<0.05; #significantly 
different from wild type CaM, p<0.05; n=6-14. 
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             Figure 3.5.Effects of wild type and EF-hand mutant CaM on the Ca2+ concentration 
dependence of SR vesicle [3H]ryanodine binding. 
A) Comparison of No CaM (○), wt CaM (□) with Thr26Asp CaM (●) and Asn60Asp 
CaM (■). Arrows indicate Ca2+ switch point for wild type CaM (1), Thr26Asp CaM (2), 
Asn60Asp CaM (3). B) Comparison of No CaM (○), wild type CaM (□) with 
Asn97Asp (▲) and Gln135Asp (▼). Arrows indicate Ca2+ switch point for wild type 
CaM (1), Asn97Asp CaM (4), Gln135Asp CaM (5). C and D) SR vesicle 
[3H]ryanodine binding expressed as binding with one of the CaM variants as 
fraction of SR vesicle ryanodine binding without CaM. Symbols and numbers in C 
and D have the same meaning as in A and B respectively. For comparison and 
clarity the No CaM and wild type CaM data from A and C are duplicated in B and D 
respectively. 
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To verify the effects of our Asn97Asp mutant on the Ca2+-dependence of RyR1 
channel opening, we compared the effects of wild type CaM and Asn97Asp CaM on the 
open probability (Po) of RyR1 channels incorporated into planar lipid bilayers. Based on 
a switch point for wild type CaM of 3.8 μM Ca2+, in recording media containing 4 μM Ca2+, 
the addition of wild type CaM should not reduce channel Po. In contrast, because 
Asn97Asp CaM switches from a channel activator to an inhibitor at 1.2 μM Ca2+, 
Asn97Asp should decrease channel Po. Indeed, this was observed (Figure 3.6). In the 
representative experiment in 7A, the addition of 3 μM wt CaM increased channel Po from 
0.032 to 0.058. Figure 3.6.B shows an experiment in which two channels incorporated 
into the bilayer simultaneously. The addition of 3 μM Asn97Asp CaM reduced the 
average Po of the two channels from 0.028 to 0.017. Summary data is presented in 
Figure 3.6.C. In media containing 4 μM Ca2+, wtCaM did not significantly alter RyR1 Po 
(No CaM = 0.040 ± 0.025, 3 μM wild type CaM = 0.033 ± 0.017). In contrast, the addition 
of Asn97Asp significantly reduced channel Po (No CaM = 0.032 ± 0.013, 3 μM Asn97Asp 
CaM = 0.011 ± 0.004).  
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       Figure 3.6.Effects of wild type and N97D CaM on single channel open probability. 
RyR1 channels were incorporated into artificial bilayers and currents recorded as 
described under Experimental condations. Panels A and B show representative 
experiments in which channel activity was recorded before and after adding 3 μM 
wt CaM (A) or 3 μM N97D CaM (B). Lines to the left of the figure indicate the closed 
current level; openings are upward. Panel C shows that the addition of wt CaM did 
not significantly alter channel Po. *Significantly different from No CaM; p < 0.05. 
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3.5.  Conformational changes and interactions with peptide affect Ca2+ binding 
affinities to the two domains of CaM 
 
Ca2+-induced conformational changes to the two domains of CaM are coupled 
phenomena 85,86. Thus, changes in the Ca2+ affinity of either the N- or C-domain could 
cause a change in Ca2+ affinity of the opposite domain. However, the direction of affinity 
change of the opposite domain does not appear to be linked to the direction of affinity 
change of the mutated domain. Indeed, in the CaM variants under study the direction of 
change could be the same in both lobes (Thr26Asp) or in opposite directions with the 
Asn97Asp mutation increasing the C-domain Ca2+ affinity and decreasing the N-domain 
affinity while the Gln135Asp mutation had the opposite effects.  
 
The decreased C-domain Ca2+ binding affinity of the site IV Gln135Asp mutation and 
the increased N-domain affinity further support the notion that EF-hand motif IV 
mutations often result in a large change of Ca2+ binding affinity, possibly due to alteration 
in inter- and intradomain interactions. Fefeu et al 69 reported that similar to our 
Gln135Asp mutation, the Val136Gly mutation altered CaM‟s inter domain interaction, 
and substantially decreased the C-domain Ca2+ affinity while increasing the N-domain 
affinity. The near-by very conservative Asp133Glu substitution not only drastically 
decreased the site IV Ca2+ affinity but also decreased the affinity of the coupled site III 
within the C-domain73. Such significant alterations in site IV Ca2+ affinity are likely due to 
the clustering of a large number of negatively charged residues in both liganding 
positions 1, 3, 5, and 12 and in non-liganding position 11. This EF-hand motif also lacks 
the positively charged residues (Lys) at position 2 in EF-hand III and at positions 2 and 
11 in EF-hand I.  
60 
 
 In wild type CaM, the difference in the Ca2+ affinity of the two domains is such 
that the C-domain Ca2+ binding sites may be nearly saturated while the N-domain 
binding sites are only partially filled. Under the conditions used here, the N-domain Ca2+ 
Kd of wild type CaM was approximately 5.6 times higher than the C-domain Kd. 
Mutations in Ca2+ binding sites I and II had little effect on the relative difference in the 
domain Ca2+ affinities (N-domain Kd/C-domain Kd: Thr26Asp ~6.4; Asn60Asp ~5.7).  
Although the Thr26Asp CaM variant bound Ca2+ at lower concentrations than wild type 
CaM, because of the similar increases in the N- and C-domain Ca2+ affinity, the relative 
Ca2+ saturation of N-and C-domains was not significantly altered. In contrast, the C-
domain mutation significantly altered the ratio of N- to C-domain saturation. The site III 
mutation, Asn97Asp, doubled the N-domain Kd/C-domain Kd ratio to 11.8 while the site 
IV mutation, Gln135Asp reduced the ratio by half to ~2.1. Thus, based on the fits to the 
Hill equation shown in Table 3.1 and Figure 3.3, at a free Ca2+ concentration of 1 μM, 
the N-domain saturation of wild type, Asn97Asp and Gln135Asp CaM for Ca2+ would be 
~1.5, 1.3 and 9.8% respectively. The C-domain saturation of these variants for Ca2+ 
would be 16.2, 36.5, and 6.0% respectively.  
 
In this regard, the N-terminal variants were not informative as neither mutation 
changed the relative domain Ca2+ affinity and therefore did not alter the Ca2+ switch point. 
The C-terminal CaM variants were more useful. The Asn97Asp mutation decreased the 
C-domain Kd and lowered the Ca
2+ concentration at which CaM switched from activating 
RyR1 to inhibiting the channel. Conversely, the Gln135Asp mutation increased the C-
terminal Ca2+ Kd and increased the Ca
2+ concentration at which CaM was converted from 
a channel activator to a channel inhibitor. Thus, the Ca2+ switch-point moved in the same 
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direction as the change in C-domain Kd.  Further, there was an inverse relationship 
between the N-terminal Ca2+ Kd and the Ca
2+ concentration at which the switch-point 
occurred (see Gln135Asp in Tables 3.1 and 3.2). We attribute the effects of the 
Asn97Asp mutant on the RyR1 activation profile to alteration in the variant‟s Ca2+ affinity. 
The concentration dependences of CaM activation and inhibition by the Asn97Asp 
overlapped those of wild type CaM suggesting this variant binds RyR1 in a mode that is 
functionally indistinguishable from wild type CaM. However, interpretation of the 
Gln135Asp results is more complex. Although the concentration dependence of 
activation by the Gln135Asp variant was similar to wild type CaM, the extent of inhibition 
by saturating concentrations of the mutant was significantly less than wild type. Thus, 
the large shift in the Ca2+ switch-point associated with this variant is the result of both the 
altered Ca2+ affinity of the CaM and the blunted maximal extent of inhibition. Further, 
upon binding to the RyR13614-3643 peptide there was a decrease in the ellipticity at 222 nm 
of the Ca2+-loaded form of this CaM mutant rather than an increase as seen in wild type 
CaM. Therefore, this mutant likely binds RyR1 in a mode that differs from wild type CaM. 
However, in spite of these caveats, the current results, particularly those regarding the 
Asn97Asp CaM variant, are consistent with the initial proposal that Ca2+ binding to 
CaM‟s C-terminal is the inhibitory switch. We are currently carrying out detailed 
structural studies to examine the binding modes of these CaM variants. 
 
 Binding to target molecules can significantly alter the CaM Ca2+-affinity87. 
Therefore, we determined the lobe-specific Ca2+ affinities of wild type CaM and the 
mutant Asn97Asp when the protein was bound to a peptide from the putative RyR1 
CaM-binding domain (RyR13614-3643)
35,88. Binding CaM to the RyR13614-3643 peptide 
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similarly increased the Ca2+ affinity of the N-domain for wild type and Asn97Asp CaM (Kd 
with the peptide/Kd without the peptide: wild type ~5; Asn97Asp ~6) (Figure 3.7.A and 
B). Peptide binding had only a small effect on the wild type C-domain Ca2+ affinity (Kd in 
absence of peptide/Kd in presence of peptide: wild type ~3) but dramatically increased 
the Asn97Asp affinity (Kd ratio: ~18). As a result in media containing 1 μM Ca
2+, the N-
domain saturation of wild type and Asn97Asp CaM was similar, ~25.0 and 25.9% 
respectively. In contrast, the C-domain saturation of these variants was different with 
56.7 and 99.9% respectively. Thus by selectively and substantially increasing the Ca2+ 
saturation of the C-domain, we were able to specifically enhance the RyR1 inhibitory 
function of CaM. 
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Figure 3.7.Domain-specific Ca2+ binding affinities to the wt CaM –RyR13614-3643 
complex and the N97D-CaM –RyR13614-3643 complex. 
A) Ca2+-induced decrease in N-terminal Phe fluorescence; B) Ca2+-induced 
increase in C-terminal Tyr fluorescence were determined by equilibrium Ca2+ 
titration. RyR13614-3643 peptide was mixed with wild type CaM (○) or Asn97Asp CaM 
(●) in a 1 to 1 ratio. Ca2+ titration was monitored by λex = 250 nm, λem = 280 nm 
(phenylalanine) for the N-domain and by λex = 265 nm, λem = 292 nm (tyrosine; to 
minimize the contribution from Trp in the peptide) for the C-domain of CaM. 
64 
 
 
3.6. Summary and potentials 
 
We engineered a series of mutant CaMs designed to individually increase the Ca2+ 
affinity of each of CaM‟s EF-hands by increasing the number of acidic residues in Ca2+ 
chelating positions. Domain-specific Ca2+ affinities of each CaM variant were determined 
by equilibrium fluorescence titration. Mutations in sites I (Thr26Asp) or II (Asn60Asp) in 
CaM‟s N-terminal domain had little effect on CaM Ca2+ affinity and regulation of RyR1. 
However, the site III mutation Asn97Asp increased the Ca2+ binding affinity of CaM‟s C-
terminal domain and caused CaM to inhibit RyR1 at a lower Ca2+ concentration than wild 
type CaM. Conversely, the site IV mutation Gln135Asp decreased the Ca2+ binding 
affinity of CaM‟s C-terminal domain and caused CaM to inhibit RyR1 at higher Ca2+ 
concentrations. These results support the hypothesis that Ca2+ binding to CaM‟s C-
terminal acts as the switch converting CaM from a RyR1 activator to a channel inhibitor.  
These results further indicate that targeting CaM‟s Ca2+ affinity may be a valid strategy to 
tune the activation profile of CaM-regulated ion channels. 
 
A number of skeletal muscle diseases including malignant hyperthermia (MH) and 
Duchenne muscular dystrophy (DMD) are genetic disorders leading to impaired cellular 
Ca2+ regulations. Mutations in RyR1 account for the majority of MH cases89 and leaky 
RyR1 channel may contribute to DMD90. RyR1 channels from MH susceptible individuals 
exhibit an enhanced sensitivity to CaM activation91,92 and possibly a decreased 
sensitivity to Ca2+-CaM inhibition93. Therefore, targeting these muscles with a CaM that 
will reduce channel opening at low Ca2+ may be of therapeutic benefit. Further, the 
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enhanced Ca2+-CaM inhibition of RyR1 may reduce the resting Ca2+ leak through the 
channels in DMD muscle. Because CaM regulates numerous cellular signaling pathways, 
an obstacle to this strategy will be to specifically target RyR1. As the CaM Ca2+-binding 
site that acts as the regulatory switch varies with the CaM binding partner, we have 
taken an initial step toward achieving that specificity by targeting the Ca2+-affinity of a 
single EF-hand. 
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4. Binding mode determination of CaM- RyR1 complex using a peptide mode 
through NMR study 
 
 
4.1.  Introduction of current knowledge about CaM binding sites on the 
ryanodine receptor determined by various methods 
 
As discussed in Chapter 1 and 3, the type 1 ryanodine receptor (RyR1) with a 
tetramer structure is one of the major CaM binding proteins in sarcoplasmic reticulum 
(SR) membranes isolated from skeletal muscle (Figure 1.4) 94,95. CaM shifts the Ca2+ 
dependence of RyR1 opening to lower Ca2+ concentrations, effectively increasing 
channel opening at sub-micromolar Ca2+ and inhibiting the channel in micromolar Ca2+ 
concentration43. The switch from a channel activator to a channel inhibitor is due to Ca2+ 
binding to CaM as Ca2+ insensitive mutants of CaM activate but do not inhibit RyR1 36. 
The Ca2+-induced conversion of CaM from a RyR1 activator to a channel inhibitor 
suggests that the RyR1 activation profile might be manipulated by tuning the CaM Ca2+ 
affinity. So far, there are three potential CaM binding sites reported. A critical region for 
CaM binding within the RyR1 primary sequence, (RyR13614-3643) , have been identified by 
Hamilton and co-workers35. It has reported that a peptide derived from this region 
displays a high affinity for both apo- CaM and Ca2+-CaM 96. More recently, a second 
noncontiguous region within RyR1,  RyR11975-1999, has also been implicated in CaM 
binding 97, and current models suggest that the CaM binding pocket is formed by 
neighboring subunits of tetrameric RyR184. Hamilton‟s group also discovered that a 
fragment of RyR1 from amino acid 4064-4210 is able to fold to be an EF- hand lobe to 
67 
 
bind to two Ca2+ ions and result in conformational change through binding to Ca2+ similar 
as CaM98. Ikemoto and Gangopadhyay also confirmed that the interaction of the CaM - 
binding domain (Lys3614–Asn3643) with the Cys4114–Asn4142 region (a region 
included in the CaM-like domain) serves as an intrinsic regulator of the RyR1 99. The 
intrinsic tryptophan fluorescence of the RyR13614-3643 peptide in complex with CaM 
100 
indicated that this peptide target promotes a substantial increase in CaM‟s affinity for 
Ca2+, suggesting that only nanomolar Ca2+ concentrations were required to inhibit the 
channel. On the other hand, functional studies demonstrate that much higher Ca2+ 
concentrations (~1 µM) are required for the inhibition of full-length RyR1 channels 101,36,34. 
Our previous results (Chapter 3) indicated that the C – terminal domain of CaM 
exhibited more important role to inhibit the channel than the N- terminal. In addition, 
using a Ca2+-sensitive fluorescent derivative of CaM to probe affinity of CaM to the 
peptide, we have shown that CaM retains a high affinity for both the RyR13614-3643 peptide 
and full-length RyR1. The N97D- CaM- RyR13614-3643 complex displayed the highest 
binding affinity to Ca2+ than wild type CaM102. Therefore, the particular structure and Ca2+ 
sensitivity of CaM when in complex with RyR1 remain undefined, which is the key 
information to resolve the potential roles of CaM as a regulatory channel subunit. The 
solution structures of both Ca2+ free and Ca2+ loaded forms were determined by NMR 
spectroscopy 103,104. A high degree of mobility near the middle of the central helix region 
in CaM, from residue K77 through S81 was observed by studying the backbone 
dynamics of Ca2+ - saturated recombinant Drosophila CaM using 15N longitudinal and 
transverse relaxation experiments, combined with 15N(1H) NOE measurements105.  CaM 
binds to the target enzymes in various binding modes and the two domains of CaM may 
play distinguish roles in the regulation of these enzymes. CaM-dependent kinases are 
activated when Ca2+-CaM binds to the auto inhibitory region of the target with 
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hydrophobic patches in each of its two lobes to contact two hydrophobic anchor residues 
located at „„1-10,‟‟ „„1-14,‟‟ or „„1-16‟‟ spacing in the primary sequence of the kinase 106,13 
107,108. Other targets, including ion channels such as the ryanodine receptor, interact with 
CaM both in the presence and absence of Ca2+ 109.  Although it is well established that 
CaM modulates Ca2+ activation of RyR1, the precise structural interaction between CaM 
and RyR1 is poorly defined. Further, the role of CaM in depolarization-induced Ca2+ 
release from skeletal muscle has not been established. The precise mechanisms by 
which CaM regulates RyR1 remain unknown due mainly to three major obstacles. First, 
RyR1, like a number of other CaM targets, is a Ca2+ regulated protein. Thus, it is difficult 
to unambiguously distinguish between the effects of Ca2+ directly on the channel and the 
effects of Ca2+ mediated via CaM. Second, because of its massive size (>2,000 kDa) 
and membrane localization, the structure of RyRs is not known at the atomic level as it is 
for a number of other ion channels. Although the location of the CaM binding site on 3-
dimensional reconstructions of RyR1 is known, the molecular nature of binding site is not 
understood. This necessitates an indirect approach combining structural studies of CaM 
binding to synthetic peptides or minidomains based on the sequence of the putative 
RyR1 CaM binding site and CaM mutants designed to test specific models of the 
functional interaction between CaM and RyR1. Third, CaM modulates Ca2+ activation of 
RyR1, however, in vivo, the primary mechanism by which RyR1 is activated via an 
allosteric coupling to the L-type Ca2+ channel in the transverse-tubule membrane, with 
Ca2+ activation possibly playing a secondary role. CaM modulation of this allosteric 
activation of RyR1 has not yet been demonstrated due to the difficulty of simultaneously 
manipulating concentration and type of CaM in the skeletal muscle triad and controlling 
the membrane potential of the transverse-tubule membrane. We have developed a 
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unique approach to manipulate the intracellular milieu of muscle fibers will 
simultaneously controlling the membrane potential of the transverse-tubules.  
 
Based on these previous studies, several questions need to be addressed: 
1. Does apo CaM have the same binding mode as the Ca2+ loaded CaM? 
2. Whether RyR11975-1999 bind to both apo and holo- CaM or not, and what is the 
binding ratio? 
3. How to distinguish the two binding regions of RyR1 with CaM?  
In this chapter, we use peptide model and high resolution NMR to reveal the 
interaction modes of CaM to RyR by addressing these questions.  To further investigate 
effects of RyR1 binding on CaM structure and Ca2+ sensitivity, the changes of chemical 
shift of CaM as a function of peptide: complex ratio in the absence and presence of 
calcium were examined based on the NMR assignments provided by Dr. Hing Wong. 
We have also performed RDC studies to confirm the binding modes. We then discussed 
the potential interaction working model and created mini domains encompassing multiple 
CaM binding sites for CaM to test the working model. Using this system we will examine 
the effects of CaM on the depolarization-induced Ca2+ release, the physiological 
activation process. 
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4.2. NMR studies of interactions of CaM with RyR13614-3643 binding region using 
peptide model 
 
Peptides were designed and synthesized from Anaspec, INC. CaM and its 
variants were bacterially expressed, 15N-labeled and purified using established methods 
as detailed in Chapter 2. All NMR data were collected at 600 MHz varian NMR at GSU 
at 37 °C in 10 mM Tris base buffer, pH 7.4.  1H-15N HSQC data of holo form CaM were 
collected and processed through NMR-pipe. Most residues can be assigned for the 
Ca2+-CaM and the CaM – peptide complex Figure 4.1). The chemical shifts from the 
residues in both N- and C-terminal domains are observed as shown in Figure 4.1. All 
the chemical shifts for the residues of CaM were calculated in Figure 4.2.  The chemical 
shift changes were analyzed with different ratios of protein / peptide. Most changes of 
chemical shifts occur at the titration point of 1 to 0.9 (Figure 4.2 C) which indicated that 
CaM interacts with RyR13614-3643 at a ratio of one to one. Almost no chemical shifts 
changes when the ratio increased from 1:0.9 to 1:1.2 (Figure 4.2 D).  The chemical 
shifts chart was analyzed for each residue in CaM – RyR13614-3643 complex at a 1:1.2 
interaction ratio (Figure 4.3). Significant chemical shifts were observed in both domains 
and especially in the EF – loop region, suggesting that both the N - and C – terminal 
domains contributed to the interaction of CaM with the peptide.  
Table 4.1 summarized the residues with dramatic signal intensity changes for 
CaM - RyR13614-3643 peptide complex.  Most of these residues are located in the EF – 
loop region, such as K21, T29, A102, and I130. Some are even in the binding pocket, 
such as T26, D64, N137, indicating that the conformational changes occurs in the whole 
CaM protein during interacting with the peptide. 
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                      Figure 4.1.HSQC spectra of 15N-Ca2+- CaM and CaM-RyR13614-3643 complex. 
HSQC spectra of 15N-wt CaM in the presence of 10 mM Ca2+ (red), Ca2+-CaM mixed 
with RyR1 3614-3643 peptides at a 1 to 1.2 ratio (blue). Residues were labeled based 
on their chemical shifts and references. 
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                       Figure 4.2.Chemical shift calculated from the HSQC experimental spectra 
 for Ca2+-CaM with the RyR13614-3643 complex. 
Chemical shift calculated from the HSQC experimental spectra for 15N-Ca2+-CaM 
with the RyR13614-3643 peptide at a gradually increasing ratio from 1:0.3 (A), 1:0.6 (B), 
1:0.9 (C) until to 1:1.2 (D) which is the saturated point. 
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                 Figure 4.3.Chemical shift for Ca2+-CaM -RyR13614-3643 complex with 1 to 1.2 ratios.  
Chemical shift changes of individual residues of 15N-Ca2+-CaM with the RyR13614-
3643 peptide at the ratio of 1 to 1.2. Four EF – hand binding loops were labeled in 
the figure to be compared their chemical shifts changes. 
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             Table 4.1.HSQC spectra Signal intensity of selected residues of the 15N-Ca2+-CaM 
with the RyR13614-3643 peptide complex 
[RyR13614-3643]/[CaM] 0.3 0.6 0.9
Residues Signal Intensity Signal Intensity Signal Intensity
N-terminal
domain
K13 n.d.a 0.69 0
K21 6.25 0.82 0
G25 n.d. 1.11 0
T26 n.d. 0.93 0
T29 5.26 0.67 0
G33 4.76 0.69 0
D64 4.76 0.62 0
C-terminal 
domain
K94 8.33 1.48 0
A102 3.57 0.68 0
L116 7.14 0.65 0
I130 5.26 0.68 0
N137 n.d. 0.67 0
A147 9.09 0.57 0
K148 9.09 0 0
 
an.d. stands for not determined 
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HSQC spectra of the 15N-apo-CaM with the RyR13614-3643 peptide complex were 
also collected on the 600 MHz spectrometer. The spectra of apo- CaM titrated with 
gradually increased ratio of RyR13614-3643 peptide were shown in Figure 4.4 A–D. The 
chemical shifts changes introduced by the addition of the peptide suggested that the apo 
– CaM interact with the RyR13614-3643 peptide at a one to one ratio, similar to the         
Ca2+ - CaM. Figure 4.5 is the comparison of chemical shift changes in apo –CaM (blue) 
and holo –CaM (orange). The changes of chemical shifts were observed in both N- and 
C -terminal domains for the CaM- RyR13614-3643 complex in the present of Ca
2+. However, 
mainly C- terminal has obvious chemical shift changes for the complex in the present of 
EGTA. These results indicated that CaM interacts with the RyR13614-3643 peptide in 
different modes in the apo – and holo – forms. Furthermore, the conformations for the 
CaM- RyR13614-3643 complex are distinguished with and without Ca
2+. These NMR studies 
suggest that CaM interacts with the RyR1 peptide with both domains in the presence of 
calcium while with mainly C-terminal domain of the protein in the absence of calcium. 
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                 Figure 4.4. HSQC spectra of EGTA-CaM and CaM-RyR13614-3643 complex. 
   HSQC spectra of 15N-wt CaM of 10 mM EGTA with gradually adding RyR1 3614-3643 
peptide as the ratio of 1:0.3 (A), 1:0.6 (B), 1:0.9 (C), and 1:1.2 (D). 
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Figure 4.5.Chemical shifts comparison of CaM - RyR13614-3643 complex on 600 MHz 
in the   presence of Ca2+ and EGTA. 
Chemical shift changes of HSQC signals from selected residues of the 15N-Ca2+-
CaM-RyR13614-3643 complex (orange) and 
15N- EGTA-CaM - RyR13614-3643 complex 
(blue) obtained on 600 MHz. 
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4.3. RDC study of interactions of CaM with at RyR13614-3643 binding region using a 
peptide model 
 
 
Residual dipolar coupling (RDC) 88 has been used to assist in homology modeling, 
determine relative domain orientations in multidomain proteins, and characterize 
molecular binding. Here, we used RDC to study the binding mode of the apoCaM-
RyR13614-3643 complex using high resolution NMR at 800 and 800 MHz. First, the 
1H-15N 
isotropic couplings of the complex are measured by TROSY-based J-modulation 
experiments 110. Second, the complex was put into Pf1 phage media, and the couplings 
were measured again. Then RDCs were obtained by subtracting the isotropic couplings 
from the values measured in the second experiment. 
 
To assess the binding mode, we compared the measured RDCs with calculated 
values from structures deposited in the protein data bank. We selected structures in 
which CaM binds by wrapping around the peptide using both N- and C- terminal 
domains (2HQW, 1CDM, 1SY9, 1IQ5, and 2BCX), as well as binding in an extended 
conformation (2IX7, 1CFF, 1K93, and 1G4Y). We also compared the data with the 
structure of the CaM by itself, both apo (1CFC) and holo (3CLN) forms. We found that 
our data fit best with the crystal structure of a complex between apoCaM and the IQ 
motif of myosin V 111, especially if only the coordinates of the N-terminal domain was 
used in the calculation (Figure4.6 and Table 4.2). This was not surprise because most 
of the complexes were loaded with calcium, therefore the helices were in the open 
conformation, and will not fit well with the closed conformation of apoCaM. Interestingly, 
the N-terminal domain of the CaM-anthrax exotoxin complex (1K93, Table 2) also fit well 
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with our data, because in the structure, the N-terminal domain was free of metal ion 
even though they grew the crystal with saturating amount of calcium 18. 
 
The C-terminal domain does not fit well with available structures, suggesting that 
our complex has unique binding mode. These RDC data revealed binding mode about 
apoCaM are consistent with the NMR chemical shift analysis in Figure 4.4.indicated that 
only the C-terminal tail of apoCaM bind to the peptide. On the other hand, in the 
structures found in the PDB, the whole C-terminal domain is involved in binding.  
 
In summary, our RDC data suggested that apoCaM binds in the extended 
conformation with the RyR13614-3643 peptide, the N-terminal domain of CaM remains 
unchanged while the C-terminal domain binds to the peptide in a unique fashion.  
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            Figure 4.6.Calculated RDC of apo-CaM formed RyR13614-3643 complex fitted 
      Residues in the N- and C-terminal domains were fitted separately with 
reasonable Q values for both two domains. 
N- CaM 
C- CaM 
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            Table 4.2. RDC fitted factor comparison of apo CaM-RyR1 complex  
with complexes of CaM with other enzymes. 
Pdb Target Binding mode Q-factor Ra No. of  RDC in f itting
2HQW NMDA 
receptor 
NR1C1
1-7
0.58 0.74 63
Nb 0.31 0.93 36
Cc 0.74 N/Dd 31
1CDM
CaMKII 1-10
0.55 0.74 56
N 0.31 0.94 44
C 0.68 0.21 29
1SY9 CNG
channel
f ragment
1-14
0.68 0.29 57
N 0.31 0.94 40
C 0.49 0.77 33
1IQ5
CaMKK 1-16
0.62 0.59 68
N 0.28 0.95 38
C 0.63 0.56 29
2BCX Ryanodine
receptor 
peptide
1-17
0.62 0.59 72
N 0.27 0.95 36
C 0.62 0.46 29
2IX7
IQ motif  
myosin V
Extended, peptide 
bound mostly with C-
terminal domain
0.38 0.91 69
N 0.25 0.96 54
C 0.47 0.84 31
1CFF
Ca2+ pump
Extended, peptide 
bound only to C-
terminal domain
0.55 0.75 64
N 0.48 0.81 33
C 0.61 0.68 35
1K93
Edema 
factor
Extended, peptide 
bound both domains
0.51 0.74 68
N 0.25 0.96 44
C 0.56 0.61 32
1G4Y
K+ channel
Extended, peptide 
bound both domains
0.64 0.49 69
N 0.34 0.93 38
C 0.71 N/A 30
1CFC
none apoCaM
0.45 0.86 72
N 0.27 0.96 51
C 0.67 0.56 31
3CLN
none Ca2+-CaM
0.60 0.58 64
N 0.35 0.91 36
C 0.71 N/A 30
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4.4. NMR study of interactions of CaM with RyR11975-1999 binding region using a 
peptide model 
 
 
Since a second noncontiguous region within RyR1, RyR11975-1999,  has also been 
implicated in CaM binding as recently reported97, we collected the HSQC data on the 
600 MHz spectrometer to detect interactions between CaM and RyR11975-1999. Similar to 
the RyR13614-3643 peptide, the RyR11975-1999 peptide also interacts with CaM at a one to 
one ratio (Figure 4.7). Most residues in the Ca2+ - CaM- RyR11975-1999 complex were able 
to be assigned based on the original assignment of Ca2+ - CaM103,104 . The chemical 
shifts changes for each residue of CaM in the complex was calculated and summarized 
in Figure 4.8. The chemical shifts changes were observed in both two domains of CaM 
and even in the flexible linker region. Some residues in the EF – loop displayed dramatic 
chemical shift change. It is possible that the whole protein was involved in the interaction 
with this peptide and introduced a significant conformational change. Chemical shift 
changes of individual residues of 15N-Ca2+-CaM with the RyR11975-1999 peptide at the ratio 
of 1 to 1.2. Four EF – hand binding loops were labeled in Figure 4.8 in order to compare 
their chemical shifts changes. 
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             Figure 4.7.HSQC spectra of Ca2+ loaded CaM and CaM-RyR11975-1999 complex. 
HSQC spectra of 15N-wt CaM in the presence of 10 mM Ca2+ (red),    Ca2+-CaM 
mixed with RyR11975-1999 peptides at a 1 to 1.2 ratio (cyan). Residues were 
labeled based on their chemical shifts and references. 
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Figure 4.8.Chemical shifts CaM – RyR11975-1999 complexes collected on 600 MHz.  .  
Four EF loops were labeled out and the  residues with significant chemical shift 
changes in bout N- and C- terminal domains bigger than 0.05 were labeled. 
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4.5. Summary of CaM- RyR1 complex formations in both apo and holo forms 
with a proposed working model 
 
CaM regulates Ca2+ release channel RyR1 in a Ca2+ dependent manner112
,113. As 
shown in Figure 4.9, one of the conserved CaM binding domains in the RyR1 is 
believed in the region of 3614-3643114
,35. In the apo form, CaM binds to site 2 (RyR3614-
3643) through the C-terminal domain. If site 1 (RyR1975-1999) is close to site 2, the N-
terminal domain may also bind to site 1. After loading with calcium, CaMs can bind to 
both sites 1 and 2 using both N- and C- terminal domains. Apo- and Ca2+-CaM may 
themselves induce RyR1 states that favor channel opening and closing. Alternatively, an 
interaction between site 2 (RyR13614-3643) and site 3 (RyR14114-4142) may be required for 
channel opening and disrupting the interaction may close the channel99. Thus, the Ca2+-
induced shift in CaM binding to RyR13614-3643 may disrupt the RyR13614-3643 /RyR14114-4142 
interaction and close the channel. 
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      Figure 4.9.Our designed working Models of CaM Regulation on RyR1 in three 
possible binding regions. 
Symbols labeled 1, 2, and 3 represent three sites on RyR1 composed of sequences 
1975-1999, 3614-3643, and 4114-4142 respectively. CaM molecule is in green. Black 
dots were used to represent as Ca2+ ions. 
 
 
A B 
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As shown in our working models of CaM regulation on RyR1 (Figure 4.9), three 
sites located at separate positions in the channel are the potential binding regions for 
CaM.  Symbols labeled 1, 2, and 3 represent three sites on RyR1 composed of 
sequences 1975-1999, 3614-3643, and 4114-4142 respectively. Apo-CaM binds to site 
2 (RyR3614-3643) via the C-terminal (Figure 4.9.A top). If site 1 (RyR1975-1999) and site 2 are 
in close proximity, it is also possible that apo-CaM may span the two sites (Figure 4.9.B 
top). However, our NMR data is more supportive to the first model. At this point we have 
no data suggesting that the N-terminal domain of apo-CaM can interact with RyR1975-1999.   
 
In the Ca2+ -bound state, CaMs may bound to sites 1 and 2 (Figure 4.9.A 
bottom). Or alternatively, CaM may span sites 1 and 2 (Figure 4.9.B bottom). Given 
that [35S]CaM binding 36 and cryo-EM studies 40 reported a single CaM binding site per 
RyR1 monomer, the spanning model is more likely. Our NMR data cannot eliminate 
either model 1 or model 2. In the peptide approach, both N- and C-terminus of CaM bind 
to peptides 1 and 2. However, this may not occur with the intact RyR1 molecule. This will 
be further tested using min domain encompassing both binding sites (see next section). 
Site 3 is composed of RyR4114-4142. In both Figures 4.9.A and B, an interaction between 
this RyR14114-4142 region and RyR3614-3643 is illustrated along with its disruption by Ca
2+-
CaM.  
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If only one site is recognized by CaM, we expect that the chemical shifts of CaM 
will be changed at 1:1 binding ratio of the peptide/protein complex. The affinity of CaM 
for the RyR1 peptide and mini domain is expected to be similar. However, our 
preliminary results by NMR shown in Figures 4.1, 4.4, 4.7 have demonstrated that both 
peptides   RyR13614-3643 and RyR11975-1999 interact with CaM in a 1 to 1 ratio.  There is 
uncertainty about how the N-terminal domain of Ca2+-CaM interacts with RyR1.  
According to   model 1 (Figure 4.9A), the N-terminal binds to RyR11975-1999.  On the other 
hand, the N-terminal may not bind to RyR11975-1999 according to model 2 (Figure 4.9B).  
Similar to our NMR results, a recent crystal structure of Ca2+-CaM/RyR1 peptide 
complex shows that both the N- and C-terminus are bound to RyR13614-3643 
88.  To clarify 
these controversies, we will pay special attention to any NOE interaction between the N-
terminal domain of CaM and RyR1 peptides.  If there is no interaction between CaM and 
RyR11975-1999, then the 
1H-15N HSQC spectrum should show no change when we switch 
from RyR13614-3643 to mini domains.           
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4.6. Create mini domain encompassing multiple CaM binding sites of RyR1 
 
To further test the above possibilities of CaM interaction both models and the 
potential interactions of CaM binding to several regions simultaneously, we have created 
mini domian of RyR1 encompassing multiple CaM binding sites from RyR1 showing 
below. A mini domain encompassing multiple CaM binding sites from RyR1 was 
designed. Two peptide fragments RyR13614-3643 and RyR11975-1999, encompassing 3614-
3643 and 1975-1999 have been synthesized and were shown to bind CaM by several 
spectroscopic methods. This mini domain contains a flexible linker GGSGG to connect 
two putative CaM binding sites. The length of the linker is designed to cover the distance 
between two lobes of CaM based on a report assuming they bind to two different regions 
of RyR1 (Figure 4.9). Cornea et al used FRET between CaM and FKBP to estimate 
these distances115. When the FRET donor was on FKBP and the acceptor was on the N-
terminal of CaM, the distance was 67±3 Å in 30 nM Ca2+ and 65±3 angstroms in 30 μM 
Ca2+. When the acceptor was on CaM's C-lobe the distances were 91± 9 Å in 30 nM 
Ca2+ and 84±5 Å in 30 μM Ca2+. The distances between the N- and C-lobes were 24 Å in 
30 nM Ca2+ and 19 Å in 30 uM Ca2+. Two different orientations are designed since CaM-
complexes were reported to have both parallel and antiparell binding modes10,116. 
Studying both peptide models and mini domains allows us to unambiguously reveal the 
possible binding modes (orientation, stoichiometry) and binding affinity in the absence 
and presence of calcium. The peptide fragments have been produced using solid phase 
peptide synthesis.  The mini-domains will be expressed by bacterial and purified using 
our tag-less method. In addition mini domains allow the protein fragments to be 
heterolabeled at a relative low costs.  
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Sequence of RyR11975-1999  
                   Ac-SRYALLMRAFTMSAAETARRTREFR-NH2 
Sequence of RyR11975-1999   
                  Ac – DRYGILMKAFTMTAAETARRTREFR-NH2 
           Minidomain  
                   
DRYGILMKAFTMTAAETARRTREFRGGSGGKSKKAVWHKLLSK
QRRRAVVACFRMTPLYN 
 
 
 
The mini domain containing two CaM binding sites in RyR1 was designed into a 
pGEX-2T vector with a GST tag. The protein was expressed using BL21 (DE3) system 
and purified by glutathione sepharose 4B beads. The purified protein was further 
analyzed by mass spectrum (Figure 4.10). Mass spec result demonstrates that the 
protein was well purified with a correct molecular weight of 7271.7 Da. 
 
 
 
 
 
 
 
 
 
 
91 
 
 
 
7090.0 7388.2 7686.4 7984.6 8282.8 8581.0
Mass (m/z)
1598.8
0
10
20
30
40
50
60
70
80
90
100
%
 I
n
te
n
s
it
y
4 7 0 0  R e f le c t o r  S p e c  # 1  M C [ B P  =  7 2 7 2 . 3 ,  1 5 9 9 ]
7
2
7
1
.7
7
2
5
5
.3
7
2
8
0
.6
7
2
2
9
.9
8
3
2
1
.0
7
4
4
6
.8
8
4
9
6
.7
7
7
7
2
.2
 
     Figure 4.10. Maldi - Mass spectrum of RyR11975-1999&3614-3643 mini domains after 
purification.  
       The molecular weight of the mini domain is about 7 kDa which shown in the 
spectra as a main peak. 
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5. The activation and inhibition of Ryanodine receptor channels by CaM isolated half 
domains and CaM with the linker region deleted 
 
 
5.1. Introduction 
 
CaM is a well known intracellular protein that plays a significant role in regulating 
the biological functions of numerous enzymes in the cell. The two globular domains are 
connected by a flexible helical tether105. Upon binding of Ca2+, the secondary structure of 
each domain is not significantly changed but the helices and the linker region undergoes 
a large conformation reorientation as shown by the 3-D structures of CaM (Figure1.1A). 
The B, C helices and F, G helices in each domain move away from the hydrophobic core 
due to the  binding of Ca2+ ,which results in the exposure of the core in each domain to 
the solvent and greater availability for target binding to other enzymes. In addition, CaM 
may adjust [Ca2+]i via regulation of ion channel and pumps and differentiate between 
local and global [Ca2+]i changes among its different domains 
30, 117 . Persechini, A., et.al 
performed a additionalmutation by deleting seven amino acid residues (DQLTEEQ, 
residues 2–8)  in the N terminal domain of CaM and reported that no activity was 
observed in CaM-dependent activation of skeletal muscle myosin light chain kinase 
indicating that the first several residues in the N –terminal domain were essential for the 
function 118. 
 
As discussed in Chapter 1 and 3, RYR1 functions as a calcium release channel 
in the sarcoplasmic reticulum, as well as a connection between the sarcoplasmic 
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reticulum and the transverse tubule. Mutations in the RYR1 gene are associated with 
malignant hyperthermia susceptibility, central core disease, and minicore myopathy with 
external ophthalmoplegia.  Alternatively spliced transcripts encoding different isoforms 
have been described. The RyR1 channel opening exhibits biphasic Ca2+ dependence. 
CaM shifts this activation profile to lower Ca2+ concentrations, enhancing channel 
opening at low Ca2+ concentration and inhibiting opening at higher concentrations.  
 
In vitro, RyR1 channel opening exhibits a biphasic Ca2+  dependence attributed 
to high- and low-affinity Ca2+ binding sites which when occupied will activate or inhibit 
channel opening respectively 41. CaM shifts the Ca2+ dependence of RyR1 opening to 
lower Ca2+ concentrations, effectively increasing channel opening at sub-micromolar 
Ca2+ and inhibiting the channel in micromolar Ca2+ 43. The switch from a channel 
activator to a channel inhibitor is due to Ca2+ binding to CaM, as Ca2+ insensitive 
mutants of CaM activate but do not inhibit RyR1 36. Hamilton‟s group found that adding 
three amino acid in the N-terminal domain of Drosophila CaM  increases the affinity for 
the RyR1, and noted that the N – terminus contributes greatly to the binding to RyR1 96; 
they also suggested that both N- and C-terminus were required for the channel function 
with C- terminus as the primary factor 100.  
 
Based on the lack of channel inhibition by a Ca2+-insensitive CaM mutant, the 
RyR1 activation at low Ca2+ concentrations is ascribed to the Ca2+-free form of CaM 
while the inhibition is attributed to Ca2+ bund to CaM. However, the contribution of each 
structural component of CaM to the regulation of RyR activity is not clear yet.  
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In this chapter, we use domain variants of CaM, the N- and C- terminal domain, 
the mutant with five amino acids deleted in the flexible linker region to dissect the 
contributions of these structural components of CaM to the RyR1 regulation. We first 
performed conformational analysis of these CaM variants using Circular Dichroism 
spectra.  Then the equilibrium [3H]ryanodine binding studies have been performed by Dr. 
E. Balog to determine the binding capability of these structure components of CaM using 
the same procedures described in Chapter 2. Based on the additional studies of metal 
binding affinities of these structural domains detailed in Chapter 6, we show that the two 
half terminus and the flexible linker of CaM play different roles in regulating the function 
of RyR1. 
 
 
 
 
 
 
 
95 
 
         
  Table 5.1.Steady-state kinetic parameters for binding and activation of enzymes by 
CaMs with deletions in the N-terminal leader sequence118. 
skMLCK smMLCK nNOS
K act Ki Fact K act Ki Fact K act Ki Fact
ΔNCaM 1.00 <0.01 1.60 0.48
Δ1CaM 1.60 0.98 0.90 1.04 2.20 1.18
Δ2CaM 1.10 0.55 1.80 1.12
Δ3CaM 1.90 0.04 2.80 0.78
ΔNCaMNN 10.50 1.10
ΔNCaM 0.30 0.40 0.10
 
Kact is the concentration of CaM or engineered CaM required for half-maximal 
activation of enzyme activity. Ki is the apparent dissociation constant based on 
competitive inhibition of CaM-dependent enzyme activity. Fact is the maximal 
enzyme activity expressed relative to the level of activity achieved with 100 nM 
CaM. 
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Ca2+
Possible sites on RyR1 for C- CaM
Possible sites on RyR1 for N- CaM
 
 
Figure 5.1.Model for the interaction of apoCaM and Ca2+_CaM with RYR1.C1, C2 
and N1, N2 are the C and N lobe binding sites on RYR1, respectively. The red 
sphere represents the C lobe of apoCaM. The red square represents the C lobe of 
Ca2+-CaM. The blue sphere represents the N lobe of apoCaM. The yellow sphere 
represents Ca2+ 100. 
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5.2. The structural analyses using NMR and CD spectra 
  
 
N- C-+ CaM(a)
N- C-
8 Å
N- C-
(b)
(c)
 
 
 
 
         Figure 5.2.Structural models of CaM variants, the isolated N- terminal, C-terminal 
domain and five residues deleted in the linker region. 
a). N- and C- terminal domain of CaM comprise the whole globular protein CaM in 
a direct way. b).The helical linker between the two domains of CaM with a 
calculated size around 8 Å. c). The two domain combined together without the 
liker region to form an incomplete protein analog of CaM. 
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Fig.5.2 shows the CaM variants with different structural domains (see chapter 6 
for additional information. Near UV (250 nm ~ 320 nm) and far UV (190 nm ~260 nm) 
CD spectra were collected on the Jasco-810 spectropolarimeter at room temperature 
using a Tris-KCl buffer (10 mM Tris pH 7.4, 100 mM KCl) in a 1 cm light-path quartz 
cuvette. All spectra are background subtracted and the average of at least 10 scans. All 
the protein concentrations are 10 µM in 10 mM Tris buffer with pH 7.4 was used for far 
UV and near UV CD, respectively. 
 
Figures 5.3 D-F shows  that both the isolated half domains and wt CaM have 
similar far UV CD spectra with only the difference being ellipticity intensitiesbetween the 
far UV (right figures) CD spectra of wt CaM and the isolated N- terminal and C- terminal 
domains of CaM. All the proteins have similar secondary structures with typical helix 
spectra peak at 222 and 208 nm.                
 
To further detect the tertiary structure of these CaM mutants, we used near UV 
CD scanned from 310 to 260 nm. Since the near UV signals are from the aromatic 
residues (Tryptophan, Tyrosine and Phenylalanine), it is well confirmed that all the CD 
signals at 260 - 265 nm for N –terminus (Figure 5.3.B) are generated by Phenylalanine 
residues located at  positions 12, 16, 19,65, 68. On the other hand, the CD signals at 
280 nm for C –terminus (Figure 5.3.C) mainly originateed from the two Tyr residues 
(Y99 and Y138) as well as from the three Phe residues (F89, F92 and F141). The CD 
signals were the combination of these two domains as shown in   Figure 5.3.A. 
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                Figure 5.3. Near UV and far UV CD spectra of wt CaM and N- , C- terminal   
domains of CaM. 
A). Near UV CD spectra of wtCaM. B). Near UV CD spectra of N- CaM. C). Near UV 
CD spectra of C-CaM. D). Far UV CD spectra of wtCaM. E). Far UV CD spectra of N-
CaM. F). Far UV CD spectra of C-CaM. 
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5.3. Equilibrium [3H]ryanodine Binding 
 
5.3.1. The procedures of measuring equilibrium [3H] ryanodine binding 
 
Skeletal muscle heavy sarcoplasmic reticulum (HSR) vesicles were prepared from 
porcine longissimus dorsi muscle as previously described119. [3H]Ryanodine binding was 
performed by incubating HSR vesicles (0.2 mg/ml) for 90 min at 37 °C in medium 
containing 150 mM KCl, 10 mM PIPES, ± wild-type or mutant CaM (see figure legends 
for details), pH 7.0, 100 nM [3H]Ryanodine, 1 mM EGTA and CaCl2 to obtain the 
indicated free Ca2+ concentration120. HSR vesicles were then collected on Whatman 
GF/B filters and washed with 8 ml of ice-cold 100 mM KCl buffer. Radioactivity retained 
by the filters was determined by liquid scintillation counting. Estimates of maximal 
[3H]ryanodine binding capacity of each HSR vesicle preparation were determined in 
medium that in addition contained 500 mM KCl, 5 mM ATP, and 100 µM Ca2+. 
Nonspecific binding was measured in the presence of 20 µM nonradioactive ryanodine. 
[3H]Ryanodine binding is expressed as a percent of maximal [3H]Ryanodine  binding.   
[3H]Ryanodine binds to the open RyR with high affinity and specificity and is therefore a 
sensitive indicator of channel activity21. Due to the number of mutations examined, it was 
not feasible to include all CaM variants in the same assay run. However, variants were 
always assayed with a control, either wild type CaM in the concentration dependence 
experiments or no CaM and wild type CaM when examining the Ca2+ concentration 
dependence. As there were no statistical differences between the subsets of control 
experiments, the control experiments were pooled. 
    The CaM concentration dependence of SR vesicle [3H]Ryanodine binding was fit 
with a four parameter Hill equation. Data relating the dependence of SR vesicle 
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ryanodine binding to Ca2+ concentration were fit with equation 3, where Bo is the 
maximal Ca2+-activated SR [3H]Ryanodine binding, EC50 is the Ca
2+ concentration 
required to achieve the half-maximal binding, and IC50 is the Ca
2+ concentration required 
to half-inhibit SR vesicle [3H]Ryanodine binding.   
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5.3.2. The results and discussion for the equilibrium [3H]ryanodine binding 
 
The activity of the isolated CaM half domains and deletion linker CaM were 
tested by [3H] Ryanodine bound assay in both the low (Figure 5.4, 100 nM) Ca2+ and 
high (Figure 5.5, 700 µM ) Ca2+ conditions. From the results shown in Figure 5.4 and 
Figure 5.5, in 100 nM Ca (apo-CaM), it appears that the N-terminal half CaM activates 
RyR1 but this a lower affinity than seen in wild type CaM. The linker deletion CaM also 
appears to activate RyR1, but with a lower affinity and to a lesser extent than in wild type 
CaM. The C-terminal half-CaM does not appear to activate RyR1. In 700 uM Ca (Ca-
CaM), the N-terminal half CaM inhibits with a lower affinity than wild type. The C-terminal 
and Deletion CaMs do not appear to inhibit RyR1 even at high concentrations (10 µM).  
From the summarized table on the right of both figures, we can see that wild type CaM 
provides the lowest EC50 with stronger activity and inhibition compared with its variants in 
both the low Ca2+ and high Ca2+ solvent. 
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Wt CaM
100 nM Ca
2+
Mean
±SEM
Extent of 
Activation
(% maximal 
binding)
nH EC50 (nM)
Wild 
Type
22.9±1.2 1.08±0.14 46.8±6.1
N-CaM 20.2±1.9 1.35±0.29 1350±272
Del-
CaM
12.0±1.2 1.43±.038 1296±298
Bold indicates significantly different from wild
type CaM p<0.05; One-Way ANOVA with a Holm-
Sidak test vs Wild type as a post-hoc analysis. 
N=4  
           Figure 5.4.The [3H] Ryanodine bound assay of CaM and its mutants  
at lower Ca2+ concentration. 
[3H]ryanodine bound assay of CaM mutants at lower Ca2+ concentration:  
( ●) N-CaM, (○ in red) C-CaM, (○ in green) Del-CaM and wt CaM (○) in the 100 nM 
Ca2+ (apo-CaM) condition. The extent of activation, the hill number and the EC50 
was shown in the table on the right. 
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Figure 5.5.The [3H] Ryanodine bound assay of CaM and its mutants at 
high Ca2+ concentration. 
The [3H] Ryanodine bound assay of CaM mutants at high Ca2+ concentration:      
( ●) N-CaM, (○ in red) C-CaM, (○ in green) Del-CaM and wt CaM (○) in the 700 µM 
Ca2+ (holo-CaM) condition. The extent of activation, the hill number and the EC50 
was shown in the table on the right. 
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Using domain-specific EF-hand knockdown mutations, Rodney et al 82 and Fruen 
et al 83 showed that Ca2+ binding to the C-domain of CaM is the switch to convert CaM 
from a RyR1 activator to a channel inhibitor. However, recently published work conflicts 
with this view. Boschek et al 84 compared the Ca2+ dependence of skeletal muscle SR 
[3H]ryanodine binding with Ca2+-induced change in signals from CaM that had been 
fluorescently labeled on either the N- or C-domain and bound to a putative RyR1 CaM-
binding peptide. Further, the Ca2+-dependent conformational changes in the N- domain 
of CaM occurred in the same concentration range as the Ca2+ inhibition of SR vesicle 
[3H]ryanodine binding. Therefore, the authors concluded that Ca2+ binding to CaM‟s C-
domain caused activation of RyR1 and Ca2+ binding to CaM‟s N-domain resulted in 
channel closure.  
We used our CaM variants to determine the activation and inhibition of CaM 
fractions on RyR1. We reported that increasing the Ca2+ affinity of the functionally 
important CaM domain, with no change in the affinity of the opposing domain, would 
lower the Ca2+ concentration at which CaM was converted from a channel activator to a 
channel inhibitor (switch-point).The N-terminal variants were not informative as neither 
mutation changed the relative domain Ca2+ affinity and therefore did not alter the Ca2+ 
switch point, while the C-terminal CaM variants were more useful 102. The switch points 
for all the fraction mutants as wild type CaM overlapped those of wild type CaM (Figure 
5.5) suggesting domain mutant of CaM binds RyR1 in a mode that is functionally 
indistinguishable from wild type CaM. We determined the CaM concentration 
dependence of the SR vesicle [3H]ryanodine binding in media containing either 100 nM 
or 700 μM Ca2+ to determine whether the fraction mutations of CaM altered the ability of 
CaM to regulate RyR1. The reduced efficacy of inhibition suggests that the variants 
interact with RyR1 in a mode that differs from that of wild type CaM (Figure 5.4). 
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The concentration dependences of CaM activation and inhibition by the N-
terminal CaM (1-75) require higher concentration than wild type indicating a function 
change for the isolated domain. However, the C- terminal domain of CaM (76-148) can 
neither activate nor inhibit the RyR1 channel even though it has a stronger binding 
affinity to Ca2+ than the N- terminal domain. In sub-micromolar Ca2+ the linker deletion 
CaM (Δ76-81) activated RyR1 to a lesser extent and with a lower affinity than wild type 
CaM. All these results confirm that the flexible linker region between the N- and C- 
terminal domain plays an essential role for the interaction of CaM with its targeting 
enzymes. The function will be damaged or even eliminated when this linkeris destroyed. 
In addition, it seems that the C – terminal domain of CaM encountered more functional 
effects compared to the N- terminal and Del- CaM. We are currently carrying out detailed 
structural studies to examine the binding modes of these CaM variants. 
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6. Metal Binding, Conformational properties and Activity of PDE Analysis by 
Structural Components of CaM 
 
 
6.1. Introduction 
 
The 148 residue protein CaM contains four canonic EF – hands with Ca2+ binding 
loops denoted I-IV and helices A-H. Each EF-hand pair in CaM forms a globular domain, 
in which the two EF- hands are linked by a short antiparallel β - sheet.  The two domains 
are connected by a flexible helical tether 105. Upon Ca2+ binding the secondary structure 
of each domain is not significantly changed but the helices and the linker region undergo 
a large conformation reorientation as shown by the 3-D structures of CaM. The B, C 
helices and F, G helices in each domain move away from the hydrophobic core due to 
Ca2+ binding which results in increased solvent exposure of the hydrophobic core in 
each domain, thus preparing CaM for targeted binding to other enzymes. The tryptic 
fragments of CaM 121,122, have shown to be very similar to the corresponding domains of 
intact CaM in terms of 3D structures as well as Ca2+ binding characteristics 123,25. 
Although the „central helix‟ linker of CaM in complex withCa2+ is α-helical in the 
crystalline state, NMR relaxation data conclusively shows that this linker is nonhelical 
and highly flexible near its mid-point 105. The functional importance of this plasticity was 
highlighted by the structures of CaM in complex with target peptides. In these complexes, 
the two CaM domains come together and clamp around the helical target peptide 106,13,107. 
Clearly, the flexibility of the inter-domain linker plays a key role in allowing the two 
domains to come together and permitting rearrangement of the relative positions of the 
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two domains to fit a wide array of target sites. Persechini’s group has reported that 
contacts with residues Ser-81 to Glu-84 are not critical in the CaM target complexes 
through their study of CaM mutants with selectively deletion of these residues. In 
addition, Persechini, A. et al proposed that the bending of the central helix may also 
occur in the native CaM target complex as well as in the Del-CaM-target complex 124 as 
shown in Figure 6.1. Metal binding was demonstrated to be essential for the activation 
of CaM to form complex. The properties of Ca2+ binding to CaM have been well studied 
since CaM is the most important Ca2+ binding regulatory protein. However, the role of 
the central helix in the formation of target proteins in different binding modes is not clear.  
     
Figure 6.1. Superposition of the lowest energy structures. 
 a, the N-terminal domain (Thr5−Arg 74) and b, the C-terminal domain (Glu 82 − Thr 
146) of Ca2+−CaM, derived using three different starting structures: apo CaM (1F70 
and 1F71), a parvalbumin-derived homology model and Paramecium Ca2+−CaM 
(1EXR). The backbone r.m.s. deviation relative to the mean is 0.24 Å 125. 
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Ca2+/CaM- dependent cyclic nucleotide phosphodiesterase (PDE1) is one of the key 
enzymes involved in the complex interactions between the cyclic nucleotide and Ca2+ 
second messenger systems. The overall structure of PDE1 isoforms is well conserved, 
consisting of four domains; two CaM-binding domains, an inhibitory domain and a 
catalytic domain126,127.  Zhang et al have reported that only mutations in the N-terminal 
lobe of CaM affect the activity of CaM  to PDE1 although there are eight methionines in 
the hydrophobic clefts of Ca2+-CaM that are required for the binding and activation of 
PDE1 128.  Thus, it is not clear what the contribution of different structural components of  
Ca/CaM is to the overall activation of PDE. 
 
In this study, we first evaluate the thermal stability of the CaM variants with 
different structural components using circular dichroism (Figure 6.3), we then investigate 
their calcium binding affinities and compared with that of w.t. We then use PDE as an 
example to reveal the contribution of these structural components of CaM in the 
enzymatic activity of PDE.  
 
 
 
6.2. CD analyses of secondary structures and unfolded temperatures.  
 
The melting temperatures of these mutants in the presence of both Ca2+ and EGTA 
were determined by detecting secondary structural changes observed at 222 nm in a 
temperature range from 4°C to 94°C. The unfolded temperatures (Tm) were determined 
by CD spectra. The Tm of Del-CaM was 110.02 °C in the presence of 1 mM Ca
2+, while it 
decreased to 40.6 °C in the presence of EGTA, which is almost three times less than 
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Ca2+ form. This clearly demonstrated that Del-CaM has higher stability after binding to 
Ca2+. We were unable to obtain the Tm of the Ca
2+ form CaM due to the high stability of 
CaM in the presence of Ca2+ making the Tm higher than 100 °C. Tm values were obtained 
by fitting the data with sigmoid function as shown in Equation 6.1 
 
Y = m1+ (m’-m1) / (1+exp(x-m3)             Equation 6.1 
 
In Equation 6.1, m1 is the value of the starting point of Y, m‟ is the value of the last point 
of Y. m2 = m‟-m1. m3 is the middle value of X and m4 is the rate of Y to X(Y/X) when 
close to the middle point. 
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           Figure 6.2. Melting temperature of CaM with five residues deleted in the 
flexible helical linker region. 
A and B). CD spectra in the presence of Ca2+, C and D). CD spectra in the presence 
of EGTA. Figure B and D were fitted by sigmoid function. 
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            Figure 6.3. Melting temperature of CaM and its variants in the presence of Ca2+ 
and EGTA determined by temperature based CD spectra. 
A). Melting temperatures of CaM structural components fitted by sigmoid function 
in the presence of Ca2+. B). Melting temperatures of CaM structural components 
fitted by sigmoid function in the presence of EGTA. 
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         Table 6.1. Unfolded temperature determined by CD spectroscopy. 
 wt- CaM  Del-CaM N-CaM C-CaM 
Tm (⁰C)- apo 53.3 ± 2.3 39.5 ± 0.5 51.1 ±3.0 44.0 ± 1.7 
Tm (⁰C)-holo N/A N/A 62.5 ±10.1 57.1 ±1.5 
 
 
6.3. Ca2+ binding affinities of isolated half domain of CaM and CaM with the 
flexible linker region deleted 
 
Domain specific titrations of the N- , C- terminal CaM and Del – CaM were 
carried out by monitoring the Phe signals in the N- terminal domain and the Tyr signals 
in the C – terminal domain using the same method as wild type CaM. Figure 6.4. and 
Table 6.1 summarize the domain specific Ca2+ binding affinities of wild type CaM and 
the fractions. Both N- terminal ( Kd is ~ 6.43 µM) and C – terminal (Kd is ~ 1.18 µM) 
isolated domains of CaM have almost two folds increase in  Ca2+ binding affinities 
compared to the wild type (Kd is ~11.5 µM for N - terminal and 2.04 µM for C – terminal). 
For the mutants with five residues deleted in the linker region (Del-CaM), the Kd 
decreased in both N- (Kd is ~ 6.38 µM) and C- domains (Kd is ~ 1.38 µM) compared to 
the wild type. The hill numbers of this deletion mutant are different in N- terminal and C –
terminal domain for the deletion mutant (nH = 1.4 in the N –terminal domain of del-CaM, 
nH = 2.4 in the C –terminal domain) indicating that the coorperativity had changed (nH = 
1.7 in the N –terminal domain of Del-CaM, nH = 2.0 in the C –terminal domain in wild 
type CaM) due to the deletion of the central linker. 
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             Figure 6.4.Ca2+ binding affinities of CaM and its variants tested by domain 
specific fluorescence spectrometry. 
Ca2+ binding affinities of CaM and its variants were tested using fluorescence 
titration by domain specific method:  wt-CaM (○), N- terminal domain (□), C-
terminal domain of CaM (╬) and CaM with the linker region deletion (◊). 
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              Table 6.2.Domain specific binding affinities and hill numbers of CaM isolated half  
domains and CaM with the linker region deleted 
CaM
variants
N-domain C-domain
Kd (µM) nHill Kd (µM) nHill
WT 11.5 ± 0.03 1.7 ± 0.03 2.04 ± 0.01 2.3 ± 0.04
N-CaM 6.43 ± 0.02 1.2 ± 0.03 N/A N/A
C-CaM N/A N/A 1.18 ±0.03 1.8 ±0.03
Del-CaM 6.38 ± 0.02 1.4 ± 0.03 1.38 ± 0.02 2.4 ± 0.04
 
 
Lobe-specific Ca2+ binding affinities of the CaM variants were determined via 
monitoring intrinsic fluorescence changes during equilibrium calcium titrations 57,58. The 
Ca2+ dependence of phenylalanine and tyrosine fluorescence of wild type and mutant 
CaMs were fit with the Hill equation and are illustrated in Figure 6.4. CaM Ca2+ 
dissociation constants (Kd) and Hill coefficients (nH) were derived from these fits and are 
summarized in Table 6.2. As previously established, C-terminal lobe Ca2+ binding 
occurred with a significantly higher affinity that the N-terminal Ca2+ binding in the 
compact CaM protein102; the isolated C – terminal domain still exhibits more than 5 folds 
stronger affinity than isolated N –terminal domain. The Ca2+ binding affinity to both the 
isolated N – terminal domain and C –terminal domain nearly doubled compared to the 
compact protein. These results confirmed the cooperative Ca2+ binding properties 
between the two domains of CaM. The hill numbers of the two domains are close to one 
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instead of two in the wild type CaM.  Interestingly, Del-CaM provided stronger binding 
affinities in both domains with the Kd values similar to the isolated domains. This 
indicated that the helical linker probably plays a role for the binding to Ca2+. The Hill 
numbers of this deletion mutant are close to one instead of two, as seen in the whole 
compact CaM or in the isolated N- terminal, while they are close to two in the C –
terminal domain. This result indicates that the deletion of the central linker decreased the 
cooperativity of the Ca2+ binding to the two domains of CaM. 
 
6.4. Size determination of isolated half domain- CaM and the mutant deleting 
flexible linker by pulse - field- gradient diffusion NMR 
 
Figure 6.5 shows several highly-simplified models for the formation of the whole 
CaM molecule from its N and C-terminal domains.  In the first case (Figure 6.5a); it is 
assumed that the N and C-terminal domains are spherical with hydrodynamic radii of 
~16 Å.  They bind to each other to form a larger globular protein with a volume of 4R3/3, 
which is equal to 2[4(16)3]/3, where R is the radius of the resulting protein.  In other 
words, the resulting larger protein will have a radius of 20.2 Å. This is 26% increase, 
closer to the value suggested from a study by Altieri et al 129.  However,   CaM is a 
protein of an elongated shape, with a central helix connecting the two globular sub 
domains (Figure 6.5b).  In this case, the radius of the molecule would be the average of 
the three perpendicular axes.  We measured the length of the central helix from the pdb 
file 3cln, which is ~8 Å.  Therefore, the radius of the longest axis of CaM would be     32 
+ 4 = 36 Å; and the average radius of CaM would be equal to (16 + 16 + 36)/3 = 22.7 Å.  
This is very close to our measured hydrodynamic radius of CaM by NMR diffusion 
experiments.  In the third case (Figure 6.5c); we considered that the individual sub 
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domains form an elongated molecule without the central linker.  In this case, the average 
radius would be (16 + 16 + 32)/3 = 21.3 Å, which is also close to our experimental result 
for the Ca2+ loaded form of Del-CaM.      
 
N- C-+ CaM(a)
N- C-
8 Å
N- C-
(b)
(c)
 
            Figure 6.5.Structural models of CaM variants, the isolated N- terminal, C-terminal 
domain and five residues deleted in the linker region. 
a). N- and C- terminal domain of CaM comprise the whole globular protein CaM in 
a direct way. b).The helical linker between the two domains of CaM with a 
calculated size around 8 Å. c). The two domain combined together without the 
liker region to form an incomplete protein analog of CaM. 
 The isolated N- , C- terminal domains of CaM and the linker deletion variant of 
CaM were expressed and purified using the same method as wild type CaM. NMR 
samples contained 0.23 mM proteins in 10% D2O, 100 mM KCl, and 10 mM imidazole at 
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pH 6.5, with 10 mM Ca2+ for Ca2+-bound or 1 mM EGTA for Ca2+-free sample. The 
intensities of the protein signals collected on 600 MHz Varian Inova spectrometer were 
integrated from the methylene and methyl region of ~2 ppm spectral width (-0.2 – 1.8 
ppm). The integrate regions for each species were carefully selected to avoid or reduce 
interferences from buffer signals. The integrated intensities were further normalized to 
minimize the experimental errors from phase adjustment and baseline correction during 
the processing.     The data of isolated half domain CaM, CaM with the linker region 
deleted in both the Ca2+ loaded (Figure 6.6.A) and Ca2+ free (Figure 6.6.B) forms were 
fitted by mono exponential equation 
                   Y = exp(-m1* M0^ 2); m1 = 0.002               Equation 6.2 
The radii of each mutant were calculated based on the fitting results using the equations 
described in Chapter 2. 
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                  Figure 6.6.PFG diffusion data of CaM and its variants in the presence of Ca2+ 
and EGTA on 600 MHz magnetic field strength. 
PFG- diffusion data of isolated half domain CaM, CaM with the linker region 
deleted in both the Ca2+ loaded (A) and Ca2+ free (B) forms. The collected data 
points were fitted by one exponential equation based on the gradient strength 
function with the relative intensity processed on Felix 98. 
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Table 6.3 summarized the diffusion data for the apo and holo forms of CaM and 
its variants.  All of our diffusion data can be fitted by equation 2 with correlation 
coefficient ≥ 0.999.  The hydrodynamic radius of Ca2+-CaM was determined to be 22.2 ± 
0.4 Å.  This result is compared to the crystal structure of Ca2+-CaM (3CLN)130, which has 
the well known dumbbell shape.  The long axis of the crystal structure has a diameter of 
68 Å, while the two perpendicular short axes have diameters of 30 and 40 Å, 
respectively. This gives an average radius of 23 Å, which agrees well with our 
hydrodynamic radius. 
 The apo form of CaM has a hydrodynamic radius of 21.4 ± 0.4 Å. This is 
comparable to the solution structure103, which has an average radius of 22 Å (diameters 
of the long axis and the two short axes are 67, 33, and 33 Å, respectively).  Our results 
indicated that there is no significant difference in the size of the Ca2+ free and bound 
forms of CaM.        
For N60D, N97D double mutant CaM, the hydrodynamic radii were calculated to 
be 22.2 and 22.5 Å for the apo and Ca2+-bound forms, respectively.  As expected, these 
values are close to those of wt-CaM since the mutations should not change the size of 
the molecule. 
 For the CaM mutant that has 5 residues deleted from its central linker (Del-CaM), 
the apo form has a radius of 22.4 Å, which is essentially the same as that of wt-CaM.  
This indicats that the central linker is very flexible in the apo form so that it can 
accommodate changes in its length.  However, after adding calcium, the radius 
decreased to 21.0 Å.  The hydrodynamic radii of the N and C-terminal domains (N-CaM 
and C-CaM, respectively) were measured to be ~16 Å.  They are almost identical in size, 
independent of the presence of Ca2+. 
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      Table 6.3.Summary of diffusion constants and hydrodynamic radii from PFG   
diffusion experiment of CaM variants 
Proteins Diffusion constant (  107 cm2/s) Hydrodynamic radius (Å) 
CaM apo 10.0 ± 0.2 21.4 ± 0.4 
holo 9.6 ± 0.2 22.2 ± 0.4 
C-CaM apo 13.3 ± 0.1 16.1 ± 0.1 
holo 12.9 ± 0.1 16.6 ± 0.2 
N-CaM apo 13.2 ± 0.2 16.2 ± 0.2 
holo 13.2 ± 0.1 16.2 ± 0.1 
Del-CaM apo 9.5 ± 0.1 22.4 ± 0.2 
holo 10.2 ± 0.2 21.0 ± 0.3 
N60D, N97D 
CaM 
apo 9.6 ± 0.1 22.2 ± 0.3 
holo 9.5 ± 0.1 22.5 ± 0.3 
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6.5. Biological function test of the isolated half domain- CaM and CaM with the 
deleted linker region by PDE assay. 
 
Ca2+/CaM- dependent cyclic nucleotide phosphodiesterase (PDE1) is one of the key 
enzymes involved in the complex interactions between the cyclic nucleotide and Ca2+ 
second messenger systems. The overall structure of PDE1 isoforms is well conserved, 
consisting of four domains; two CaM-binding domains, an inhibitory domain and a 
catalytic domain126,127.  Zhang et al have reported that only mutations in the N-terminal 
lobe of CaM affect the activity of CaM  to PDE1 although there are eight methionines in 
the hydrophobic clefts of Ca2+-CaM that are required for the binding and activation of 
PDE1 128.   
In our study, the functional effects of PDE on the substrate of mant-cGMP 
resulting from interactions with Ca2+-CaM of various concentrations was studied through 
a time based fluorescence titration method.  The EC50 obtained through fitting the 
fluorescence data demonstrated the activation capabilities of wt CaM and its variants.  
Figure 6.7 and Table 6.4 summarize the time based fluorescence results which 
were fitted by the Hill equation.  Wild type CaM activated PDE with an EC50 of 7.1× 10
-9 
± 0.02 M. The Del-CaM mutant exhibited lower activation capability than wtCaM with an 
EC50 of 3.8 × 10
-7 ± 0.03M. However, the capability of activation for the N- terminal 
domain of CaM on PDE decreased with nearly a four-fold increase of the EC50       
(2.55× 10-8 ± 0.03 M) compared to wt CaM (7.1× 10-9 ± 0.03 M). Conversely, the C – 
terminal domain of CaM lost its activity by dramatically increasing the EC50 to 3.3 ×10
-7 ± 
0.06 M, which are more than 40 folds greater than the wtCaM. 
Zhang et al found that although there are eight methionine residues within the 
hydrophobic clefts of Ca2+-CaM required for the binding and activation of PDE1 in both 
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two lobes of bovine CaM), only mutations in the N-terminal domain of CaM affect the 
activity on PDE1. They hypothesized that the C-terminal lobe of CaM may serve to 
target CaM to PDE1, while the N-terminal lobe activates the enzyme 128a. Mutating the 
glutamate cluster of residues 82-84 to lysines abolishes and greatly impairs its activation 
of NAD kinase and MLCK respectively, but has no effect on phosphodiesterase 131.  On 
the other hand, deletion of residues 79-80 abolishes its activation of phosphodiesterase 
but has no effect on MLCK 132 . Therefore, the central linker may play a role of selectivity 
towards different targets of CaM.  Biological analysis in Yuan‟s group suggested that it is 
the helical structure in CaM binding domain 1 of PDE induced by the insertion of the 
indole ring from Tryptophan residue that allows this domain to bind both lobes of CaM 133.  
We further analyzed the functional effects on PDE of our three mutants: the isolated N – 
terminal (1-75), C – terminal (76-148) and the Del-CaM mutant (i.e., deletion of residues 
81-85). The half domains of CaM were found to activate PDE at a reduced activity with 
higher EC50s compared to the wild type protein. The C – terminal domain of CaM has a 
50 times higher EC50 with virtually complete loss ofactivity. However, the N – terminal 
domain decreased the functional activity less than four times. These results confirmed 
the functional coorperativity between the two domains of CaM and indicated the effect 
on the C – terminal domain due to the lack of the N – terminal domain is more apparent. 
On the other hand, the mutant with the flexible linker also decreased the activating 
capability with an EC50 ~50 times higher than wtCaM. This may be explained by the 
reason that only five residues were deleted and the remaining residues in the linker still 
maintained the activated function assay to PDE although the activity was reduced to a 
lower level compared to the wt CaM. However, the isolated domains completely lost the 
coorperativity and were not able to function separately. 
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Figure 6.7.PDE function assay of CaM and its variants through time based 
fluorescence spectroscopy on the PTI fluoremeter. 
Data were fitted by hill equation. 
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            Table 6.4.Summary of PDE function assay for wt CaM and the related mutants. 
 wt- CaM Del-CaM N-CaM C-CaM 
EC50(×10
-8M) 0.71± 0.02 38.2± 0.03 2.5± 0.003 32.76± 0.06 
 
6.6. Conclusions and significance 
 
We engineered structural components of CaM by molecular cloning. Our analyses 
indicated that these mutants maintain their structures similar to the wtCaM. The half 
domains of CaM exhibited stronger binding affinities with Ca2+ than what we observed in 
the compact wtCaM. These results indicated that Ca2+ undergoes cooperative binding to 
the two domains in CaM. Domain specific fluorescence results showed that the C – 
terminus has higher Ca2+ binding affinity than the N – terminus. Interestingly, the Del-
CaM mutant also provided stronger Ca2+ binding affinity than the wild type in both the N- 
and C- terminal domains. Tm calculated from analyses of CD spectra suggested that all 
these structural components decreased their stability compared with wild type CaM. In 
vitro PDE function assay was carried out through time based fluorescence spectroscopy. 
The activity of CaM on PDE was abolished for the Del-CaM and the activity was greatly 
decreased for the C- terminal domain. However, the N-terminus was able to maintain its 
activity with an EC50 value close to that of wtCaM. These results suggested that the N – 
terminal domain of CaM may play the essential role for the activity on PDE while the C – 
terminal and the central linker region may contribute to the binding between CaM and 
PDE instead of function. 
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7. Engineering Protein Based Contrast Agent with Multiple Metal Binding Sites and 
HER-2 Targeting Capability   
 
 
7.1.  Protein based contrast agents 
 
Magnetic resonance imaging (MRI) has unique advantages in capturing 3-
dimensional images of living systems with high spatial resolution and without many 
limitations or problems associated with other methods, particularly limited imaging 
penetration of tissue/organs and ionized radiation134,135. MRI has emerged as a leading 
diagnostic technique in clinical and preclinical settings 136,137. In addition, it allows for 
non-invasive and repetitive assessment of biological processes with the same living 
subjects at different time points, which significantly reduces the number of animals 
required and cost138. However, the application of MRI to assess specific disease markers 
for diagnosis and monitoring drug effects has been severely hampered by the lack of 
contrast agents with desirable properties including high relaxivity, minimal or no toxicity, 
and optimized in vivo retention time 139,140. For example, gadolinium-diethylenetriamine 
pentaacetic acid (Gd-DPTA) 141,142, a current clinically approved MRI contrast agent, has 
a low relaxivity value of ~5 mM-1 s-1 and requires an injection dose of up to 0.1 mmol kg-1 
body weight for clinical application in animals and humans 143. In addition, Gd-DPTA may 
not be suitable for some advanced in vivo MRI applications due to a high glomerular 
filtration rate for this small chelator molecule 144,145. The non-covalent binding of small 
chelators to plasma proteins, such as albumin (MS-325)146, greatly increases the 
relaxivity with a good MR angiography146-147. There is a strong need to develop MRI 
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contrast agents with improved relaxivity, optimized pharmacokinetics, and application to 
molecular imaging 138a.  
 
HER-2 is a tyrosine kinase growth factor receptor and belongs to the human 
epidermal growth factor receptor (EGFR) family. HER-2 was first discovered as a rat 
oncogene called neu, found in rat neuroblastoma in the late 1970‟s. It is expressed in a 
number of normal tissues which probably plays a role in normal cell function, growth 
regulation and proliferation148,149    
 
HER-2 is over expressed in many malignances, such as breast cancer, urinary 
bladder carcinomas, and carcinomas in the gastrointestinal tract, to promote the growth 
of cancer cells150,151
,152.  Figure 7.1 (cited from the published work of Wang, SE et al, 
2011 ) shows the sequence ,structure and dynamic conformational changes of the HER-
2 affibody molecule. HER-2 serves as a co-receptor with related members of the HER 
family of tyrosine kinase–associated growth factors153
,154. Acquired amplification of the 
HER2/neu gene on chromosome 17 in HER-2-positive breast cancer leads to marked 
overexpression of HER-2 on the cell surface 155, which alters normal signaling function 
156,157. Several targeted drugs such as Trastuzumab, a humanized monoclonal antibody 
that binds to HER-2, have been developed and  very effective in  inhibiting tumor-cell 
growth through a variety of intracellular, and possibly extracellular, mechanisms 158,159. 
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Figure 7.1.Structure and dynamics of the Z-HER-2 affibody molecule. (A) Sequences of 
the Z domain and Z-HER-2. Gray, randomized positions in affibody libraries; yellow, 
selected side chains at Z-HER-2 interface; cyan, other residues at Z-HER-2 interface; 
black boxes, dynamic nonpolar side chains in core; red boxes, Asn and Gln side 
chains with alternating conformations. Insets above and below sequences show 
secondary structure and surface exposure, with darker blue shading reflecting less 
surface exposure. Residues for which backbone NMR resonances in Z-HER-2 are 
broadened by dynamics are in gray and ordered regions in orange (matching coloring 
in C–E). (B) Backbone traces of the Z-HER-2 structure ensemble. The blue/gray colors 
of residues 1 to 12 at the N terminus show two conformers obtained with unrestrained 
SA. (C) Z-HER-2 conformational exchange dynamics: orange, no backbone dynamics; 
gray, backbone dynamics; white spheres, methyl groups at the interface between 
helices 1 and 2 that undergo conformational dynamics; sticks, dynamic Asn and Gln 
side chains. (D) The alternative Z-HER2_alt structure with an intact helix 1. (E) 
Illustration of how dynamics (as in D) coincides with mutations at the HER2 binding 
surface (yellow sticks corresponding to yellow shading in A 
151
.  
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       Figure 7.2.Tumor-promoting function of TGF-β in HER2-overexpressing cancer cells 
is mediated by TGF-β-driven autocrine and paracrine ErbB ligands160. 
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While HER2 does not have nature ligand, several proteins such as antibody and 
affibody have been developed to interact with HER2 with high affinity. Affibody 
molecules are small proteins being developed by a Swedish biotechnology company, 
Affibody AB. The original affibody protein scaffold was designed based on the Z domain 
(the immunoglobulin G binding domain) of protein A 161.  Protein A is a protein localized 
on the surface of Staphylococcus aureus which protects the bacterium from the immune 
system of the host. A slightly modified pattern of domain B, also known as domain Z 
consisting of 58 amino acids, has been extensively used as an affinity purification 
reagent. Thirteen solvent - exposed amino acids localized on helix 1 and helix 2 of this 
domain Z construct an affibody library by random organization.  These affibody 
molecules are designed to imitate monoclonal antibodies (mAbs) and are engineered to 
bind to a large number of target proteins or peptides with high affinity. Affibody 
molecules are used in biochemical research and are being developed as potential new 
biopharmaceutical drugs162
,163. Affibody molecules have also been reported to maintain 
stability under conditions of high temperature and high pH, which makes them 
interesting as potential molecules for tumor targeting applications 164,165.  To date, 
affibody has been reported to successfully target to HER2 over-expressed in different 
cancer types using various imaging technique such as PET (Fig 7.3) and NIR with high 
sensitivity.    
 
Yang lab has successfully developed protein based contrast agents (ProCA1) by 
designing a singly metal binding site into a scaffold protein CD2 166.By controlling 
correlation time and increase water numbers in the coordination shell, ProCA1 has 
significantly increased relaxivity (Chapter 9).  Based on the tunable calcium binding 
affinity and multiple metal binding sites and our detailed studies on the structural and 
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dynamic properties of CaM and our success in design protein based contrast agent, in 
this chapter and next chapter, we report our effort in engineering CAM as a MRI contrast 
agents for molecular imaging.  We first examined the metal binding affinity especially for 
Gd3+ and selectivity over several physiological metal ions of several CaM variants (Table 
1.1). We then examined the relaxation properties and water numbers of these variants. 
Serum stability and metal toxicity were also investigated. Further, we eliminate the 
endogenous biological function of CAM in regulation by Pegylation. Finally, we further 
developed them to be targeted MRI contrast agents to against HER by addition of 
affibody moiety and GRPR by addition of peptide targeting sequence. They have been 
successfully applied to in invivo imaging using MRI and NIR by conjugating with NIR dye.    
 
 
 
Figure 7.3 PET images from affibody with its specific target peptide. 
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Figure 7.4.Electrostatic model of designing protein based contrast agent  
with specific biomarker targeting. 
 
 
7.2. Determining the metal binding affinities of designed protein based contrast 
agent with Gd3+ 
 
Gd3+-binding affinity of ProCA2 series protein-based contrast agents was 
determined by a competition titration with Fura-6F (a metal ion indicator, Invitrogen 
Molecular Probes) applied as a Gd3+ indicator. The fluorescence spectra of Fura-6F 
were obtained with a fluorescence spectrophotometer (Photon Technology International, 
Inc.) with a 10 mm path length quartz cell at 22 °C. Fura-6F excitation spectra were 
acquired at two wavelengths 340 and 380 nm with an emission wavelength at 510 nm. 
Gd3+-binding affinity of Fura-6F, Kd1, was first determined by a Gd
3+ titration with Gd3+ 
buffer system of 1 mM nitrilotriacetic acid (NTA). Free Gd3+ concentration was calculated 
with a NTA Gd3+-binding affinity of 2.6 × 10-12 M. Fura-6F was mixed with Gd3+ in 1:1 
ratio for a competition titration. The experiment was performed by a gradual addition of 
ProCA22. An apparent dissociation constant, Kapp, was estimated by fitting the 
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fluorescence excitation intensity ratio of Fura-6F at 340 and 380 nm with different 
concentrations of CaM and designed ProCA22 concentrations as a 1:1 binding model.  
Gd3+-binding affinity of ProCAs, Kd2, was calculated with the following    equation: 
                          
Td
d
appd
FFuraK
K
KK
]6[1
1
2

           Equation 7.1     
Fluorescence dye competition experimenta (Figure 7.5. a and b) were carried 
out to estimate the Gd3+ binding affinities with designed protein based contrast agents. 
The apparent binding constant Kapp was obtained by fitting the fluorescence signal 
intensity ratio at 340 nm and 380 nm (Figure 7.5.b). The dissociation constant Kd was 
further calculated based on the Equation 7.1. The results indicated that protein based 
contrast agents had strong binding affinities to Gd3+ with a small dissociation constant Kd 
in the range of 10-13 M. In addition, ProCA22 also exhibits high metal selectivity as 
determined by comparing the binding affinities between vary metals. The binding affinity 
of CaM to Ca2+ has been well studied for quite long time. The N- and C- domain of CaM 
have different binding affinities to Ca2+, but both are in the µM range. The modified 
ProCA had similar binding affinity as wt CaM based on our experimental data.  These 
data clearly showed that the designed ProCA22 has a strong binding affinity to Gd3+ with 
a reasonable metal selectivity to other metal ions, for example Ca2+. 
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Figure 7.5. Gd3+ binding affinity determination by a dye competition method. 
Fura-6F with two excitation wavelengths at 340 nm and 380 nm and emission 
wavelength at 510 nm was selected to compete with ProCA22. The Kd for Gd
3+ to 
Fura-6F is 8.4 × 10-12 M. The Kapp of Gd
3+ with wt CaM and modified ProCA22 are ~ 
1.2 × 10-6 M and the calculated Kd are ~5×10
-13 M. 
7.3. Water coordination number measurement of the designed protein based 
contrast agent by Tb3+ lifetime luminescence 
 
Wild type CaM and ProCA22 samples were initially prepared in H2O buffer 
system solutions, and then replaced with D2O by lyophilizing the samples and re-
dissolving them in D2O. This procedure was repeated at least three times. Tb
3+-
luminescent decay in both H2O and D2O were measured to determine the number of 
water ligands coordinated to the Gd3+-ProCA22 complex. The Tb3+ excited-state lifetime 
was measured using a fluorescence spectrophotometer (Photon Technology 
International, Inc.) with a 10 mm path length quartz curvet at room temperature (22 °C). 
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Following excitation at 265 nm with a XenoFlash lamp (Photon Technology International, 
Inc.), in a time based decay fluorescence experiment, Tb3+ emission was monitored at 
545 nm in both H2O and D2O systems. The luminescence decay lifetime was obtained 
by fitting the acquired data with a mono exponential decay function. The water number 
coordinated to the Tb3+-ProCA22 complex was then obtained by fitting the acquired Δkobs 
value to the standard curve.  
The life time of free Tb3+ in H2O and D2O were found to be 410 and 2796 µs, 
respectively. The formation of the Tb3+ -wt CaM and ProCA22 in H2O significantly 
increases Tb3+ lifetime to 821 μs and 798 μs respectively. Tb3+ life time values of wtCaM 
and ProCA22 were 1653 and 1606 μs respectively in D2O, suggesting a hydration 
number of 1.6 and 1.8 (Figure 7.6.).  
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                   Figure 7.6.Determine the water coordination number of ProCA22 
 by measuring Tb3+ life time luminescence. 
Tb3+ luminescence decay was measured in both H2O and D2O. Tb
3+ emission 
was monitored at 545 nm in both H2O and D2O systems with excitation at 265 
nm. The water number coordinated to the Tb3+-ProCA22 complex was 
obtained by fitting the acquired Δkobs value to the standard curve.  
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7.4. In vitro relaxivity of the designed protein based MRI contrast agents  
 
Relaxation times (T1 and T2) of various protein-based contrast agents were 
determined at 1.41 T using a 60 mq Bruker Mini Spec relaxometer. The lattice relaxation 
time T1 of ProCAs was determined at 1.41 T by inversion recovery pulse sequence and 
the data were fitted by Equation 2.9 in Chapter 2. The transverse relaxation time T2 of 
ProCAs was determined through t2_cp_mb pulse sequence which is the Carr-Purcell-
Meiboom-Gill (CPMG) spin echo method and the data were fitted by Equation 2.10 in 
Chapter 2. The protein based contrast agent samples (200 μL) with different 
concentrations were placed in matched glass tubes. The tubes were kept into water bath 
at 37°C for 10 min before measurement. r1 and r2  values were calculated based on 
Equtions 2.11 and 2.12 in Chapter 2, where T1s and T2s are relaxation times with 
contrast agent and T1c and T2c are relaxation times without contrast agent. C is the 
concentration of contrast agent in the mM units.  
The designed protein based contrast agent exhibited high relaxivity in both T1 
and T2 relaxation test (Figure 7.7. A - D).  Relaxivity of the modified protein was similar 
to that of the wt CaM. However, Table 7.1 shows that the r1 of ProCA22 (~50 mM
-1●S-1) 
is almost 20- folds higher than Gd-DTPA (~ 3 mM-1●S-1). The relaxivity was even higher 
for ProCA22 (~70 mM-1●S-1) compared with Gd-DTPA (~ 3.4 mM-1●S-1).  Since relaxivity 
is one of the most important factors for designing contrast agent, the high relaxivity is 
one of the potential advantages of our designed ProCAs, which indicated that it is 
possible that we can obtain significant MR images using lower doses compared to the 
commercial agents. 
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            Figure 7.7.Relaxivity measured in 1.41 T Mini Spec relaxometer  
in 10 mM Tris buffer of pH 7.4 at 37 °C. 
T1 relaxation time was measured using an inversion recovery pulse sequence 
(A) and T2 reaxation time was measured by cp_mb pulse sequence (B). 
Concentration dependent experiments were applied to determine the 
relaxivities r1(C) and r2 (D). 
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          Table 7.1. Relaxivities r1 and r2 of contrast agents determined by concentration 
dependent measurement at 37°C on the magnetic field strength of 1.41 T. 
Contrast agents r1 (mM•s
-1) r2 (mM•s
-1) 
Gd-DTPA 3.8 4.5 
Wt CaM 53.9 76.4 
ProCA22 50.0 67.3 
 
 
7.5. Serum stability and PDE function test of ProCA22 
 
Given that CaM is an important intra cellular protein and that it can modulate 
functions of a number of enzymes as well as regulate various channels, it is necessary 
to make sure that the designed protein- based contrast agent is no longer capable of 
functioning as wt CaM. We carried out phosphodiesterase (PDE) assay to test the 
function of ProCA22. 
 
The phosphodiesterase (PDE) functional assay was conducted in 10 mM MOPS, 
100 mM KCl buffer at pH 7.4. The PDE enzyme and the substrate 2‟-methylanthraniloyl-
cGMP (Mant-c-GMP) were purchased from Sigma Company. The experiment was 
completed using the PTI Fluorometer by choosing the time base acquisition at room 
temperature. The excitation wavelength of the labeled substrate is 282 nm and the 
emission wavelength is 442 nm. 
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Figure 7.8 A and B shows that the time-based fluorescence signal of Mant-c-GMP 
decreased with the addition of wt CaM, while the slope increased. However, almost no 
signal change was observed from the fluorescence spectra with the addition of ProCA22. 
These results indicated that ProCA22 has lost the ability to activate cGMP due to 
modification by PEGylation and insertion of targeting peptide of affibody. The wt CaM 
has EC50 value about 10
-8 M (A), while the ProCA22 almost lost the activity. 
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                   Figure 7.8.Phosphodiesterase (PDE) assay on time based fluorescence. 
Protein samples were prepared in the buffer containing10 mM MOPS +100 Mm KCl 
with 200 µM EGTA +10 mM CaCl2. The final concentration of PDE is 0.25 µM, using 
Mant-c-GMP as a substrate.  
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7.6. Cell targeting test of the designed contrast agent grafting with cancer 
targeting peptide 
 
Two human cancer cell lines, SKOV-3 and MDA-MB-231 were selected to 
examine whether the designed ProCA22 can target to cancer cells 167. SKOV-3 is an 
ovarian cancer cell line with estimated 3 x 106 HER2/cell 161a. MDA-MB-231 is a breast 
cancer cell line with modest HER2 levels (~3 x 104 HER-2 / cell). Binding of the Gd-
ProCA2-affi to the selected cells was first analyzed by immuno-fluorescence staining 
using the polyclonal antibody against PEGylated parental protein ProCA22. The cell 
binding analyses showed that the SKOV-3 cancer cells bind more ProCA22 compared to 
MDA-MB-231. These results indicated that the designed ProCA22 was able to target the 
cancer cells with high HER-2 expression level. 
Cell binding analyses was applied to examine whether the designed ProCA22 can 
target to cancer cells. Binding of the Gd-ProCA22 to the selected cells was first analyzed 
by immuno-fluorescence staining using the polyclonal antibody against PEGylated 
parental protein. A substantial staining intensity of ProCA22 bound to SKOV-3 cells was 
observed. However, the MDA-MB-231 cells demonstrated very weak staining. The 
immunostaining results were consistent with NIR fluorescence imaging results. Under 
the assumption that 1x107 cells comprise a volume of 50 – 100 µL, this binding capacity 
led to the accumulation of Gd3+ at 10 – 20 µM in the cell pellets. This local concentration 
is sufficient to produce strong MRI contrast, especially the protein contrast agent with 
high relaxivity reported here (Figure 7.9). 
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0CA22 negative cell line MDA-MB-231
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CA22-negative cell line MDA-MB-231
CA22-positive cell line SKOV-3
 
0ProCA22 negative cell line MDA-MB-231 +ProCA22 negative cell line MDA-MB-231  
                   Figure 7.9.Cell targeting of CA22 for both cancer cells with high level (SKOV-3) 
and low level (mda-mb-231) of HER2 expression. 
A). SKOV-3 cell image without adding ProCA22 as a control. B).SKOV- 3 cell image 
with the addition of ProCA22. C). MDA-MB-231 cell image without adding ProCA22 
as a control. D). MDA-MB-231 image with the addition of ProCA22. 
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7.7. MR imaging and NIR images obtained from animals with the injection of 
designed protein based contrast  
 
7.7.1. MR images obtained on 4.7 Tesla 
 
MR images were acquired by applying the in vivo performance of MRI of CD-1 mice 
(20-25g, N = 4) on a 4.7 T Varian MRI system using a dedicated rodent coil with 
modified parameters and vary pulse sequences. During the MR scan, mice were 
anesthetized with 1.5% isoflurane and kept warm with a heated pad. MR images were 
acquired by T1- and T2-weighted fast spin echo sequences (TR=2 s, TE=0.022 s, and 
ESP = 0.01 s) with field of view of  3×3 cm, matrix of  256×256, and slice thickness of 1 
mm. The tumors were dissected after MRI experiments.   We examined the in vivo 
performance of MRI of CD-1 mice (20-25g, N = 4) using a 4.7 T Varian MRI system. 
Figures 7.10 and 7.11 shows the MR images of mice before and a series of time points 
after administration of approximately 100 µL of PEGylated Gd-ProCA22 (~3 mM) 
through the tail vein. Significant contrast enhancements were observed in several 
organs with the greatest enhancement in the kidney, liver, and blood vessels by 
comparison with pre- and post-contrast T1 and T2 weighted images obtained at 4.7 T.  
Meanwhile, the positive tumor injected SKOV-3 breast cancer cells with high HER-2 
expression level gave stronger enhanced images compared with the negative tumors 
injected MDA-MB-231 with lower HER-2 expression level. The injection dose of 4.8 mol 
kg-1 was 20-fold lower than Gd-DTPA dose typically used in clinics (0.1 mmol/ kg). The 
tissue-dependent enhancement was consistent with the biodistribution of IHC staining 
results. we further observed, consistent with MR imaging, a strong NIR light emission 
from the SKOV-3 tumor at 24-hour post-administration of the contrast agent, however, 
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the NIR intensities at the MDA-MB-231 tumor site were much less than that of the 
SKOV-3 tumor (Figure 7.10 and 7.11).  
Pre-scan-s2 Pt 15 min-s3 Pt 3 hr-s3
Pt 26 hr-s5 Pt 51 hr-s6
TR = 2 s,
esp = 10 ms, sk = 2;
Field of View
4(cm) х 4 (cm)
 
         Figure 7.10.MR images of mice with HER -2 tumor at 4.7 T with  
fast spin echo pulse sequence. 
Special slices were selected to compare the images focusing on kidneys of this 
mouse. Images taken from post injected with ProCA22 at different time points (15 
min, 3 hr, 26 hr and 51 hr) were compared to the pre-injection one. 
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Pt 26 hr-s16 Pt 51 hr-s16
TR = 2 s,
esp = 10 ms, sk = 2;
Field of View
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             Figure 7.11.MR images of xenograft tumor models in mice at 4.7 T using fast spin 
echo as the pulse sequence. 
Slice 16 was selected to compare the images focusing on tumor of this mouse. 
Images taken from post injected with ProCA22 at different time points (15 min, 3 
hr, 26 hr and 51 hr) were compared to the pre-injection one. 
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7.7.2.  Near Infrared (NIR) imaging of ProCA22 labeled with Cy5.5 
 
Cy5.5 Mono Maleimide dye produces an intense signal in the Near IR (NIR) 
region of the spectrum. NIR imaging has high sensitivity and is coupled with the MR 
imaging to confirm accurate targeting of selected biomarkers to cancer cells 168. We 
observed a strong NIR light emission from the SKOV-3 tumor at 24-hour post-
administration of the contrast agent; however, the NIR intensities at the MDA-MB-231 
tumor site were much less than that of the SKOV-3 tumor (Figure 7.12 and 7.13).  
Here we introduced an optical imaging capability by conjugating a near-IR dye, 
Cy5.5 Mono Maleimide, to a Cystine residue at C-terminal of the protein to facilitate 
imaging analyses.  The Cy5.5 Mono Maleimide has a maximum absorbance at 674 nm 
and a maximum emission wavelength at 689 nm. The labeling yield is as high as 70%; 
the unlabeled free dye was separated from labeled proteins by dialysis in 10 mM HEPES 
buffer. NIR images are shown before (Figure 7.12.A) and after (Figure 7.12.B) injecting 
ProCA22 into the mouse. It can be clearly observed that the kidney and liver were lit up 
4 hours after injecting the contrast agent (Figure 7.12.C). Moreover, tumors and organs 
from the imaged mice were collected 48 hours post injection of ProCA22 to further 
analyze the HER2 targeting properties of the designed ProCA22(Figure 7.13). The 
organs and tumors were imaged using optical animal imaging. High levels of 
accumulation of Cy5.5 in the liver, kidneys, and the SKOV-3 tumor were observed. In 
comparison, the level of Cy5.5 at the MDA-MB-231 tumor was quite low (Figure 7.12). 
The results strongly suggested that our protein contrast agent is able to target the tumor 
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with high HER-2 expression level and produce the HER-2 specific MR image 
enhancement.  
Pre-scan Post injection 4 hrPositive 
Tumor
Negative 
Tumor
A B C
 
                Figure 7.12.NIR images of both positive tumor with SKOV-3 cell line and negative 
tumor with MDA-MB-231 cell line in the same mouse. 
 A, B).Image scanned before the administration of our designed contrast agent. C). 
Image scanned after the injection of ProCA22 for 4 hr. 
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                        Figure 7.13.Quantitive analysis of NIR images of tumor and organs from 
the mouse injecting ProCA22 after MR imaging. 
  A). NIR images of organs from the mouse with injection of ProCA22 post 48 hr. 
  B). Quantities analysis of NIR intensities from the images of organs on Figure A. 
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7.8. Immunohiston chemistry staining of tissues from the mice injected with 
our designed protein based contrast agent.  
 
To further verify the contrast agent targeted to the HER-2 positive tumor, we 
applied immune histo-chemistry (IHC) staining using the antibody PAb with tissue slides 
made from the tumor samples and selected organs collected from the imaged mice. 
Strongest staining was observed with liver and the SKOV-3 tumor tissue slides     
(Figure 7.14). Close examination of the staining patterns of the tumor slides revealed 
distribution of the designed protein both inside and outside the cancer cells with 
substantial stronger staining inside the cancer cells, indicating internalization of the 
protein contrast agent. The kidney slides also presented strong immune staining 
consistent with the NIR imaging finding.  Interestingly, the areas near proximal tubes 
showed strongest staining (Figure 7.14), suggesting that the protein contrast agent may 
be secreted through kidney. In contrast, immune staining of negative tumor sections 
grown from MDA-MB-231 cell line revealed very weak staining (Figure 7.14). 
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             Figure 7.14. IHC staining of tissues from the mouse injected with ProCA22. 
A). positive tumor with SKOV - 3 cancer cells. B). negative tumor grown with MDA-
MB-231 cancer cells. C). Liver tissue injected with ProCA22. D). Left kidney 
injected with ProCA22. 
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Figure 7.15. IHC staining of liver from the mouse injected with ProCA22. 
A). over all image of IHC staining of liver. B). red color shows the protein stained 
by our antibody. C) Green color is the blood vessel stained by CD31. D). blue color 
is the nucleus acid. 
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7.9. Testing the toxicity of ProCA 22 
 
The toxicities of the designed protein contrast agent were analyzed with CD-1 mice. 
No acute toxicity was observed upon the tail vein injection of 4-fold greater dosages than 
those used in MR Image over a 2-day test period. Characterization of serum samples 
from the tested mice receiving the agent suggested that no kidney, liver, and heart 
damages were detected (Figure 7.14). 
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      Figure 7.16.Toxicity test of the designed protein based MRI contrast agent with 
injection into the CD- 1 mouse. 
The salt (Na+, K+ and Ca2+) concentrations were measured and compared to the 
blank mouse which was injected with saline.  
 
 
152 
 
 
7.10. Gastrin Releasing Peptide and Gastrin Releasing Peptide Receptor 
 
 
        Gastrin-releasing peptide, also known as GRP, is an important regulatory molecule 
that has been implicated in a number of physiological and pathophysiological processes 
in humans 169,170. GRP is a bombesin structural related peptide with twenty-seven amino 
acids which was isolated from porcine gastric tissue recently 171,172. Gastrin-releasing 
peptide is a regulatory human peptide that elicits gastrin release and regulates gastric 
acid secretion and motor function. Bombesin is a 14-amino acid peptide originally 
isolated from the skin of a frog Bombina bombina in 1971173. It has two known homologs 
in mammals called neuromedin B and gastrin releasing peptide. Bombesin and gastrin 
releasing peptide have the same amidated C- terminal heptapeptide 174,175. The gastrin-
releasing peptide receptor (GRPR), also known as BB2 is a G protein-coupled receptor 
whose endogenous ligand is gastrin releasing peptide 176. GRPR mediates the function 
of GRP. GRP and its receptors are highly expressed in the pancreas in human 177.  
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Figure 7.17. Interrelationship between gastrin, histamine  
and somatostatin in control of gastric acid secretion178.  
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Luminal acid directly inhibits the G-cells and gastrin release but stimulates the D-
cells to release somatostatin which by paracrine pathway inhibits gastrin release from 
the G-cells and indirectly reduces gastric acid secretion. The H. pylori infection of antral 
mucosa increases gastrin release by acting on the G-cells through Nalpha-methyl-
histamine produced by infected mucosa and increase the release of proinflammatory 
cytokines that stimulate the G-cells to release gastrin and ECL-cells to release histamine, 
both leading to increased gastric acid secretion. 
It has been reported that a high GRP expression level was detected in those 
neuroendocrine tumors, such as small cell lung cancer and androgen-dependent 
prostate cancer 179. GRP acts as growth factors to stimulate cell growth through its 
receptor (Gastrin Releasing Peptide Receptor) by autocrine and paracrine pathways180. 
The expression level of GRPR has been found to correlate with tumor stages. The 
binding affinity of GRPR to its agonist is variable and depends on the type of cells and 
agonists. GRPR was found to be aberrantly expressed by various cancer cells, which 
suggests potentially important clinical impacts for future drug development. Based on the 
importance of GRP, we are going to apply our protein-based contrast agents to include 
specific targeting to the GRPR and detecting the prostate cancer through MR imaging. 
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8. Developing Protein Based Contrast Agents using Half Domains of CaM 
 
 
8.1. Introduction  
 
The properties of Ca2+ binding to CaM have been well studied since CaM is the most 
important Ca2+ binding regulatory protein. However, the impact of Mg2+ on Ca2+ binding 
to CaM is important physiologically, and has long been a matter of debate. Baudier, J. et 
al had proposed that not only Ca2+ but also Zn2+ can bind to the S100 proteins and result 
in conformational changes. They also pointed out the binding sites for Ca2+ and Zn2+ are 
quite distinct 181. The tryptic fragments of   CaM 121,122, have been shown to be very 
similar to the corresponding domains of intact CaM in terms of 3D structures123 as well 
as Ca2+ binding characteristics 25. Shea MA et al have reported inter domain 
cooperativity of paramecium calmodulin bound to melittin preferentially increases 
calcium affinity of sites I and II 28.  We have discussed the Ca2+ binding properties of 
these half domain CaM subunit in Chapter 6, and we are going to  continue analyze the 
binding affinities of Zn2+ and Lanthanides in this chapter.    
Signal intensity in MRI was produced mainly from the local value of the longitudinal 
relaxation rate 1/T1 and the transverse rate, 1/T2 of water protons. Signal is expected to 
increase with shortening T1 and decrease with longer T2
182. Contrast agents increase 
both 1/T1 and 1/T2 rates to varying degrees depending on their nature as well as the 
applied magnetic field strength. Contrast agents such as gadolinium (III) are selected for 
T1-weighted images since the percentage change in 1/T1 in tissue is much greater than 
that in 1/T2 because they can increase 1/T1 and 1/T2 at similar amounts
183.  The 
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presence of a gadolinium (III) complex will increase the longitudinal and transverse 
relaxation rates, 1/T1 and 1/T2, respectively, of solvent nuclei
184. Diamagnetic and 
paramagnetic relaxation rates are additive and given by Equation 8.1, where (1/Ti)obs is 
the observed solvent relaxation rate and the subscripts “d” and “p” refer to diamagnetic 
and paramagnetic, respectively. The paramagnetic contribution is dependent on the 
concentration of paramagnetic species. Relaxivity, ri, is defined as the slope of the 
concentration dependence as observed in Equation8.2. Thus a plot of (1/Ti)obs versus 
concentration would give the relaxivity as the slope. Relaxivity is normally expressed in 
units of mM-1 s-1; however, molal concentrations should be used when dealing with non 
dilute systems 185. The origin of paramagnetic relaxation enhancement is generally 
divided into two components, inner sphere and outer-sphere as shown in Equation8.3. 
Inner-sphere relaxation refers to relaxation enhancement of a solvent molecule directly 
coordinated to the paramagnetic ion, and outer-sphere relaxation refers to relaxation 
enhancement of solvent molecules in the second coordination sphere and beyond (i.e., 
bulk solvent). This separation is used in an attempt to explain observed relaxivities in 
terms of existing theories 186. As in the previous review, the emphasis will be on the 
longitudinal relaxation rate (1/T1) enhancement of water hydrogen atoms since this is the 
effect which is of most interest in MRI 139a. 
 
             (1/Ti)obs ) = (1/Ti)d + (1/Ti)p  i = 1, 2                      Equation8.1 
             (1/Ti)obs  =  (1/Ti)d + ri[Gd]  i = 1, 2                       Equation8.2 
                (1/Ti)p = (1/Ti)inner-sphere + (1/Ti)outer-sphere  i = 1, 2     Equation8.3 
 
As discussed in Chapter 7, MRI provides good contrast between the different soft 
tissues of the body, which make it especially useful in imaging the brain, muscles, the 
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heart, and different cancers. Moreover, MRI scans are fast and harmless to the patient184, 
187. Utilizing strong magnetic fields and non-ionizing radiation in the radio frequency 
range unlike CT scans and traditional X-rays, which both use ionizing radiation188,189.  
We have already created a protein based contrast agent, ProCA22, with a HER -2 
affibody fused into the compact CaM.  Enhanced images were obtained with both 4.7 
and 7 tesla Varian MRI instruments with lower dosage injections of ProCA22. However, 
more space exists for further improvement of this contrast agent. For example, it took 
more than 2 hours to target to the tumor and most contrast agents accumulated in the 
liver and kidney instead of the tumor.  
In this chapter, we report our studies to optimize the design of MRI contrast agents 
by using half domain of CaM, which not only have smaller molecular weight, but also 
abolish most of their biological function in cells. We first examined metal binding for Zinc 
and Gd. We then examine their relaxarion properties using 1.4 T relaxometer.  
 
 
 
8.2. Metal binding affinities and selectivity of wild type CaM and half domains 
determined by fluorescence spectroscopy 
 
Gd3+ and Zn2+ binding affinities of wild type and the mutant CaMs were determined 
by competition fluorescence titration methods using Fura-6F and Fluozin-1 (metal ion 
indicators, Invitrogen Molecular Probes) as Gd3+ and Zn2+ indicator respectively. The 
fluorescence spectra of Fura-6F and Fluozin-1 were acquired using a fluorescence 
spectrophotometer (Photon Technology International, Inc.) with a 10 mm path length 
quartz cell at 25 °C. Fura-6F excitation spectra were acquired at two wavelengths, 340 
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and 380 nm, with an emission wavelength at 510 nm. Fluozin-1 emission spectra were 
acquired at 495 nm with emission wavelength from 500 to 600 nm. Gd3+-binding affinity 
of Fura-6F, Zn2+ binding affinity of Fluozin-1, the Kd1, were first determined by a Gd
3+ / 
Zn2+ titration to the dyes. A solution of Fura-6F/Fluozin-1 was mixed with Gd3+ / Zn2+ at a 
1:1 ratio for a competition titration accompanied with gradual addition of proper amount 
of protein aliquots. An apparent dissociation constant, Kapp, was estimated by fitting the 
fluorescence excitation intensity ratio of Fura-6F at 340 and 380 nm and Fluozin-1 at 
520 nm with a various concentrations of wt CaM and its mutants by a 1 to 1 binding 
model. The real Gd3+-/ Zn2+ binding affinity to CaMs, the Kd2s, were calculated with the 
following equation: 
                              
Td
d
appd
dyeK
K
KK
][1
1
2

            Equation8.4 
 
 Zinc binding affinities to these mutants were determined by dye competition 
method by monitoring the fluorescence signals (Figure8.1). CaM displays higher binding 
affinities to Lanthanide metal ions, such as Gd3+ (Figure8.4) and Tb3+ (Figure 8.3) with 
the Kd about ~ 10
-12 M range. From the summary in Table 8.1, the two domains of CaM 
have varied affinities to Tb3+ and Gd3+ with 4 folds higher affinity for Gd3+ in the N – 
terminal domain (0.5 ×10-12 M) than C – terminal domain (2.0 ×10-12 M). However, the Kd 
of C – terminal CaM is ~ 7.9 ×10-12 M, which is similar as wild type (7.0 ×10-12 M), but the 
N – terminal CaM cannot be obtained due to the limitations associated with method 
requirement. In addition, Gd3+ has a smaller Kd than Tb
3+ for both domains of CaM. CaM 
with the five residues deleted in the linker range has almost two folds stronger binding 
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affinities for Tb3+ (~4.5 ×10-12 M) and Gd3+ (~3.7 ×10-12 M) compared to wild type 
(~7.0×10-12 M for Tb3+ and 5.0 ×10-12 M for Gd3+).  
 
 
 
 
 
 
 
 
 
 
        
Figure 8.1. Zn2+ binding affinity to Fluozin1 by fluorescence titration. 
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                         Figure 8.2. Zn2+ binding affinity determined using protein competing with 
the fluozin-1. Data were fitted by 1 to 1 equation. 
 
 
 
 
 
 
 
 
 
                                Figure 8.3.Gd3+ binding affinity determined using protein competing with 
the   Fura-6F. Data were fitted by 1 to 1 equation. 
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      Figure 8.4.Tb3+ binding affinity determined FRET. Data were fitted by hill equation. 
 
     Table 8.1.Summary of metal binding affinities of wild type CaM and the half domains. 
Kd (x10
-12), M wt- CaM N-CaM C-CaM 
Ca2+ 6.77 × 106 ± 0.4 6.43 ×106± 0.1 1.18 ×106± 0.2 
Zn2+ 1.82 ×106±  0.2 1.11×106 ±  0.1 0.0027×106 ±  0.3 
Tb3+ 7.0 ± 0.1 N/A 7.9 ± 0.2 
Gd3+ 0.50± 0.1 0.50 ± 0.1           2.0 ± 0.1 
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Lobe-specific Ca2+ binding affinities of the CaM variants were determined via 
monitoring intrinsic fluorescence changes during equilibrium calcium titrations as 
previously described 57,58. CaM / Ca2+ dissociation constants (Kd) and Hill coefficients (nH) 
as well as free energy were derived from these fits and summarized in Chapter 3. As 
previously established, C-terminal lobe Ca2+ binding occurred with a significantly higher 
affinity that N-terminal Ca2+ binding in the compact CaM protein102; the isolated C – 
terminal domain still exhibits more than 5- folds stronger affinity than isolated N –
terminal domain. While the Ca2+ binding affinity to both the isolated N – terminal domain 
and C –terminal domain increased 2-fold compared to the compact protein. These 
results confirmed the cooperative Ca2+ binding properties between the two domains of 
CaM. The Hill numbers for both the two domains are close to one instead of two in the 
wild type CaM.   
CaM and its variants exhibited much stronger binding affinities to lanthanide metal 
ions (Tb3+ and Gd3+) than Ca2+. The log pKa of CaM and its variants to Tb3+ and Gd3+ are 
6 times greater than those to Ca2+. Based on the fact that oxygen is the only chelator in 
the metal binding pocket of CaM, and that lanthanide metal ions have higher interaction 
ability to oxygen, the binding affinities we obtained are reliable. As previously 
established, Ca2+ has higher binding affinities in the C –terminal domain of CaM than N – 
terminal domain. However, the lanthanide metal ions show an opposite trend where the 
N – terminal domain has stronger binding affinities than C- terminal domain. The Kd of 
Gd3+ is slightly lower than Tb3+ indicating that it has higher binding affinity than Tb3+.  
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8.3. Relaxivities of CaM half domains detected on the 60 MHz.  
 
Relaxivity is used to improve the contrast of the image, and to study tissue specific 
areas where the contrast agent better diffuses or to perform functional magnetic 
resonance imaging135b. It refers also to the ability of magnetic compounds to increase the 
relaxation rates of the surrounding water proton spins. The relaxivity of MRI contrast 
agents depends on the molecular structure and kinetics of the complex. To increase the 
number of water molecules in the inner sphere of the complex, or to slow down the 
molecular rotational correlation time, are possibilities to improve the water relaxivity.  
For CaM, we applied the 1.41 T relaxometer to measure both the r1 and r2 relaxivities of 
these CaM variants and further study the properties of the engineered N- and C- domain, 
and the deletion linker region of CaM (Fig 8.6.A and B) as well as the modified CaM 
variants by PEGylation with PEG40 (Fig 8.6.C and D). Purified protein samples were 
prepared in 10 mM HEPES buffer, pH 7.4 at concentrations of 5, 10, 20, and 40 µM 
mixed with Gd3+ as 1 to 2 ratio for half domains and 1 to 4 ratio for wt CaM and Del-CaM. 
The experiments were completed at 37 °C maintained by the water bath. 
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        Figure 8.5.Concentration dependence of relaxavities of CaM and the isolated 
variants bond with Gd3+ as 1 to 4 ratios on 1.41 T. 
r1 and r2 relaxavities calculated from T1 and T2 relaxation times measured on 1.41 T 
of isolated N-(black circles), C- domain (blue squares) and CaM with the linker 
region deleted (green diamond). A). r1 relaxivities of CaM variants. B). r2  
relaxivities of CaM variants. C). r1 relaxivities of Pegylated CaM variants). r2 
relaxivities of Pegylated CaM variants. 
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Table 8.2 shows the relaxivities of isolated half domains and Del-CaM as well as 
the modified mutants by PEGylation.  All of these mutants of CaM prohibited high 
relaxivities especially the r2 relaxivity. Del –CaM showed the highest relaxivities 
compared to others. In addition, modification of CaM half domains by PEGylation with 
(PEG) 40 does not affect their relaxivities apparently. This may be due to the fact that 
many of the lysine residues used for PEGylation were not in the binding site and the 
relaxivities were not changed after PEGylation 135b,190. 
 
 
Table 8.2. Relaxivities of wt-CaM, CaM variants and PEGylated variants. 
 wt-CaM Del-CaM N-CaM N-CaM-p40 C-CaM C-CaM-p40 
r1(mM
-1•s-1) 47.9 75.7 49.3 46.0 30.7 33.2 
r2(mM
-1•s-1) 53.3 106.2 63.7 62.5 41.1 44.6 
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9. PEGylation of Protein Based MRI Contrast Agents Improves MRI Properties 
 
9.1.  Introduction 
 
We have reported the development of protein-based MRI contrast agents (ProCA1, 
previously named as CA1.CD2) by rational design of Gd3+ binding sites into a stable 
protein using amino acid residues as metal coordinating ligands 166. Our designed 
specialized Gd-binding protein-based contrast agents are different from other reported 
macromolecular MRI contrast agents, for example, Gd-DTPA-based dendrimers, or 
nano-sized contrast agents that are developed by multiple attachment of an existing 
small chelator for Gd3+. Our designed protein MRI contrast agent exhibits higher r1 and r2 
relaxivities compared to Gd-DTPA. Here, we report a further improvement in the design 
of protein based contrast agents ProCA1 for in vivo imaging by protein modification with 
various sizes of polyethylene glycol (PEG) chain („PEGylation‟). Our experimental results 
demonstrate that modified contrast agents exhibit significant improvement of in vivo MR 
imaging and biocompatibilities including increase in relaxivities, protein solubility, blood 
retention time and decreased immunogenicity.  
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9.2. Results and discussion 
 
9.2.1. Protein engineering and PEGylation 
 
Bacteria expressed and purified protein ProCA1 was PEGylated with Methyl-PEOn-
NHS esters with different molecular weights of 0.3, 0.6, 2.4, 5, 12 and 20 kDa, 
respectively, and further purified by FPLC and confirmed by the MALDI-TOF mass 
spectrometric analysis with one to three PEG chains attached. First, we confirmed that 
PEGylated proteins maintain a native structure monitored by Trp fluorescence. 
PEGylated ProCA1 exhibited similar disassociation constants for Gd3+ with a 1 to 1 
binding ratio to those of ProCA1 (Figure9.1.and Table 9.1)166. 
 
Figure 9.1.Gd3+-binding affinity measured through fluorescence.  
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The Gd3+-binding affinity of native ProCA1 was determined by a competition 
titration using commercially available fluorophore Fluo-5N as a Gd3+ indicator. 
 
 
           Table 9.1.Properties of Gd-DTPA, ProCA1 and its PEGylated variants. 
 
 
 
 
 
 
 
 
Table 9.1 shows that the native ProCA1 had a hydration number of 2.4, PEGylation 
resulted in an increase of hydration number 0.2 - 0.8. Subsequently, the hydrodynamic 
radii of modified ProCA1s were determined by a pulse-field-gradient diffusion NMR and 
it increases from 16.9 ± 0.2, to 18.2 ± 1.1, 19.4 ± 0.55 and 40.2 ± 0.2 Å, with 0.6, 2.4 and 
12 kDa PEG respectively (Table 9.1 and Figure9.4).  
 
 
 
 
 
 
 
Table 1. Properties of Gd-DTPA, ProCA1 and its PEGylated variants. 
Sample Gd-
DTPA 
ProCA1 ProCA1 
0.6k 
ProCA1 
2.4k 
ProCA1 
12k 
D 
(107cm2s-1) 
- 13.9 12.9 12.1 6.5 
Radius (Å) - 16.9 18.2 19.4 40.2 
Log Ka 22.45
* 11.46 11.26 11.70 11.08 
q 1.1# 2.4 3.2 3.0 2.6 
r1 (mM
-1s-1) 4.5 22.9 34.4 55.6 83.8 
r2 (mM
-1s-1)  5.2 28.7 40.8 65.6 100.8 
* From reference 11. # From reference 12. 
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9.2.2. Relaxivity and metal binding affinity measurement  
 
Next, we observed that the PEGylation modifications dramatically increased 
longitudinal and transverse relaxivities of the ProCA1 at different field strengths tested 
(0.47, 1.4, 3.0 and 9.4 T). The r1 and r2 values of ProCA1-PEG0.6k were increased 
almost 66 and 110%, and ProCA1-PEG2.4k increased 100 and 125%, respectively. The 
ProCA1-PEG12k exhibited 19-fold higher r1 and r2 values compared with Gd-DTPA 
(Figure 9.2 and Table 9. 1). More interestingly, at high field strength of 9.4 T, ProCA1-
PEG2.4k still exhibited great increase of relaxivities for r1 and r2. The number of water 
ligands coordinated to the Gd3+ ProCA1 complex was determined by measuring Tb3+ 
luminescence decay in H2O or D2O 
166. The Tb3+ excited-state lifetime was measured 
using a fluorescence spectrophotometer (Photon Technology International, Inc.) with a 
10 mm path length quartz cell at 22 °C. Following excitation at 265 nm with a XenoFlash 
lamp (Photon Technology International, Inc.), Tb3+ emission was monitored at 545 nm in 
a time series experiment in both H2O and D2O systems. Luminescence decay lifetime 
was obtained by fitting the acquired data with a mono exponential decay function. H2O in 
ProCA1 solution was replaced with D2O by lyophilization and re-dissolved in D2O for at 
least three times.  
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Figure 9.2.Relaxivity values on vary magnetic field strengths. 
 Relaxivity values r1 (A) and r2 (B) at 3.0 (blue) and 9.4 T (red) of Gd-DTPA, 
ProCA1and its PEGylated variants. Relaxivity values r1 (C) and r2 (D) of Gd-DTPA 
(blue), ProCA1 (red), ProCA1-PEG0.6k (yellow), and ProCA1-PEG2.4k (green) at 
different field strengths. 
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Figure 9.3.Measurement of Water Coordination Number of protein based contrast 
agents by Tb3+ lifetime. 
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Figure 9.4.Hydrodynamic radii of ProCA1 measured on 600 MHz. 
(♦) and PEGylated with variant PEGs, PEG0.6k (●), PEG2.4k (■) and PEG12k (▲), 
were determined by pulse-field-gradient diffusion on 600 MHz NMR. PEGylation 
increased the radii gradually based on PEG size increased. Data were fitted by 
one component equation: exp (-m1*m0^ 2). 
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9.2.3.  In vivo toxicity test 
 
The ProCA1 variants also exhibit low in vivo toxicity. Metal complexation is a key 
mediator or modifier of enzyme structure and function, especially group IA metals Na+ 
and K+ play important and specific roles that assist function of biological macromolecules. 
Ca2+ plays a pivotal role in the physiology and biochemistry of organisms and the cell. As 
a result, it is essential to test the chemical properties. Selected metal ion concentrations 
(K+, Na+ and  Ca2+) and enzyme activity were measured from the collected blood of mice 
with the injection of ProCA1 and the PEG variants (Research Animal Diagnostic 
Laboratory, University of Missouri). The results (Table 9.2) show that all the metal ion 
concentrations of the mice injected with ProCA1-PEGs are in the same level as those 
with saline. In addition, alanine transaminase, the enzymes related with liver function, is 
in the normal level for mice with administration of ProCA1-PEGs compared to those 
injected with saline. However, another enzyme, alkaline phosphatase (ALP), which 
indicates the function of kidney; was tested to have fewer amounts for the mice injected 
with ProCA1-PEGs than those with saline. In summary, we were able to say that no 
apparent in vivo toxicity of ProCA1 is observed compared with the control group. 
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Table 9.2.In VivoToxicity of designed protein contrast agents. 
 Sodium 
(mmol/L) 
Potassium 
(mmol/L) 
Calcium 
(mg/dL) 
Creatinine 
(mg/dL) 
ALT 
(U/L) 
ALP 
(U/L) 
ProCA1 151.9±1.6 11.7±0.5 11.2±0.1 0.27±0.02 32±4 22±1 
ProCA1-PEG0.6k 150.8±4.0 10.3±1.4 10.5±0.5 0.22±0.02 49±4 35±4 
ProCA1-PEG2.4k 156.3±2.0 11.2±0.5 10.2±0.2 0.20±0.02 65±8 38±6 
Saline 151.8±11.0 11.8±2.3 11.0±0.5 0.32±0.01 39±5 89±11 
 
 
9.2.4. In vivo Imaging and specifically cell targeting 
PEGylation increased the solubility of protein contrast agents in aqueous solutions 
20- to 100-fold, most likely due to the strong hydrophilicity of the PEG chains. Significant 
increases in the solubility of contrast agents permit us to perform in vivo studies. 
Figure9. 5A shows the T1-weighted fast spin-echo MR images of the mouse before (left) 
and 0.5 hr after administration (right) of PEGylated Gd-ProCA1 (dose of 4.8 mol kg-1) 
through tail vein injection. Significant contrast enhancements were observed in the 
kidney, liver, and blood vessels by comparison with pre- and post-contrast T1 weighted 
images. The injection dose used was 20-fold lower than Gd-DTPA dose typically used in 
clinics (0.1 mmol kg-1). The tissue dependent enhancement was consistent with the 
biodistribution of 153Gd isotope analysis. 
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            Figure 9.5.MRI and cell targeting study of ProCA1. 
 (A) T1-weighted fast spin-echo (TR = 2 s, TE = 0.022 s, ESP = 0.01 s, slice thickness = 1 
mm) MR images of a mouse before (left) and 0.5 hr after administration (right) of Gd-
ProCA1-PEG2.4k. (B) ELISA of antibody produced in rabbits serum before (Pre) and weeks 
3 (black) and 6 (red) after i.p. injection of ProCA1 and ProCA1-PEG2.4k mixed with 
adjuvant (ProCA1-Adjuvant) or with buffer saline (ProCA1). PabCD2 is the anti-serum from 
rabbits produced by CD2 (commercial source) as antigen. (C) Two types of cancer cell 
lines were stained by ProCA1-affi and ProCA1-affi-PEG2.4k respectively. SKOV-3 is over-
expressed with HER2 receptor. MDA-MB-231 is negative of HER2. Red: ProCA1-affi or 
ProCA1-affi-PEG2.4k; Blue: DAPI for nucleolus. 
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9.2.5.  Blood retention and immunogenicity 
 
The effect of PEGylation on blood retention and biodistribution of ProCA1 and its 
PEGylated variants in mice were then examined by immunochemical assays (Figure 
9.6A) and γ-radiation of 153Gd isotope (Figure 9.6C). PEGylation increased the blood 
retention time of the agents. ProCA1-PEG2.4k exhibited the greatest increase in blood 
retention time. PEGylation reduced immunogenicity. Rabbits were administrated 
intraperitoneally with Gd-ProCA1 and its PEGylated variants mixed with or without 
adjuvant according to the standard protocol. The rabbits were subjected to repeat 
immunizations over a 3-week interval. Blood samples were examined by ELISA (Figure 
9.5B) and immunoblotting (Figure9.7) using polyclonal antibody PabCD2 as positive 
control and the pre-bleed as negative controls. Our results suggest that the 
immunogenecity of the protein contrast agent may not be very strong, especially without 
addition of adjuvant. PEGylation substantially reduced the immune responses monitored 
by poly-antibodies. Antibody generativity against the protein contrast agent (both 
PEGylated and native protein) in the rabbits was examined by Western blotting. The 
experiments were carried out by SDS-PAGE of ProCA1-PEG2.4k, ProCA1-PEG0.6k and 
ProCA1 and detected by anti-serum collected from immuno-inoculated rabbits. 
 Appropriate dose of Gd-ProCA1-PEG2.4k, Gd-ProCA1-PEG0.6k and Gd-
ProCA1 were injected intravenously into the mouse via the tail vein. Blood samples (~50 
L) were collected via orbital sinus at different time points. The contents of the protein 
MRI contrast agents in the blood were monitored by dot-blotting. Equal volumes of 
serum were loaded on the plate and identified by the commercial CD2 polyclonal 
antibody PabCD2. The amount of the ProCA1-PEG2.4k (1) and ProCA1-PEG0.6k (2) 
left in blood serum were higher than ProCA1 (3) at 3 hr. At 19 hrs, the amount of 
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ProCA1-PEG2.4k (4) left in blood serum is more than ProCA1-PEG0.6k (5) and ProCA1 
(6). (B) Is control with different amount of ProCA1. The results show that the longer 
blood retention time was observed for the protein with higher degree of PEGylation and 
longer PEG chain modifications. Although the addition of adjuvant indeed resulted in a 
strong immunoresponse it was clear that without adjuvant, injection of ProCA1 did not 
lead to significant antibody production even after a double dose immunization 
suggesting that the immunogenicity of the ProCA1 is not strong, especially without 
addition of adjuvant. Additionally, this immunoresponse was dramatically reduced 
(~80%) by PEGylation with PEG2.4k. This data is consistent with observation for other 
protein drugs191. 
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      Figure 9.6.PEGylation increased in vivo blood retention time of the agent in the 
mouse model. 
A). Dot Blotting and B) γ-radiation of 153Gd isotope. (C) Accumulation of 153Gd in 
blood circulation (% of total injected dose) for GdCl3, ProCA1, ProCA1-PEG2.4k, 
and ProCA1-PEG12k at time points of 1 (blue), 4 (brown), 8 (yellow) and 12 hrs 
(green) after injection. 
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We have also created a targeted contrast agent against the HER-2 receptor over 
expressed in various cancer cells by fusion of a HER-2 affibody192 to the C-terminal of 
ProCA1 (denoted as ProCA1-affi). Fig. 9.5C shows that both ProCA1-affi and ProCA1-
affi-PEG2.4k have similar capability to specifically bind to SKOV-3 ovarian cancer cells 
with HER2 highly expressed (~3  106/cell). On the other hand, they do not bind to MDA-
MB-231 cancer cells with a low expression level of HER-2 (~2.7  103/cell) 192 . 
Therefore, PEGylation does not impede targeting capability and specificity of ProCA1 
reagents, which is important for molecular imaging of biomarkers. 
 
 
 
Figure 9.7.The other antiserum was prepared from the blood collected after two 
times of injection of native protein ProCA1 mixed with adjuvant. 
 (A). ProCA1 in the absence of adjuvant (B). ProCA1-PEG2.4k mixed in absence of 
adjuvant (C). The results showed that addition of adjuvant induced stronger 
immune responses (B). PEGylation modifications of the protein dramatically 
reduced immune responses in the rabbits (C). The commercial CD2 polyclonal 
antibody PabCD2 was used as positive control (D). 
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9.3.  Conclusions 
Different from the modest effect (15% increase) reported 139a for a small chelator 
as contrast agent, here we reported the first observation of significant relaxivities 
increase of protein contrast agents (up to 200%) by PEGylation. Understanding the 
mechanisms for the increased relaxivity by PEGylation may allow us to identify new key 
factors contributing to the substantial improvement in relaxivities which is the major 
challenge in the field of molecular and biomarker targeted imaging. PEGylation may be a 
novel avenue to increase relaxivity at high field strength to overcome the limitation of 
current small Gd3+ chelate contrast agents that suffer reduction of r1 relaxivty under a 
high magnetic field (Figure 9.2). Such improvement can be important to the animal 
imaging and pre-clinical research under high or ultra-high field where there is an urgent 
need for molecular imaging probes and optimized contrast agent. 
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10.  Significance of This Study 
 
 
10.1. Review 
 
CaM is a small (148 amino acids; MW: 16.7 KDa) intra cellular protein with pI 
~4.0.  It consists of two globular and autonomous domains, each of which contains two 
helix-loop-helix EF-hand motifs. CaM is featured as a Ca2+ binding protein with the 
cooperatively binding properties between its two domains. Through its reversible or 
irreversible binding to Ca2+, the flexible conformational changes and the interactions with 
target enzymes, CaM is capable to transduce the intracellular Ca2+ signal changes into a 
number of diverse cellular events, including apoptosis, cell differentiation and cell 
proliferation. Ca2+ is one of the most important second messengers in eukaryotic cells 9. 
Temporal and spatial changes of the Ca2+ concentration in different compartments of 
cells affect the regulation of cellular signalling.  Among  myriad of Ca2+-binding proteins 
which modulate cell signalling, CaM plays an essential role and is extensively studied 
due to its ubiquitous expression in eukaryotes in addition to its versatile ability to activate 
or inhibit more than 100 functional enzymes, cellular receptors and ion channels 10 11 12. 
Although quite a few studies have been done on CaM, there are still large numbers of 
unknown scopes for this protein. For example, the binding sites of CaM to distinct 
enzymes are different and it may relate with the function. This study aims to investigate 
the structural and functional characteristics of CaM. We attempt to answer the following 
questions: 1. What is the metal selectivity and binding affinity of CaM except to Ca2+?     
2. What are the contributions from the structural components of CaM on regulating the 
biological functions?  3. Can we really tune the biological functions of those targeted 
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enzymes by varying the Ca2+ binding affinities to CaM?  4.  How to determine the binding 
modes of CaM with targeted proteins and what are the differences between Ca2+-CaM 
and Apo –CaM binding?   5. Can we engineer CaM to be applied as a MRI contrast 
agent? 
 
10.2. The selectivity of metal binding and the contributions from the structural 
components of CaM on regulating the biological functions. 
 
The two domains of CaM exhibit diversities as well as similarities. They have similar 
secondary structures while different tertiary structures. They produce close relaxivity 
value with varying metal binding affinities. Chapter 6 reports  the metal selectivities and 
binding affinities of CaM with Ca2+ , Zn2+, Tb3+ and Gd3+ for the isolated half domains. 
The Del-CaM and isolated half domain metal affinities were measured using the same 
method as wt CaM. The half domains of CaM exhibited stronger binding affinities to Ca2+ 
than they have in the compact wild type CaM, which indicates that Ca2+ undergoes 
cooperative binding to the two domains in CaM. Tb3+ and Gd3+ have Kd values 10
6 times 
smaller than Ca2+ and Zn2+ indicating that lanthanides bind to CaM with stronger 
affinities. This is  an advantage for CaM as a MRI contrast agent (Chapter 7 and 8).The 
melting temperature measured by CD spectra suggested that all these structural 
components decreased their stability compared with wild type CaM (twice decrease in 
the Tm values). In Chapter 3, PDE function assay using time based fluorescence 
spectroscopy was selected as an example to study the functional roles of structural 
component CaMs. The activity of CaM on PDE was eliminated after deleting five 
residues in the central linker and the activity was greatly decreased in the isolated C- 
terminal domain. However, the N-terminus was able to maintain its activity with a similar 
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EC50 as the wild type CaM. These results demonstrate that the N – terminal domain of 
CaM is the key factor to the activity on PDE activity.  While C – terminal and the central 
linker region may contribute less to the interactions between CaM and PDE. 
 
10.3. Tune the biological functions of those targeted enzymes by varying the Ca2+ 
binding affinities to CaM. 
 
A number of skeletal muscle diseases including malignant hyperthermia (MH) and 
Duchenne muscular dystrophy (DMD) are genetic disorders leading to impaired cellular 
Ca2+ regulations. Mutations in RyR1 account for the majority of MH cases 89 and leaky 
RyR1 channel may contribute to DMD 90 . RyR1 channels from MH susceptible 
individuals exhibit an enhanced sensitivity to CaM activation 91,92 and possibly a 
decreased sensitivity to Ca2+-CaM inhibition 93. CaM shifts the biphasic Ca2+ dependence 
of RyR1 activation leftward, effectively increasing channel opening at low Ca2+ and 
decreasing channel opening at high Ca2+. The conversion of CaM from a RyR1 activator 
to an inhibitor is due to the binding of Ca2+ to CaM, however which of CaM‟s four Ca2+ 
binding sites serves as the switch for this conversion is unclear. In Chapter 4, we 
engineered a series of mutant CaMs designed to individually increase the Ca2+ affinity of 
each of CaM‟s EF-hands by increasing the number of acidic residues in Ca2+ chelating 
positions. Domain-specific Ca2+ affinities of each CaM variant were determined by 
equilibrium fluorescence titration. Mutations in sites I (Thr26Asp) or II (Asn60Asp) in 
CaM‟s N-terminal domain had little effect on CaM Ca2+ affinity and regulation of RyR1. 
However, the site III mutation Asn97Asp increased the Ca2+ binding affinity of CaM‟s C-
terminal domain and caused CaM to inhibit RyR1 at a lower Ca2+ concentration than wild 
type CaM. Conversely, the site IV mutation Gln135Asp decreased the Ca2+ binding 
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affinity of CaM‟s C-terminal domain and caused CaM to inhibit RyR1 at higher Ca2+ 
concentrations. These results support the hypothesis that Ca2+ binding to CaM‟s C-
terminal acts as the switch converting CaM from a RyR1 activator to a channel inhibitor.  
These results further indicate that targeting CaM‟s Ca2+ affinity may be a valid strategy to 
tune the activation profile of CaM-regulated ion channels. Therefore, targeting these 
muscles with a CaM that will reduce channel opening at low Ca2+ may be of therapeutic 
benefit. Further, the enhanced Ca2+-CaM inhibition of RyR1 may reduce the resting Ca2+ 
leak through the channels in DMD muscle. 
 
10.4. Determine the binding mode between CaM and target enzymes. 
 
As we know, CaM can interact with more than 300 enzymes in the cell.  But the 
mechanisms for most of them are not clear yet, so there is a strong need to understand 
the binding mode between CaM and these target molecules. In Chapter 6, we use 
RyR1as an example to determine the binding modes of CaM with its target enzymes. 
Three potential binding sites were observed in RyR1 and one of them was well proved. 
We confirmed the binding of CaM with RyR13614-3643 peptide in both the presence and 
absence of Ca2+. We found that both N- and C- terminal domains contribute the binding 
with the peptide. However, only C –terminal domain bond to the peptide when CaM was 
in an apo form. These data tell us that CaM bind to the RyR1 in a different mode for apo- 
and holo- forms. 15N- labeled HSQC spectra also indicated that the two domains of CaM 
involved in the binding with another region in the channel which is RyR11975-1999 in the 
presence of Ca2+. RDC data suggested that the apo CaM binds to RyR13614-3643 peptide 
in the same mode as the IQ motif of mysin V-2IX7. A mini domain consists of both these 
185 
 
two regions was created to further determine the binding properties of CaM with the 
ryanodine channel and this will be a promising study as a future work. 
 
10.5. Engineering CaM as a MRI contrast agent. 
 
Magnetic resonance imaging (MRI) is a powerful diagnostic tool which is able to 
provide detailed information about the structure and composition of tumors 193 194. The 
use of exogenously administered contrast agents allows compartment-specific 
enhancement of diseased tissues by changing local proton relaxation times. So there is 
a strong need to create novel contrast agent satisfying the criteria to generate high 
quality images and targeting special cancers 195,196. We have reported the development 
of protein-based MRI contrast agents (ProCA1, previously named as CA1.CD2) by 
rational design of Gd3+ binding sites into a stable protein using amino acid residues as 
metal coordinating ligands 166. CaM exhibit strong binding affinity with Gd3+ and high 
physiological stabilities.  It also provides high relaxivities (~ 20 times higher than Gd –
DTPA) and large water numbers as described in Chapter 7 and 8. Based on these 
properties, we further engineered CaM as a MRI contrast agent candidate by fusing an 
affibody peptide which specifically target to HER-2 receptor and modified it by 
PEGylation to reduce the immunogenicity (ProCA22). ProCA22 was injected into the 
mice with xenograft tumor model. The mice were scanned on MRI instrument and tumor 
enhanced images were achieved. All the results indicate that our designed ProCA22 has 
the promising potential to be optimized as a protein based contrast agent. 
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